



# Asset Map of Canadian Clinical Practice Guidelines

**Prepared By:**

Janet Crain, Principal of [KTE Bridge Consulting](#) (contracted by SPOR Evidence Alliance)

**Date published:** April 30, 2018

**Contact:**

Andrea C. Tricco

**E:** [triccoa@smh.ca](mailto:triccoa@smh.ca)

**T:** 416-864-6060 ext. 77521

## **Author Information**

The SPOR Evidence Alliance contracted **Janet Crain**, Principal of [KTE Bridge Consulting](#) to develop the *Asset Map of Canadian Clinical Practice Guidelines*.

## **Funding Acknowledgements**

The SPOR Evidence Alliance is supported by the Canadian Institutes of Health Research ([CIHR](#)) under Canada's Strategy for Patient-Oriented Research ([SPOR](#)) Initiative.

## Table of Contents

---

Introduction.....	3
Objectives.....	3
Methods.....	3
Eligibility Criteria.....	4
Synthesis .....	4
Limitations .....	4
Findings.....	5
Aboriginal People's Health .....	6
Aging.....	7
Cancer .....	11
Circulatory and Respiratory Health.....	96
Gender and Health / Women's Health .....	117
Genetics / Genetic Disorders.....	136
Health Services and Policy Research.....	138
Human Development, Child and Youth Health .....	154
Infection and Immunity .....	186
Musculoskeletal Health and Arthritis.....	199
Neurosciences, Mental Health and Addiction .....	203
Nutrition, Metabolism and Diabetes / Endocrine .....	216
Population and Public Health .....	232
Other.....	234
List of Sources .....	235

## Introduction

The Strategy for Patient-Oriented Research (SPOR) Evidence Alliance is a Canada-wide alliance of researchers, healthcare providers, patients, policy makers and other knowledge users. The SPOR Evidence Alliance was established to provide national coordination and project management in support of knowledge synthesis, clinical practice guideline development, relevant knowledge translation, and patient-oriented research.

As a core mandate to support clinical practice guideline development and adoption, the SPOR Evidence Alliance is creating an asset map of some currently available Canadian clinical practice guidelines (CPGs). This will provide opportunity to reduce redundancies or duplication and set the stage for future collaboration between guideline groups, end-users of guidelines, as well as identifying opportunities to build capacity. For the purposes of this report, clinical practice guidelines are defined as "*systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances.*" (Field & Lohr 1990, page 38).

## Objectives

To develop an asset map of Canadian clinical practice guidelines presenting information on the developer, access, methods, funding and cycle of development or updates of the guideline, as well as whether the guideline is intended for primary or specialty care audiences and whether it includes comorbidities. The asset map will include provincial, national and local guidelines. It is important to note that this asset map is not intended to be a comprehensive list of all guidelines developed in Canada, but rather a significant sample to demonstrate the guidelines available.

The clinical practice guideline asset map is intended to:

- Demonstrate a sample of the vast number of guidelines currently available and use this as an opportunity to reduce duplication and redundancy.
- Provide a foundational list of key clinical practice guidelines and developers in Canada.
- Identify skills/expertise of guideline developers in Canada and identify potential gaps.
- Set the stage for future collaborative opportunities between guideline groups or opportunities to provide capacity-building in approaches to guideline development.

## Methods

### Search Strategy

A literature search of targeted databases and websites was conducted to identify Canadian CPGs. The following databases and websites were searched:

- Alberta Medical Association. Toward Optimized Practice (TOP)
- British Columbia Ministry of Health: BC Guidelines
- Canadian Medical Association (CMA). CMA Infobase: Clinical Practice Guidelines
- Canadian Partnership Against Cancer Corporation: Cancer Guidelines Resource Centre

- Canadian Standards Association
- The College of Physicians and Surgeons of Ontario (CPSO). CPGs & Other Guidelines
- Ontario Association of Medical Laboratories (OAML) Lab Test Guidelines
- National Guideline Clearinghouse (NGC)
- Public Health Agency of Canada (PHAC). Disease Prevention and Control Guidelines
- Registered Nurses' Association of Ontario: Nursing Best Practice Guidelines
- University of Ottawa. School of Rehabilitation Science. Evidence-based Practice
- Winnipeg Regional Health Authority (WRHA). Evidence Informed Practice Tools

## **Eligibility Criteria**

Duplicate entries were identified and merged; archived/inactive CPGs (as identified by the developer) were removed and CPGs without open access or restricted access were also removed. Out of date guidelines were replaced by current guidelines (but still included in databases). Information included within a database or website that could not be classified as a guideline were also removed (i.e. tool or statement). Only formal CPGs were included.

## **Synthesis**

All CPGs were recorded and categorized to the relevant areas of science based on the [CIHR Institutes](#).

Each of the CPGs under the 14 CIHR areas of science was sorted by the organization that developed the CPG and their topic. The original source of each CPG (database/website) has been referenced.

Each CPG has been examined to determine the contact information of the lead author. A current web link has been provided along with the date of the CPG and the cycle of development, where available. Funding information and author conflict of interest disclosures were also included. Methodology for each CPG has been cited and the intended audience has been categorized as either primary or specialty care. Finally, each CPG has been reviewed to determine if it covers comorbidities or not.

Gaps in information were filled through a series of emails and phone calls with appropriate organizations, authors, or experts.

The full report including 14 tables of guidelines has been reviewed by experts and guideline developers. All feedback that was within the scope of this asset map have been carefully considered and used to update and revise the report.

## **Limitations**

This asset map of CPGs and their developers in Canada is not intended to be comprehensive, and therefore does not include all available CPGs. Furthermore, many guidelines could not be included as they did not have open access or were internal documents for specialty groups or organizations. Many CPGs are suitably classified under more than one category and as such

may appear more than once within the information presented. Guideline databases that allow material beyond CPGs (e.g. patient tools, quick-reference guides, evaluation documents) required further examination to determine suitability for this report and added a significant amount of unanticipated review.

Furthermore, it was not possible to contact each developer or author of the guidelines presented to ensure the information is presented to their preference. Care was taken to be as accurate as possible; however guideline groups/authors may have additional or alternate information. The majority of guidelines did not indicate implementation initiatives or evaluation measures. Due to the limited findings in this regard, information was included anecdotally rather than within the full table(s).

## Findings

There are numerous guidelines available to both primary care and specialty health care providers in Canada. Well-known databases provided a good source for access to this information, however the inclusion of out of date information, inactive links, as well as non-CPG information makes access more difficult for the end user. Furthermore, the inclusion of CPGs only available through membership or a “pay wall” is an additional challenge for users.

Guideline databases were essential in identifying the general availability of CPGs, however current and open access links were sometimes difficult to locate. Keeping guideline databases up-to-date is a significant challenge as access links to the original source must be continually updated and producers must be motivated to share updated links in a timely manner.

The majority of guideline developers did not include consideration for implementation initiatives or evaluation measures within their guidelines. Exceptions included the Canadian Task Force for Preventative Health Care who included “Considerations for Implementation” and “Suggested Performance Measures” within their guidelines. The Registered Nurses’ Association of Ontario also included an “Implementation Strategy” and a “Structure for Evaluation” within their guidelines. A few mentioned dissemination suggestions (e.g., conferences, rounds) and / or the impact factor from medical journals in lieu of evaluation measures.

Over 1100 CPGs are presented below using the following categories:

1. [Aboriginal People's Health](#)
2. [Aging](#)
3. [Cancer](#)
4. [Circulatory and Respiratory Health](#)
5. [Gender and Health/Women's Health](#)
6. [Genetics/Genetic Disorders](#)
7. [Health Services and Policy Research](#)
8. [Human Development , Child and Youth Health](#)
9. [Infection and Immunity](#)
10. [Musculoskeletal Health and Arthritis](#)
11. [Neurosciences, Mental Health and Addiction](#)
12. [Nutrition, Metabolism and Diabetes/Endocrine](#)
13. [Population and Public Health](#)
14. [Other](#)

## Aboriginal People's Health

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Paediatric Society</b> <i>2305 St. Laurent Blvd Suite 100 Ottawa, ON</i>	Preventing unintentional injuries in Indigenous children and youth in Canada	Primary	No	<a href="#">More Details...</a>	<a href="#">Consensus</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	Date: 2017-Jan	3 year cycle.	Anna Banerji, MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Community-associated methicillin-resistant staphylococcus aureus in Indigenous communities in Canada	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	Date: 2017-Jan	3 year cycle.	James Irvine MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Tobacco use and misuse among Indigenous children and youth in Canada	Primary	No	<a href="#">More Details...</a>	<a href="#">Consensus</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	Date: 2017-Oct	3 year cycle.	Radha Jetty MD (chair)
<sup>2</sup>	<b>Diabetes Canada</b> <i>1400-522 University Ave Toronto ON</i>	Type 2 diabetes and indigenous peoples	Primary	Yes	<a href="#">More Details..</a>	<a href="#">Methods</a>	<a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>

## Aging

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>3</sup>	<b>BC Guidelines</b>  <i>Guidelines and Protocols Advisory Committee</i>  <i>PO Box 9642 STN PROV GOVT</i>  <i>Victoria, BC</i>	Cataract Treatment	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	Primary Health Care Transition Fund.	No COI to disclose by authors.	<b>Date:</b> 2007-Apr	3-5 year cycle.	Cataract Guideline Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2,3</sup>	<b>BC Guidelines</b>	Cognitive Impairment – recognition, diagnosis and management in primary care	Primary	Yes	<a href="#">More Details....</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	Primary Health Care Transition Fund.	No COI to disclose by authors.	<b>Date:</b> 2016-Jun	3-5 year cycle.	Guidelines and Protocols Advisory Committee  <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2,3</sup>	<b>BC Guidelines</b>	Frailty in older adults – early identification and management	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	Primary Health Care Transition Fund.	No COI to disclose by authors.	<b>Date:</b> 2017-Oct	3-5 year cycle.	Family Practice Oncology Network & Guidelines and Protocols Advisory Committee  <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Heart Failure (Chronic) – Diagnosis and Management	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	Primary Health Care Transition Fund.	No COI to disclose by authors.	<b>Date:</b> 2015-Oct	3-5 year cycle.	Guidelines and Protocols Advisory Committee  <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2</sup>	<b>Canadian Coalition for Seniors'</b>	Assessment and treatment of delirium	Primary	Yes	<a href="#">More Details...</a>	Update of previous (2006) recommendation based on	CIHR award.	No COI to disclose by	<b>Date:</b> 2014	Cycle not indicated.	Laura Gage, MD, FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	<b>Mental Health</b> <i>20 Crown Steel Dr. Unit #6 Markham, ON</i>					literature review.		authors.			
<sup>2</sup>	<b>Canadian Coalition for Seniors' Mental Health</b>	Assessment and treatment of mental health issues in long term care homes	Primary	Yes	<a href="#">More Details...</a>	Update of previous (2006) recommendation based on literature review.	CIHR award.	No COI to disclose by authors.	<b>Date:</b> 2014	Cycle not indicated.	David K. Conn MB, BCh, BAO, FRCPC
<sup>2</sup>	<b>Canadian Consensus Conference on the Diagnosis and Treatment of Dementia</b> <i>McMaster University, 1200 Main St W, Hamilton, ON</i>	Diagnosis and treatment of dementia: recommendations for family physicians	Primary	Yes	<a href="#">More Details...</a>	<a href="#">GRADE</a>	CIHR and Canadian Demential KT Network.	No COI to disclose by authors.	<b>Date:</b> 2014-May	Cycle not indicated.	Ainsley Moore MSc MD CCFP
<sup>2</sup>	<b>Diabetes Canada</b> <i>1400-522 University Ave Toronto ON</i>	Diabetes in older people	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	<a href="#">Diabetes Canada</a>	COI disclosed by authors.	<b>Date:</b> 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2,11</sup>	<b>Canadian Task Force on Preventative Health Care</b> <i>3280 Hospital Drive Northwest. Calgary, AB</i>	Screening for cognitive impairment in older adults	Primary	Yes	<a href="#">More Details...</a>	<a href="#">GRADE</a>	CIHR and PHAC.	No COI to disclose by authors.	<b>Date:</b> 2016 Jan	5 year cycle.	Kevin Pottie, Departments of Family Medicine, and of Epidemiology and Community Medicine, University of Ottawa

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Osteoporosis Canada  1200 Eglinton Ave East, Suite 500 Toronto, ON	Preventing fracture in long-term care	Primary	Yes	<a href="#">More Details...</a>	GRADE	ON Osteoporosis Strategy for LTC, CIHR, Osteoporosis Canada, unrestricted educ. Grants (Eli Lilly, Amgen, Merck, Warner Chilcott).	COI disclosed by authors.	Date: 2015-Sep	Cycle not indicated.	Alexandra Papaioannou MD MSc
<sup>8</sup>	Registered Nurses' Association of Ontario (RNAO)  158 Pearl Street, Toronto, ON	Preventing and addressing abuse and neglect of older adults	Primary	No	<a href="#">More Details...</a>	Methodology Report	ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2014-Jul	5 year cycle.	Dr. Elizabeth Podnieks (Guideline Co Chair)
<sup>8</sup>	RNAO	Prevention of constipation in older adults	Primary	Yes	<a href="#">More Details...</a>	Methodology Report	ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2011-Mar	3 year cycle.	Tazim Virani, RN, MScN, PhD
<sup>8</sup>	RNAO	Promoting continence using prompted voiding	Primary	Yes	<a href="#">More Details...</a>	Methodology Report	ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2005-Mar	3 year cycle.	Tazim Virani, RN, MScN, PhD
<sup>8</sup>	RNAO	Delirium, Dementia and Depression in Older Adults: Assessment and	Primary	Yes	<a href="#">More Details...</a>	Systematic review and consensus.	ON Ministry of Health and LTC.	No COI to disclose by	Date: 2016-Jul	5 year review cycle.	Michelle Acorn, Nurse Practitioner (co chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Care					authors.				
<sup>8</sup>	<b>RNAO</b>	Preventing Falls and Reducing Injury from Falls	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2017- Sep	5 year cycle.	Susan McNeill, RN, MPH Guideline Development Lead
<sup>2</sup>	<b>Toward Optimized Practice</b> <i>#200, 12315 Stony Plain Road Edmonton, AB T5N 3Y8</i>	Cognitive impairment : part 1: symptoms to diagnosis	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2017- Feb	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>2</sup>	<b>Toward Optimized Practice</b>	Cognitive impairment : part 2: diagnosis to management	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2017- Feb	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>2</sup>	<b>Toward Optimized Practice</b>	Diagnosis and management of osteoporosis	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2016- Feb	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>

## Cancer

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2,11</sup>	<b>Alberta Health Services – Cancer Care</b>  <i>Seventh Street Plaza 14th Floor, North Tower 10030 – 107 Street NW Edmonton, Alberta T5J 3E4</i>	Mitotane for adrenocortical carcinoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Nov	3 year cycle	Provincial Endocrine Tumour Team  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	<b>Alberta Health Services – Cancer Care</b>	Anal canal cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Oct	3 year cycle	AB Provincial Gastrointestinal Tumour Team:  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Malignant biliary obstruction	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-Sep	3 year cycle.	AB Provincial Gastrointestinal Tumour Team.  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Muscle invasive and locally advanced/meta static bladder cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Oct	3 year cycle.	AB Provincial Genitourinary Tumour Team:  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,11</sup>	<b>Alberta Health Services –</b>	Nonmuscle invasive	Specialty	No	<a href="#">More Details</a>	<a href="#">Guideline Utilization Resource Unit</a>	Gov't of AB.	COI disclosed by	<b>Date:</b> 2013-Oct		AB Provincial Genitourinary Tumour Team

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	<b>Cancer Care</b>	bladder cancer			<a href="#">...</a>	<a href="#">Handbook – Methodology</a>		authors.		3 year cycle.	<a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Alberta bone marrow and blood cell transplant program - standard practice manual	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit</a> <a href="#">Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2017-Jan	3 year cycle. (by section)	Alberta Bone Marrow and Blood Cell Transplant Program: <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Palliative radiotherapy: bone metastases and spinal cord compression	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit</a> <a href="#">Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-Jun	Annual cycle (by section)	Working group comprised of radiation oncologists. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Palliative radiotherapy: brain metastases	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit</a> <a href="#">Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Aug	3 year cycle.	Working group comprised of radiation oncologists. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Seizure management in patients with primary and metastatic	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit</a> <a href="#">Handbook –</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Sep	3 year cycle.	AB Provincial CNS Tumour Team: <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		brain tumours				<a href="#">Methodology</a>					<a href="#">s.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Adjuvant systemic therapy for early stage (lymph node negative and lymph node positive) breast cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2017-Oct	3 year cycle.	AB Provincial Breast Tumour Team: <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Breast reconstruction following prophylactic or therapeutic mastectomy for breast cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2017-Feb	3 year cycle.	AB Provincial Breast Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Follow-up care for early-stage breast cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2015-Oct	3 year cycle.	AB Provincial Breast Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Neo-adjuvant (pre-operative) therapy for breast cancer - general considerations	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Dec	Annual cycle.	AB Provincial Breast Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	<b>Alberta Health Services –</b>	Cancer of the uterine cervix	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook –</a>	Gov't of AB.	COI disclosed by	<b>Date:</b> 2015-Sep	Annual cycle.	AB Provincial Gynecologic Oncology Team: <a href="mailto:GURU@albertahealthservice">GURU@albertahealthservice</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Cancer Care				<a href="#">Methodology</a>		authors.				<a href="#">s.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Early stage colon cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2017-Dec	Annual cycle.	AB Provincial Gastrointestinal Tumour Team. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	Alberta Health Services – Cancer Care	Post polypectomy surveillance guidelines	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Jun	3 year cycle.	AB Colorectal Cancer Screening Program <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Metastatic colorectal cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-May	Annual cycle.	AB Provincial Gastrointestinal Tumour Team. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Stages II and III colorectal cancer surveillance	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Jan	Annual cycle.	AB Provincial Gastrointestinal Tumour Team. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Oncologic emergencies: a guide for family physicians	Primary	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Sep	3 year cycle.	Guideline Resource Unit <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Endometrial cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2015-Nov	Annual cycle.	AB Provincial Gynecologic Oncology Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Esophageal cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-Mar	3 year cycle.	AB Provincial Gastrointestinal Tumour Team. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,11</sup>	Alberta Health Services – Cancer Care	Management of patients with early esophageal cancer, dysplastic and non-dysplastic barrett's esophagus	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Mar	3 year cycle.	AB Provincial GI Tumour Team. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	Alberta Health Services – Cancer Care	Cancer-related fatigue	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2017-Jan	3 year cycle.	Guideline working group <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	Alberta Health Services – Cancer Care	Management of fluorouracil (5-fluorouracil, 5fu) infusion overdose guideline	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-Feb	3 year cycle.	AB Provincial GI Tumour Team. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Cholangiocarcinoma and gallbladder cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-Oct	3 year cycle.	AB Provincial GI Tumour Team. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Gastric cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-Apr	3 year cycle.	AB Provincial GI Tumour Team. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Extragonadal germ cell tumours	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Apr	3 year cycle.	AB Provincial Genitourinary Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Management of primary germ cell tumours of the central nervous system	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Jul	3 year cycle.	AB Provincial CNS Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	<b>Alberta Health Services – Cancer Care</b>	Low-grade gliomas	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-Dec	3 year cycle.	AB Provincial CNS Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Management of recurrent high-grade gliomas	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Jul	3 year cycle.	AB Provincial CNS Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Dexamethasone in patients with high grade gliomas	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Mar	3 year cycle.	AB Provincial CNS Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	The organization and delivery of healthcare services for head and neck cancer patients	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2015-Nov	3 year cycle.	AB Provincial Head and Neck Tumour Team: medical oncologists, radiation oncologists, surgical oncologists, nurses, pathologists, and pharmacists. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health</b>	Oral and dental care	Specialty	Yes	<a href="#">More Details</a>	<a href="#">Guideline Utilization</a>	Gov't of AB.	COI disclose	<b>Date:</b> 2017-Jan	3 year cycle.	AB Provincial Head and Neck

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	<b>Services – Cancer Care</b>	management in head and neck cancer			<a href="#">...</a>	<a href="#">Resource Unit Handbook – Methodology</a>		d by authors.			Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	<b>Alberta Health Services – Cancer Care</b>	Hepatocellular carcinoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2017-Dec	Annual cycle.	AB Provincial GI Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	<b>Alberta Health Services – Cancer Care</b>	Influenza immunization for adult and pediatric patients undergoing cancer treatment	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2017-Oct	Annual cycle.	AB Provincial Tumour Council: medical oncologists, radiation oncologists, hematologists, surgeons, content experts from AHS Province-wide Immunization Program Standards and Quality, Communicable Disease Control. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Pneumococcal vaccination in adult and pediatric patients undergoing cancer treatment	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2017-Oct	3 year cycle.	AB Provincial Tumour Council <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Acute lymphoblastic leukemia	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2016-Jul	3 year cycle.	AB Provincial Hematology Tumour Team: hematologists, medical oncologists, radiation oncologists, nurses, hematopathologists, and pharmacists. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
											<a href="#">s.ca</a>
<sup>2,4</sup>	<b>Alberta Health Services – Cancer Care</b>	Acute myeloid leukemia	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2017-Jun	3 year cycle.	AB Provincial Hematology Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Acute promyelocytic leukemia	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2015-May	3 year cycle.	AB Provincial Hematology Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	<b>Alberta Health Services – Cancer Care</b>	Chronic lymphocytic leukemia	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2017-Jan	Annual cycle.	AB Provincial Hematology Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Management of chronic myeloid leukemia	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2017-Jun	3 year cycle.	AB Provincial Hematology Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Management of in-transit disease of the limbs	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Feb	3 year cycle.	AB Cutaneous Tumour Team: surgical oncologists, radiation oncologists, medical oncologists, dermatologists, nurses, pathologists, and pharmacists. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	<b>Alberta Health Services – Cancer Care</b>	Non-small cell lung cancer: stage I	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Jul	3 year cycle.	AB Provincial Thoracic Tumour Team: medical oncologists, radiation oncologists, surgical oncologists, nurses, pathologists, and

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
											pharmacists. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Non-small cell lung cancer: stage II	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Jul	3 year cycle.	AB Provincial Thoracic Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>4</sup>	Alberta Health Services – Cancer Care	Non-small cell lung cancer - stage III	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2012	3 year cycle.	AB Provincial Thoracic Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4,11</sup>	Alberta Health Services – Cancer Care	Non-small cell lung cancer: stage IV	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Nov	3 year cycle.	AB Provincial Thoracic Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>4</sup>	Alberta Health Services – Cancer Care	Small Cell Lung Cancer: Extensive Stage	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2012-Jul	3 year cycle.	AB Provincial Thoracic Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>4</sup>	Alberta Health Services – Cancer Care	Small Cell Lung Cancer: Limited Stage	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2012-Jul	3 year cycle.	AB Provincial Thoracic Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>4</sup>	Alberta Health Services – Cancer Care	Superior sulcus (pancoast) tumours	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2012-Jan	3 year cycle.	AB Provincial Thoracic Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health	Lymphoma	Specialty	No	<a href="#">More Details</a>	<a href="#">Guideline Utilization</a>	Gov't of AB.	COI disclose	<b>Date:</b> 2018-Jan	Annual cycle.	AB Provincial Hematology

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Services – Cancer Care				...	<a href="#">Resource Unit Handbook – Methodology</a>		d by authors.			Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2.4	Alberta Health Services – Cancer Care	Medulloblastoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2014-Mar	3 year cycle.	AB Provincial CNS Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2.4,11	Alberta Health Services – Cancer Care	Adjuvant interferon for malignant melanoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2014-Feb	3 year cycle.	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2.4	Alberta Health Services – Cancer Care	Adjuvant radiation for malignant melanoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2014-Feb	3 year cycle.	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2.4,11	Alberta Health Services – Cancer Care	Systemic therapy for unresectable stage III or metastatic cutaneous melanoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2015-Aug	3 year cycle.	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2.4,11	Alberta Health Services – Cancer Care	Management of resectable stage iv primary cutaneous melanoma without nodal disease	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2013-Feb	3 year cycle.	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2.4,11	Alberta Health	Optimal excision	Specialty	No	<a href="#">More Details</a>	<a href="#">Guideline Utilization</a>	Gov't of AB.	COI disclose	<b>Date:</b> 2013-	3 year cycle.	AB Provincial Cutaneous

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	<b>Services – Cancer Care</b>	margins for primary cutaneous melanoma			<a href="#">...</a>	<a href="#">Resource Unit Handbook – Methodology</a>		d by authors.	Feb		Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2,4,11	<b>Alberta Health Services – Cancer Care</b>	Preoperative and pretreatment investigations for malignant melanoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2013-Feb	3 year cycle.	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2,11	<b>Alberta Health Services – Cancer Care</b>	Prevention of skin cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2013-Feb	3 year cycle.	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2,4,11	<b>Alberta Health Services – Cancer Care</b>	Referral and follow-up surveillance of cutaneous melanoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2013-Feb	3 year cycle.	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2	<b>Alberta Health Services – Cancer Care</b>	Sentinel node biopsy in primary cutaneous melanoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2016-Apr	Annual cycle. Endorsed as is if no change to evidence/practice	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2	<b>Alberta Health Services – Cancer Care</b>	Uveal melanoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclose d by authors.	<b>Date:</b> 2014-Nov	3 year cycle.	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2,4,11	<b>Alberta Health Services –</b>	Biopsy of a suspicious pigmented	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook –</a>	Gov't of AB.	COI disclose d by	<b>Date:</b> 2013-Feb	3 year cycle.	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Cancer Care	lesion				<a href="#">Methodology</a>		authors.			<a href="#">s.ca</a>
<sup>2,4,11</sup>	Alberta Health Services – Cancer Care	Merkel cell carcinoma	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2015-Jul	3 year cycle.	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>4</sup>	Alberta Health Services – Cancer Care	Malignant Pleural Mesothelioma	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2012-Dec	3 year cycle.	AB Provincial Thoracic Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>4</sup>	Alberta Health Services – Cancer Care	Myelodysplastic Syndrome	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2009-Nov	3 year cycle.	AB Provincial Hematology Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Multiple myeloma	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2015-Apr	3 year cycle.	AB Provincial Hematology Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,11</sup>	Alberta Health Services – Cancer Care	Nasopharyngeal cancer treatment	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Dec	3 year cycle.	AB Provincial Head and Neck Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,11</sup>	Alberta Health Services – Cancer Care	Somatostatin analogues for neuroendocrine tumours	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2015-Mar	3 year cycle.	AB Provincial Endocrine Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
2,4,11	Alberta Health Services – Cancer Care	Management of febrile neutropenia in adult cancer patients	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Jan  (By Section)	3 year cycle.	Working group: oncologists specializing in breast, ovarian, colorectal, and lung cancers, hematologists, and family physicians.  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2	Alberta Health Services – Cancer Care	Oral cavity cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Feb	3 year cycle.	AB Provincial Head and Neck Tumour Team  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2	Alberta Health Services – Cancer Care	Oropharyngeal cancer treatment	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2015-Oct	3 year cycle.	AB Provincial Head and Neck Tumour Team  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2,4,11	Alberta Health Services – Cancer Care	Epithelial ovarian, fallopian tube and primary peritoneal cancer	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Apr	3 year cycle.	AB Provincial Gynecologic Tumour Team  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
2,4,11	Alberta Health Services – Cancer Care	Ovarian germ cell tumours	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Apr	3 year cycle.	AB Provincial Gynecologic Tumour Team  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
4	Alberta Health Services – Cancer Care	Hyperbaric Oxygen Therapy for Late Radiation Tissue Injury in Cervical and Other Gynecological	Specialty	Yes	<a href="#">More Details... +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2009-Sep	3 year cycle.	AB Provincial Gynecologic Tumour Team  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Malignancies									
<sup>2,4</sup>	<b>Alberta Health Services – Cancer Care</b>	Adenocarcinoma of the pancreas	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2017-Nov	3 year cycle.	AB Provincial GI Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Systemic therapy for well and moderately differentiated unresectable pancreatic neuroendocrine tumours	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2015-Feb	3 year cycle.	AB Provincial Endocrine Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Panitumumab and Cetuximab toxicity management guidelines	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2015-Jul	3 year cycle.	AB Provincial GI Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Proton beam radiation therapy	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Mar	3 year cycle.	AHS Cancer Care Proton Therapy Guideline Advisory Group: medical oncology, radiation oncology, and pediatric neurosurgery <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>4</sup>	<b>Alberta Health Services – Cancer Care</b>	Penile Cancer	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2012-Feb	3 year cycle.	AB Provincial Genitourinary Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>4</sup>	<b>Alberta Health Services –</b>	Pituitary Adenomas	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline Utilization Resource Unit Handbook –</a>	Gov't of AB.	COI disclosed by	<b>Date:</b> 2012-Aug	3 year cycle.	AB Provincial CNS Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Cancer Care					<a href="#">Methodology</a>		authors.			<a href="#">s.ca</a>
<sup>2,11</sup>	Alberta Health Services – Cancer Care	Management of malignant pleural effusion	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-Oct	3 year cycle.	AB Provincial Lung Tumour Team: medical oncologists, radiation oncologists, surgical oncologists, respirologists, nurses, pathologists, and pharmacists.  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	Alberta Health Services – Cancer Care	Local prostate cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2018-Jan	Annual cycle.  Endorsed as is if no change to evidence/practice	AB Provincial GU Tumour Team  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Prostate cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2015-Mar	3 year cycle.	AB Provincial GU Tumour Team  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Early stage rectal cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Oct	3 year cycle.	AB Provincial GI Tumour Team  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	Alberta Health Services – Cancer Care	Renal cell carcinoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2017-Nov	3 year cycle.	AB Provincial GU Tumour Team  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	<b>Alberta Health Services – Cancer Care</b>	Renal Cell Carcinoma and Genetic Testing	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2011-Oct	3 year cycle.	AB Provincial GU Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Sentinel lymph node biopsy in high risk cutaneous squamous cell carcinoma	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Feb	3 year cycle.	AB Provincial Cutaneous Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Gastrointestinal stromal tumours (GIST)	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-Feb	3 year cycle.	AB Provincial Sarcoma Tumour Team: medical oncologists, radiation oncologists, surgical oncologists, nurses, pathologists, and pharmacists. <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,4</sup>	<b>Alberta Health Services – Cancer Care</b>	Testicular germ cell tumours	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-Mar	3 year cycle.	AB Provincial GU Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Prophylaxis and treatment of venous thromboembolism in patients undergoing treatment for solid tumours	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2017-Nov	3 year cycle.	Alberta Provincial Tumour Program: medical oncologists, radiation oncologists, surgeons, hematologists, nurses, pathologists, physiotherapists, and pharmacists.

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
											<a href="mailto:GURU@albertahealthservice.ca">GURU@albertahealthservice.ca</a>
<sup>4</sup>	<b>Alberta Health Services – Cancer Care</b>	Thymic Neoplasms	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2012-Dec	3 year cycle.	AB Provincial Thoracic Tumour Team <a href="mailto:GURU@albertahealthservice.ca">GURU@albertahealthservice.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Follow-up surveillance of soft tissue sarcoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2014-May	3 year cycle.	AB Provincial Sarcoma Tumour Team <a href="mailto:GURU@albertahealthservice.ca">GURU@albertahealthservice.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Tobacco screening and treatment for adult cancer patient	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-Aug	3 year cycle.	AB Working Group <a href="mailto:GURU@albertahealthservice.ca">GURU@albertahealthservice.ca</a>
<sup>2,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Upper tract urothelial tumours	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Apr	3 year cycle.	AB Provincial GU Tumour Team <a href="mailto:GURU@albertahealthservice.ca">GURU@albertahealthservice.ca</a>
<sup>4,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Uterine Sarcoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Sep	3 year cycle.	AB Provincial Gynecologic Tumour Team <a href="mailto:GURU@albertahealthservice.ca">GURU@albertahealthservice.ca</a>
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>	Palliative radiotherapy: superior vena cava obstruction, dyspnea, and hemoptysis	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2016-Jul	3 year cycle.	AHS Working Group of Radiation Oncologists <a href="mailto:GURU@albertahealthservice.ca">GURU@albertahealthservice.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2,4,11</sup>	<b>Alberta Health Services – Cancer Care</b>	Squamous cell carcinoma of the vulva	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	Gov't of AB.	COI disclosed by authors.	<b>Date:</b> 2013-Sep	3 year cycle.	AB Provincial Gynecologic Tumour Team <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>4</sup>	<b>Atlantic Provinces Pediatric Hematology Oncology Network</b> <i>University Avenue   PO Box 9700   Halifax, NS B3K 6R8</i>	Guidelines for the prevention and therapy of bacterial infections for children with asplenia and hyposplenia	Specialty	Yes	<a href="#">More Details..</a>	Consensus	Guideline developed independently from any funding body.	No COI disclosed.	<b>Date:</b> 2015	No specific cycle; regular updates indicated.	Tamara MacDonald, PharmD <a href="mailto:tamara.macdonald@iwk.nshealth.ca">tamara.macdonald@iwk.nshealth.ca</a>
<sup>4</sup>	<b>Atlantic Provinces Pediatric Hematology Oncology Network</b>	Administration of asparaginase in a pediatric population: acute lymphocytic leukemia (ALL), lymphoblastic lymphoma, and acute myeloid leukemia (AML).	Specialty	Yes	<a href="#">More Details..</a>	Consensus	Guideline developed independently from any funding body.	No COI disclosed.	<b>Date:</b> 2011	No specific cycle; regular updates indicated.	Tamara MacDonald, PharmD <a href="mailto:tamara.macdonald@iwk.nshealth.ca">tamara.macdonald@iwk.nshealth.ca</a>
<sup>4</sup>	<b>Atlantic Provinces Pediatric Hematology Oncology Network</b>	Guideline for Febrile Neutropenia in a pediatric population.	Specialty	Yes	<a href="#">More Details..</a>	Consensus External review	Guideline developed independently from any funding body.	No COI disclosed.	<b>Date:</b> 2017-June	3 year cycle.	Tamara MacDonald, PharmD <a href="mailto:tamara.macdonald@iwk.nshealth.ca">tamara.macdonald@iwk.nshealth.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	<b>Atlantic Provinces Pediatric Hematology Oncology Network</b>	Management of tumour lysis syndrome in a pediatric population.	Specialty	No	<a href="#">More Details..</a>	Consensus  External review	Guideline developed independently from any funding body.	No COI disclosed.	<b>Date:</b> 2007-Jul	3 year cycle.	Tamara MacDonald, PharmD <a href="mailto:tamara.macdonald@iwk.nshealth.ca">tamara.macdonald@iwk.nshealth.ca</a>
<sup>4</sup>	<b>BC Cancer Agency</b> <i>686 West Broadway, Suite 500 Vancouver, BC, V5Z 1G1</i>	Gastrointestinal Cancer Management Guidelines - Anus	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2012-Sep	3-5 year cycle.	Provincial GI Tumour Group.
<sup>4</sup>	<b>BC Cancer Agency</b>	Gastrointestinal Cancer Management Guidelines - Bile Ducts	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2005 (date not stated).	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Genitourinary Cancer Management Guidelines - Bladder	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2008-Feb	3-5 year cycle.	Kim Chi, MD (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Gastrointestinal Cancer Management Guidelines - Small Bowel Malignancies	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2007 (date not stated).	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2,3,4</sup>	<b>BC Cancer Agency</b>	Breast Cancer Management Guidelines	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2016-Feb	3-5 year cycle. Multiple chapters updated independently.	Stephen K. L. Chia, MD, FRCPC (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Gynecology Cancer Management Guidelines - Uterine Cervix	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2008-Aug	3-5 year cycle.	Dianne Miller, MD, FRCSC (Chair)
<sup>2,4</sup>	<b>BC Cancer Agency</b>	Screening for cancer of the cervix: an office manual for health professionals	Primary	No	<a href="#">More Details ...</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2017-Jun	3-5 year cycle.	Dianne Miller, MD, FRCSC (Chair)
<sup>2,3</sup>	<b>BC Cancer Agency</b>	Colorectal screening for cancer prevention in asymptomatic patients	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2016-Jun	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)
<sup>2,3,4</sup>	<b>BC Cancer Agency</b>	Follow-up of colorectal polyps or cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2013-Jan	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Gastrointestinal Cancer Management Guidelines - Colon	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2012-Sep	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	<b>BC Cancer Agency</b>	Primary Unknown Cancer Management	Specialty	Yes	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2005-Aug	3-5 year cycle. Multiple chapters updated independently.	Dr. U. Lee Medical Oncology FVCC
<sup>2,3</sup>	<b>BC Cancer Agency</b>	Genital tract cancers in females : endometrial cancer	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2014-Jun	3-5 year cycle.	Dianne Miller, MD, FRCSC (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Gynecology Cancer Management Guideline - Endometrium	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2016-Jun	3-5 year cycle.	Dianne Miller, MD, FRCSC (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Gynecology Cancer Management Guidelines - Ovarian Epithelial Carcinoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2014-Jan	3-5 year cycle.	Dianne Miller, MD, FRCSC (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Gastrointestinal Cancer Management Guidelines - Gallbladder	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2006	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)
<sup>2</sup>	<b>BC Cancer Agency</b>	Upper gastrointestinal cancer (suspected): part 1	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2016-Apr	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)
<sup>2</sup>	<b>BC Cancer Agency</b>	Upper gastrointestinal cancer (suspected):	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee</a>	Guideline developed independently from any	No COI to disclose by	<b>Date:</b> 2016-Apr	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		part 2				<a href="#">Process Doc</a>	funding body.	authors.			
<sup>4</sup>	<b>BC Cancer Agency</b>	Head & Neck Cancer Management Guidelines	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols</a> <a href="#">Advisory Committee</a> <a href="#">Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2003-May	3-5 year cycle.	Chair, Dr. Jonn Wu, Radiation Oncology, VC
<sup>2,3</sup>	<b>BC Cancer Agency</b>	Genital tract cancers in females: human papillomavirus related cancers (cervical, vaginal & vulvar)	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guidelines &amp; Protocols</a> <a href="#">Advisory Committee</a> <a href="#">Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2016-July	3-5 year cycle.	Dianne Miller, MD, FRCSC (Chair)  The Family Practice Oncology Network
<sup>4</sup>	<b>BC Cancer Agency</b>	Genitourinary Cancer Management Guidelines - Kidney	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols</a> <a href="#">Advisory Committee</a> <a href="#">Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2007-Jul	3-5 year cycle.	Kim Chi, MD (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Lung Cancer Management Guidelines	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols</a> <a href="#">Advisory Committee</a> <a href="#">Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2013-Mar	3-5 year cycle.	Stephen Lam MD, FRCPC (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Melanoma Cancer Management Guidelines	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols</a> <a href="#">Advisory Committee</a> <a href="#">Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2013-Feb	3-5 year cycle.	Graeme Duncan, MB ChB FRCPC (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Non-Melanoma Cancer Management	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols</a> <a href="#">Advisory Committee</a>	Guideline developed independently from any	No COI to disclose by	<b>Date:</b> 2016-Sep	3-5 year cycle.	Graeme Duncan, MB ChB FRCPC (Chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Guidelines				<a href="#">Process Doc</a>	funding body.	authors.			
<sup>4</sup>	<b>BC Cancer Agency</b>	Musculoskeletal and Sarcoma Cancer Management Guidelines	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2005	3-5 year cycle.	Chair, Dr. P. Clarkson, Orthopedic Surgery, Vancouver
<sup>4</sup>	<b>BC Cancer Agency</b>	Gastrointestinal Cancer Management Guidelines - Neuroendocrine	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2013-July	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)
<sup>2,3</sup>	<b>BC Cancer Agency</b>	Genital tract cancers in females: ovarian, fallopian tube, and primary peritoneal cancers	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2014-Jun	3-5 year cycle.	Dianne Miller, MD, FRCSC (Chair)
<sup>2,4,11</sup>	<b>BC Cancer Agency</b>	Palliative care for the patient with incurable cancer or advanced disease - part 1: approach to care	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2017-Feb	3-5 year cycle.	The Family Practice Oncology Network
<sup>2,4,11</sup>	<b>BC Cancer Agency</b>	Palliative care for the patient with incurable cancer or advanced disease - part 2: pain and symptom management	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2017-Feb	3-5 year cycle.	The Family Practice Oncology Network

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2,4,11</sup>	<b>BC Cancer Agency</b>	Palliative care for the patient with incurable cancer or advanced disease - part 3: grief and bereavement	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2017-Feb	3-5 year cycle.	The Family Practice Oncology Network
<sup>4</sup>	<b>BC Cancer Agency</b>	Gastrointestinal Cancer Management Guidelines - Pancreas	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2013-Jun	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Gastrointestinal Cancer Management Guidelines - Rectum	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2012-Sep	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Gastrointestinal Cancer Management Guidelines - Stomach	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2013-Jan	3-5 year cycle.	Hagen F. Kennecke, MD, MHA, FRCPC (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Genitourinary Cancer Management Guidelines - Prostate	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2009-Aug	3-5 year cycle.	Kim Chi, MD (Chair)
<sup>4</sup>	<b>BC Cancer Agency</b>	Genitourinary Cancer Management Guidelines - Testis	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Guideline developed independently from any funding body.	No COI to disclose by authors.	<b>Date:</b> 2013-May	3-5 year cycle.	Kim Chi, MD (Chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	<b>C17 Children's Cancer &amp; Blood Disorders</b>  3-590B Edmonton Clinic Health Academy (ECHA) 11405 - 87 Avenue Edmonton, AB T6G 1C9	Guideline for platelet transfusion thresholds for pediatric hematology / oncology patients	Specialty	No	<a href="#">More Details..</a>	Followed ADAPTE process: <a href="http://www.adapte.org">www.adapte.org</a>	Canadian Partnership Against Cancer, Health Canada, C17(Council of Pediatric, Hematology/Oncology Centres across Canada)	No COI to disclose by authors.	Date: 2011-Mar	Bi-annual cycle..	Dorothy Barnard, MD
<sup>4</sup>	<b>Canadian Association of Gastroenterology</b>  1540 Cornwall Rd. Suite #224 Oakville, On L6J 7W5	Guidelines on colon cancer screening	Specialty	No	<a href="#">More Details..</a>	<a href="#">GRADE methodology</a>	Health Canada.	COI not disclosed by authors.	Date: 2004	Updated when approved by committee.	Desmond Leddin MB FRCPC
<sup>4</sup>	<b>Canadian Association of Psychosocial Oncology</b>  189 Queen Street East, Suite 1, Toronto, ON M5A 1S2	A Pan-Canadian Practice Guideline: Screening, Assessment and Care of Cancer-Related Fatigue in Adults with Cancer	Specialty	Yes	<a href="#">More Details..</a>	<a href="#">ADAPTE process</a>	Funding provided in part by Health Canada.	No COI to disclose by authors.	Date: 2011-Feb	4 year cycle; reviewed bi-annually.	D Howell RBC Chair Nursing Oncology and Education, Princess Margaret Cancer Care
<sup>4</sup>	<b>Canadian Association of</b>	A Pan-Canadian Clinical	Specialty	Yes	<a href="#">More Details..</a>	<a href="#">ADAPTE process</a>	Funding provided in part by Health	No COI to disclose	Date: 2009-May	4 year cycle; reviewed bi-	D Howell RBC Chair Nursing Oncology and Education, Princess Margaret Cancer

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	<b>Psychosocial Oncology</b>	Practice Guideline: Assessment of Psychosocial Health Care Needs of the Adult Cancer Patient			<a href="#">...</a>		Canada.	by authors.		annually.	Care
<sup>4</sup>	<b>Canadian Association of Psychosocial Oncology</b>	Pan-Canadian Guidance on Organization and Structure of Survivorship Services and Psychosocial-Supportive Care Best Practices for Adult Cancer Survivors.	Specialty	Yes	<a href="#">More Details..</a> <a href="#">...</a>	<a href="#">ADAPTE process</a>	Funding provided in part by Health Canada.	No COI to disclose by authors.	<b>Date:</b> 2011-Apr	4 year cycle; reviewed bi-annually.	D Howell RBC Chair Nursing Oncology and Education, Princess Margaret Cancer Care
<sup>2</sup>	<b>Canadian Association of Radiologists</b> 294 Albert St Suite 600, Ottawa, ON	CAR practice guidelines and technical standards for breast imaging and intervention	Specialty	No	<a href="#">More Details</a> <a href="#">...</a>	Consensus. Not stated.	Not stated.	Not stated.	<b>Date:</b> 2016-Sep	Cycle not indicated.	Chair, Shiela Appavoo, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Association of Radiologists</b>	<a href="#">Canadian Association of Radiologists: guide on CT screening for lung cancer</a>	Specialty	No	<a href="#">More Details ...</a>	Consensus. Not stated.	Not stated.	Not stated.	<b>Date:</b> 2017	Cycle not indicated.	Chair, Jana Taylor, MDcM
<sup>2</sup>	<b>Canadian Association of Radiologists</b>	<a href="#">CAR practice guidelines for performing ultrasound examinations of the prostate and surrounding structures</a>	Specialty	No	<a href="#">More Details ...</a>	Consensus. Not stated.	Not stated.	Not stated.	<b>Date:</b> 2013-Apr	Cycle not indicated.	Chair, Ants Toi, MD
<sup>2</sup>	<b>Canadian Cardiovascular Society</b> <i>222 Queen St, Ottawa, ON K1P 5V9</i>	Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">CCS Guideline Development Process</a>	CCS operating budget.	<a href="#">COI Statement</a>	<b>Date:</b> 2016-Jun	Updates determined by Guidelines Committee.	Sean A. Virani, MD
<sup>4</sup>	<b>Canadian College of Medical Geneticists</b> <i>4 Cataraqui Street, Suite 310, Kingston ON K7K1Z7</i>	Indications, analysis, and reporting of cancer specimens	Specialty	Yes	<a href="#">More Details..</a>	Expert opinion/literature review.	Not stated.	No COI to disclose by authors.	<b>Date:</b> 2011	Not indicated.	A.J. Dawson PhD
<sup>2</sup>	<b>Canadian Kidney Cancer Forum</b> <i>4936 Yonge</i>	Management of advanced kidney cancer	Specialty	No	<a href="#">More Details ...</a>	consensus	<a href="#">Corporate sponsorship.</a>	COI disclosed by authors.	<b>Date:</b> 2017-Oct	Annual cycle (based on Kidney Forum meetings).	M. Neil Reaume, MD, FRCPC, MSc <a href="mailto:nreame@toh.ca">nreame@toh.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Street, Suite 226 Toronto, ON M2N 6S3										
<sup>4,7</sup>	<b>Canadian Medical Association</b>  1867 Alta Vista Dr. Ottawa, ON K1G 5W8	Care and Treatment of Breast Cancer	Specialty	No	<a href="#">Details</a>	Steering Committee  <a href="#">General Methods</a>	Health Canada committee.	No COI to disclose by authors.	Date: 2005	2 year cycle	Dr. Mark Levine (Chair)
<sup>4</sup>	<b>Canadian Medical Association</b>	Follow-up after treatment for breast cancer	Specialty	No	<a href="#">More Details..</a>  ...	Steering Committee; systematic review	Health Canada committee.	No COI to disclose by authors.	Date: 2005	Cycle not indicated.	Dr. Mark Levine (Chair)
<sup>4</sup>	<b>Canadian Medical Association</b>	Locoregional post-mastectomy radiotherapy	Specialty	No	<a href="#">More Details..</a>  ...	Steering Committee; non-systematic review	Health Canada committee.	No COI to disclose by authors.	Date: 2004	Cycle not indicated.	Dr. Mark Levine (correspondence)
<sup>4</sup>	<b>Canadian Medical Association</b>	Treatment for women with stage III or locally advanced breast cancer	Specialty	No	<a href="#">More Details..</a>  ...	Steering Committee; non-systematic review	Health Canada committee.	No COI to disclose by authors.	Date: 2004	Cycle not indicated.	Dr. Mark Levine (correspondence)
<sup>2</sup>	<b>Canadian National Expert Group on Pancreatic Neuroendocrine Tumors</b>  2075 Bayview	Pancreatic neuroendocrine tumors	Specialty	Yes	<a href="#">More Details</a>  ...	Consensus.	Unrestricted grant Novartis.	No COI to disclose by authors.	Date: 2015-Aug	Cycle not indicated.	Simron Singh MD, MPH, FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Ave., Room T2-107, Toronto, ON										
<sup>2</sup>	<b>Canadian Partnership Against Cancer</b> <i>145 King Street West, Suite 900 Toronto ON M5H 1J8</i>	Reporting on histopathology specimens from the cervix and vagina	Specialty	No	<a href="#">More Details ...</a>	Consensus.	Health Canada	No COI to disclose by authors.	<b>Date:</b> 2013- May	Cycle not indicated.	Dr. Meg McLachlin (Chair, Pan Cdn Cervical Cancer Screening Initiative)
<sup>4</sup>	<b>Canadian Task Force on Preventativ e Health Care (CTFPHC)</b> <i>3280 Hospital Drive Northwest. Calgary, AB</i>	Recommendati ons on screening for breast cancer in average-risk women aged 40-74 years	Primary	No	<a href="#">More Details.. ...</a>	<a href="#">Procedure Manual</a>	PHAC and CIHR.	No COI to disclose by authors.	<b>Date:</b> 2011	Update: due 2018  Topic Selection Working Group to determine updates.	Marcello Tonelli, MD, SM, FRCPC
<sup>2,11</sup>	<b>Canadian Task Force on Preventativ e Health Care (CTFPHC)</b>	Recommendati ons on screening for cervical cancer	Primary	No	<a href="#">More Details.. ...</a>	<a href="#">Procedure Manual</a>	PHAC and CIHR.	No COI to disclose by authors.	<b>Date:</b> 2013-Jan	Update: due 2018  Topic Selection Working Group to determine updates.	James A. Dickinson, MBBS, PhD, CCFP, FRACGP
<sup>2,11</sup>	<b>Canadian Task Force on Preventativ e Health Care</b>	Recommendati ons on screening for colorectal cancer in	Primary	No	<a href="#">More Details ...</a>	<a href="#">Procedure Manual</a>	PHAC and CIHR.	No COI to disclose by authors.	<b>Date:</b> 2016- Feb	Update: due 2021  Topic Selection Working Group to determine	C. Maria Bacchus, MD, MSc, FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	(CTFPHC)	primary care								updates.	
2,11	<b>Canadian Task Force on Preventative Health Care (CTFPHC)</b>	Recommendations on screening for lung cancer	Primary	No	<a href="#">More Details... ...</a>	<a href="#">Procedure Manual</a>	PHAC and CIHR.	No COI to disclose by authors.	<b>Date:</b> 2016-Mar	Update: due 2021  Topic Selection Working Group to determine updates.	Gabriella A. Lewin, MD, CCFP
1,2,11	<b>Canadian Task Force on Preventative Health Care (CTFPHC)</b>	Canadian Task Force Prostate Cancer Screening Guideline	Primary	No	<a href="#">More Details... ...</a>	<a href="#">Procedure Manual</a>	PHAC and CIHR.	No COI to disclose by authors.	<b>Date:</b> 2014	Update: due 2019  Topic Selection Working Group to determine updates.	Neil Bell, MD, SM, CCFP, FCFP
<sup>4</sup>	<b>Canadian Thoracic Oncology Working Group</b>  699 Concession Street, Hamilton, ON	Biomarkers in the treatment of non-small cell lung cancer.	Specialty	No	<a href="#">More Details... ...</a>	Systematic Review / Consensus Meeting	Unrestricted educational grants: Eli Lilly, AstraZeneca, Hoffman La Roche, Amgen, Pfizer, Abraxis Biosciences, and Boehringer Ingelheim.	COI not disclosed by authors.	<b>Date:</b> 2011	Cycle not indicated.	Peter Ellis, MBBS, PhD <a href="mailto:peter.ellis@jcc.hhsc.ca">peter.ellis@jcc.hhsc.ca</a>
2,4	<b>Canadian Urological Association</b>  185 Dorval Avenue, Suite 401 Dorval, QC	Non-muscle invasive bladder cancer	Specialty	No	<a href="#">More Details... ...</a>	<a href="#">CUA Guideline methods</a>	Astellas, Pfizer, Bayer, Janssen, Sanofi.	COI disclosed by authors.	<b>Date:</b> 2015	5 year cycle.	Wassim Kassouf, MD, CM, FRCSC <a href="mailto:wassim.kassouf@muhc.mcgill.ca">wassim.kassouf@muhc.mcgill.ca</a>
<sup>4</sup>	<b>Canadian Urological</b>	Prostate cancer	Specialty	No	<a href="#">More Details... ...</a>	<a href="#">CUA Guideline</a>	Astellas, Pfizer, Bayer,	COI disclosed	<b>Date:</b> 2011	5 year cycle	Jonathan I. Izawa, MD,

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Association	screening			<a href="#">...</a>	<a href="#">methods</a>	Janssen, Sanofi.	d by authors.			FRCSC
<sup>2,4</sup>	<b>Canadian Urological Association</b>	Castration resistant prostate cancer (CRPC)	Specialty	No	<a href="#">More Details ...</a>	CUA Guideline <a href="#">methods</a>	No financial support	COI disclose d by authors.	<b>Date:</b> 2015-Apr	5 year cycle	Fred Saad, MD, FRCSC
<sup>2</sup>	<b>Canadian Urological Association</b>	Postoperative surveillance of upper urinary tract urothelial carcinoma	Specialty	No	<a href="#">More Details ...</a>	CUA Guideline <a href="#">methods</a>	Astellas, Pfizer, Bayer, Janssen, Sanofi.	COI disclose d by authors.	<b>Date:</b> 2013-Sep	5 year cycle	Anil Kapoor, MD, FRCSC
<sup>2</sup>	<b>Canadian Urological Association</b>	Small cell carcinoma of the bladder	Specialty	No	<a href="#">More Details ...</a>	CUA Guideline <a href="#">methods</a>	Astellas, Pfizer, Bayer, Janssen, Sanofi.	COI disclose d by authors.	<b>Date:</b> 2013-Jan	5 year cycle	Patricia Moretto, MD
<sup>2</sup>	<b>Cancer Care Manitoba</b>  675 McDermot Avenue Winnipeg, MB R3E 0V9	Canadian recommendations for breakthrough cancer pain	Specialty	Yes	<a href="#">More Details ...</a>	Consensus	Funding for consensus meeting Teva Canada Innovation.	COI disclose d by authors.	<b>Date:</b> 2016-Apr	Cycle not indicated.	P. Daeninck MD
<sup>4</sup>	<b>Cancer Care Nova Scotia</b>  1276 South Park St, Halifax, NS B3H 2Y9	Diagnosis and Referral of Suspected Lung Cancer	Primary	No	<a href="#">More Details.. ...</a>	Working group	No financial support	COI disclose d by authors.	<b>Date:</b> 2005	3 year cycle.	Dr. Drew Bethune
<sup>4</sup>	<b>Cancer Care Ontario</b>	Stem cell transplantation	Specialty	No	<a href="#">More Details.. ...</a>	<a href="#">Guideline development</a>	ON Min of Health.	COI disclose	<b>Date:</b> 2012-Mar	<a href="#">Document assessment/re</a>	Dr. Tom Kouroukis; Chair, Hematology Disease Site

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	620 <i>University Avenue</i> <i>Toronto, Ontario</i> <i>Canada M5 G 2L7</i>	in primary systemic amyloidosis			<a href="#">More Details..</a>	<a href="#">handbook.</a>	Editorially independent from its funding source.	d by authors.		<a href="#">view protocol.</a>	Group
<sup>4</sup>	Cancer Care Ontario	Squamous Cell Cancer of the Anal Canal	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Feb	<a href="#">Document assessment/review protocol.</a>	Dr. Rebecca Wong, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Adjuvant Chemotherapy Following Cystectomy in Patients with Deep Muscle-Invasive Transitional Cell Carcinoma of the Bladder	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Oct	<a href="#">Document assessment/review protocol.</a>	Dr. Christina Canil
<sup>4</sup>	Cancer Care Ontario	Neoadjuvant Chemotherapy in Transitional Cell Carcinoma of the Bladder	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Nov	<a href="#">Document assessment/review protocol.</a>	Dr. Christina Canil  *Guideline will no longer be updated
<sup>4</sup>	Cancer Care Ontario	Dose-intensive chemotherapy with growth factor or autologous bone marrow /	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Shailendra Verma, Chair, Sarcoma Disease Site Group  *Guideline will no longer be

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		stem cell transplant support in the first-line treatment of advanced or metastatic adult soft tissue sarcoma				source.			updated		
<sup>2</sup>	Cancer Care Ontario	Extra-corporeal photopheresis in graft-versus-host disease in patients who have received allogeneic blood or bone marrow transplants	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Aug	<a href="#">Document assessment/review protocol.</a>	Dr. Chris Bredeson
<sup>4</sup>	Cancer Care Ontario	Radiopharmaceuticals for the Palliation of Painful Bone Metastases	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. Glenn Bauman, Chair, Therapeutic Radiopharmaceutical Guidelines Group
<sup>4</sup>	Cancer Care Ontario	Radiotherapy Fractionation for The Palliation of Uncomplicated Painful Bone Metastases	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2003-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. Rebecca Wong, Co-Chair, Supportive Care Guidelines Group
<sup>4</sup>	Cancer Care Ontario	Zoledronic Acid for the Treatment of Bone Metastases Secondary to	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding	COI disclosed by authors.	Date: 2010-Jun	<a href="#">Document assessment/review protocol.</a>	Dr. Sebastien Hotte; Co-Chair, Genitourinary Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Renal Cell Carcinoma				source.			updated		
<sup>4</sup>	Cancer Care Ontario	Single Brain Metastases	Specialty	No	<a href="#">More Details.. »</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2012- Mar	<a href="#">Document assessment/re view protocol.</a>  *Guideline will no longer be updated	Dr. James Perry, Co-Chair, Neuro-oncology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	PET Imaging in Brain Cancer	Specialty	No	<a href="#">More Details.. »</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2009-Jan	<a href="#">Document assessment/re view protocol.</a>	Dr. Normand Laperriere
<sup>4</sup>	Cancer Care Ontario	Adjuvant Systemic Therapy for Node-Negative Breast Cancer	Specialty	No	<a href="#">More Details.. »</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2011- Sep	<a href="#">Document assessment/re view protocol.</a>  *Guideline will no longer be updated	Dr. Wendy Shelley; Co-chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Adjuvant Taxane Therapy for Women with Early-stage, Invasive Breast Cancer	Specialty	No	<a href="#">More Details.. »</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2011- Sep	<a href="#">Document assessment/re view protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Baseline Staging Tests in Primary Breast Cancer	Specialty	No	<a href="#">More Details.. »</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2011- Nov	<a href="#">Document assessment/re view protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Cancer Care Ontario	Breast cancer reconstruction surgery (immediate and delayed)	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. Toni Zhong
<sup>4</sup>	Cancer Care Ontario	Breast Irradiation in Women with Early Stage Invasive Breast Cancer Following Breast Conserving Surgery	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Capecitabine in Stage IV Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Clinical Utility of Multigene Profiling Assays in Invasive Early-Stage Breast Cancer	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Jun	<a href="#">Document assessment/review protocol.</a>	Dr. Martin Chang, Lead Author
<sup>4</sup>	Cancer Care Ontario	Diagnostic Imaging in Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Apr	<a href="#">Document assessment/review protocol.</a>	Dr. Bob Myers, Lead Author

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	Cancer Care Ontario	Docetaxel plus Cyclophosphamide as Adjuvant Therapy for Early, Operable Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2008-Apr	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Epirubicin, as a Single Agent or in Combination, for Metastatic Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Fulvestrant for Systemic Therapy of Locally Advanced or Metastatic Breast Cancer in Postmenopausal Women	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2008-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Hormone Receptor Testing in Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2017-May	<a href="#">Document assessment/review protocol.</a>  *Guideline not considered current	Dr. Wedad Hanna, Professor, Department of Laboratory Medicine and Pathobiology Faculty of Medicine, University of Toronto
<sup>2</sup>	Cancer Care Ontario	Locoregional therapy of locally advanced breast cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding	COI disclosed by authors.	Date: 2014-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		(LABC)					source.				
<sup>4</sup>	Cancer Care Ontario	Magnetic Resonance Imaging Screening of Women at High Risk for Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Aug	<a href="#">Document assessment/review protocol.</a>	Dr. Ellen Warner
<sup>2</sup>	Cancer Care Ontario	Optimal systemic therapy for early female breast cancer	Specialty	No	<a href="#">More Details ..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Sentinel Lymph Node Biopsy in Early-stage Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Jul	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Ralph George, MD FRCSC
<sup>4</sup>	Cancer Care Ontario	Surgical Management of Early-Stage Invasive Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2010-Jun	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Cancer									
<sup>4</sup>	Cancer Care Ontario	The Continued Use of Trastuzumab Beyond Disease Progression in Patients with Metastatic Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	The Prophylactic Use of Filgrastim in Patients with Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009-Oct	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Albumin-bound Paclitaxel (Abraxane) in the Treatment of Metastatic Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2007-Jun	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Caroline Hamm (Lead author)
<sup>4</sup>	Cancer Care Ontario	Aromatase Inhibitors in Adjuvant Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-May	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Aromatase Inhibitors in the Treatment of Postmenopaus	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent	COI disclosed by	Date: 2012-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		al Women with Metastatic Breast Cancer					from its funding source.	authors.		*Guideline will no longer be updated	
<sup>4</sup>	Cancer Care Ontario	Gemcitabine in Metastatic Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	HER2/neu in Systemic and Radiation Therapy for Women with Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-May	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Melissa Brouwers, Provincial Director, Program in Evidence-based Care
<sup>4</sup>	Cancer Care Ontario	Ductal Carcinoma in Situ of the Breast	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2006-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2007-May	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Susan Dent. MD FRCPC
<sup>4</sup>	Cancer Care Ontario	Taxanes in Neoadjuvant Chemotherapy for Women with Non-metastatic Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding	COI disclosed by authors.	Date: 2011	*Guideline will no longer be updated  <a href="#">Document assessment/re</a>	Susan Dent. MD FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
							source.		<a href="#">view protocol.</a>		
<sup>4</sup>	Cancer Care Ontario	Taxanes in Metastatic Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2010-Jun	<a href="#">Document assessment/review protocol.</a>	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Trastuzumab (Herceptin) in the Treatment of Women with HER2/neu-overexpressing Metastatic Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Trastuzumab in Adjuvant and Neoadjuvant Therapy in Women with HER2/neu-overexpressing Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2006-May	<a href="#">Document assessment/review protocol.</a>	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Bevacizumab in Metastatic Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009-Apr	<a href="#">Document assessment/review protocol.</a>	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4,11</sup>	Cancer Care Ontario	Adjuvant bisphosphonates and other bone-modifying agents in	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its	COI disclosed by authors.	Date: 2017 Jun	<a href="#">Document assessment/review protocol.</a>	Mark J. Clemons, The Ottawa Hospital Cancer Centre

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		breast cancer					funding source.				
<sup>4</sup>	Cancer Care Ontario	Vinorelbine in Stage IV Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Zoledronic Acid As Adjuvant Therapy In Combination With Adjuvant Endocrine Therapy for Premenopausal Women with Early-Stage Hormone Receptor Positive Breast Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2010-Jan	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Maureen Trudeau; Chair, Breast Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Provider Tools for Advance Care Planning and Goals of Care Discussions	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Jeff Myers, lead author
<sup>4</sup>	Cancer Care Ontario	Primary Treatment for Locally Advanced Cervical Cancer: Concurrent Platinum-based Chemotherapy	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Jun	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung Kee Fung, Chair, Gynecology Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		and Radiation									
<sup>4</sup>	Cancer Care Ontario	Cervical screening	Primary	Yes	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Oct	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung Kee Fung, Chair, Gynecology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Chemotherapy for Recurrent, Metastatic, or Persistent Cervical Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Nov	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung Kee Fung, Chair, Gynecology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Follow-up for Women after Treatment for Cervical Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-May	<a href="#">Document assessment/review protocol.</a>	Dr. Laurie Elit
<sup>4</sup>	Cancer Care Ontario	PET Imaging in Cervical Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. Anthony Fyles, Princess Margaret Hospital
<sup>2</sup>	Cancer Care Ontario	Systemic therapy for recurrent, metastatic, or persistent cervical cancer	Specialty	No	<a href="#">More Details....</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Nov	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung Kee Fung, Chair, Gynecology Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Cancer Care Ontario	Adjuvant systemic chemotherapy for stage II and III colon cancer following complete resection	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Brandon Meyers, Lead Author
<sup>2</sup>	Cancer Care Ontario	Colonoscopy quality assurance in Ontario	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Hans Messersmith, Assistant Director
<sup>2</sup>	Cancer Care Ontario	Continuous versus intermittent chemotherapy strategies in inoperable, advanced colorectal cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. Rebecca Wong, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Cross-Sectional Imaging in Colorectal Cancer	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Marko Simunovic
<sup>4</sup>	Cancer Care Ontario	Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. Craig Earle, Institute for Clinical Evaluative Sciences

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		cancer									
<sup>4</sup>	Cancer Care Ontario	Follow-up of Patients with Curatively Resected Colorectal Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. Jean Maroun, Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Gastroscopy Following a Positive Fecal Occult Blood Test and Negative Colonoscopy	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009-Mar	<a href="#">Document assessment/review protocol.</a> *Guideline will no longer be updated	Dr. Johane Allard, Department of Medicine, Division of Gastroenterology, University of Toronto
<sup>4</sup>	Cancer Care Ontario	Laparoscopic Surgery for Cancer of the Colon	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2005-Sep	<a href="#">Document assessment/review protocol.</a> *Guideline will no longer be updated	Dr. Andy Smith Toronto-Sunnybrook Hospital
<sup>4</sup>	Cancer Care Ontario	Oral Capecitabine (XelodaTM) in the First-line Treatment of Metastatic Colorectal Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a> *Guideline will no longer be updated	Dr. Jean Maroun, Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	PET imaging in colorectal cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2010-Nov	<a href="#">Document assessment/review protocol.</a>	Dr. Kelvin Chan, Sunnybrook Odette Cancer Centre

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	Cancer Care Ontario	Oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Jean Maroun, Chair, Gastrointestinal Cancer Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Strategies of sequential therapies in unresectable, metastatic colorectal cancer treated with palliative intent	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Feb	<a href="#">Document assessment/review protocol.</a>	Dr. Rebecca Wong, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Bevacizumab (AvastinTM) Combined with Chemotherapy in the Treatment of Patients With Advanced Colorectal Cancer	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Dec	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Jean Maroun, Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Epidermal Growth Factor Receptor Inhibitors in Advanced Colorectal Cancer	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2008-Jul	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Derek Jonker, author
<sup>4</sup>	Cancer Care Ontario	Irinotecan (Camptosar, CPT-11)	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development</a>	ON Min of Health. Editorially	COI disclosed by	Date: 2011-Sep	<a href="#">Document assessment/re</a>	Dr. Derek Jonker, author

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Combined with 5-Fluorouracil and Leucovorin (5FU/LV) as First-line Therapy for Metastatic Colorectal Cancer			<a href="#">More Details..</a>	<a href="#">handbook.</a>	independent from its funding source.	authors.		<a href="#">view protocol.</a>  *Guideline will no longer be updated	
<sup>4</sup>	Cancer Care Ontario	Irinotecan in the Second-Line Treatment of Metastatic Colorectal Carcinoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Jean Maroun, Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Raltitrexed (TomudexTM) in Metastatic Colorectal Carcinoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. James J. Biagi, Co-Chair, Gastrointestinal Cancer DSG Cancer Centre of Southeastern Ontario
<sup>2</sup>	Cancer Care Ontario	Safe handling of cytotoxics	Specialty	No	<a href="#">More Details .....</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Dec	<a href="#">Document assessment/review protocol.</a>	Dr. Susan Dent Ottawa Regional Cancer Centre
<sup>2,4</sup>	Cancer Care Ontario	Depression in cancer patients	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-May	<a href="#">Document assessment/review protocol.</a>	Madeline Li, MD, PhD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Cancer Care Ontario	Optimal treatment options and follow-up strategies in patients with desmoid tumours	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Nov	<a href="#">Document assessment/review protocol.</a>	Dr. Michelle Ghert, Orthopaedic Oncologist
<sup>4</sup>	Cancer Care Ontario	Octreotide in Patients with Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Jun	<a href="#">Document assessment/review protocol.</a>	Dr. Brent Zanke, Chair, Systemic Treatment Disease Site Group  *Guideline will no longer be updated
<sup>4</sup>	Cancer Care Ontario	Symptom Management Guide-to-Practice: Dyspnea	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012	<a href="#">Document assessment/review protocol.</a>	Dr. Rebecca Wong, Chair, Supportive Care Guidelines Group  *Guideline will no longer be updated
<sup>4</sup>	Cancer Care Ontario	5-HT3 Receptor-antagonists in Patients Receiving Moderately or Highly Emetogenic Chemotherapy	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2003-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. Brent Zanke, Chair, Systemic Treatment Disease Site Group  *Guideline will no longer be updated
<sup>4</sup>	Cancer Care Ontario	Adjuvant Radiotherapy in Women with Stage I Endometrial Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Aug	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung-Kee-Fung, Chair, Gynecology Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	Cancer Care Ontario	Follow-up after Primary Therapy for Endometrial Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2017-Jun	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung-Kee-Fung, Chair, Gynecology Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Adjuvant Hormonal Therapy in Stage I Endometrial Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2007-Oct	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung-Kee-Fung, Chair, Gynecology Cancer Disease Site Group  *Guideline will no longer be updated
<sup>4</sup>	Cancer Care Ontario	Systemic Therapy for Advanced or Recurrent Endometrial Cancer, and Advanced or Recurrent Uterine Papillary Serous Carcinoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2017-Jun	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung-Kee-Fung, Chair, Gynecology Cancer Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Systemic therapy for recurrent epithelial ovarian cancer	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2017-Jul	<a href="#">Document assessment/review protocol.</a>	Dr. Julie Francis, lead author
<sup>4</sup>	Cancer Care Ontario	First-line Chemotherapy for Postoperative Patients with Stage II, II or IV	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding	COI disclosed by authors.	Date: 2013-Jul	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung-Kee-Fung, Chair, Gynecology Cancer Disease Site Group  *Guideline will no longer be

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer				source.			updated		
<sup>2</sup>	Cancer Care Ontario	Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, and epithelial ovarian cancer	Specialty	No	<a href="#">More Details... ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Nov	<a href="#">Document assessment/review protocol.</a>	Dr. Tien Le, Lead Author
<sup>4</sup>	Cancer Care Ontario	Combined Modality Radiotherapy and Chemotherapy in the Non-surgical Management of Localized Carcinoma of the Esophagus	Specialty	No	<a href="#">More Details... ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Oct	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Jean Maroun, Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Porfimer Sodium (PhotofrinTM) in the Ablation of High-Grade Dysplasia Associated with Barrett's Esophagus	Specialty	Yes	<a href="#">More Details... ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2006-Jan	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Jean Maroun, Chair, Gastrointestinal Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	Cancer Care Ontario	Porfimer Sodium (PhotofrinTM) in the Palliative Treatment of Esophageal Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2006-Jan	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Jean Maroun, Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	PET Imaging in esophageal cancer.	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2010-Nov	<a href="#">Document assessment/review protocol.</a>	Dr. Rebecca Wong, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Neoadjuvant or adjuvant therapy for resectable esophageal cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2004-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Rebecca Wong, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Preoperative or Postoperative Therapy for Resectable Esophageal Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Aug	<a href="#">Document assessment/review protocol.</a>	Dr. Rebecca Wong, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Optimal treatment strategies for localized Ewing's sarcoma of bone after neoadjuvant chemotherapy	Specialty	No	<a href="#">More Details ....</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Dec	<a href="#">Document assessment/review protocol.</a>	Dr. Shailendra Verma, Medical Oncologist, Lead Author

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Cancer Care Ontario	Exercise for people with cancer	Primary and Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Jun	<a href="#">Document assessment/review protocol.</a> <a href="#">Document assessment/review protocol.</a>	Dr. Roanne Segal, lead author
<sup>2</sup>	Cancer Care Ontario	Approach to fever assessment in ambulatory cancer patients receiving chemotherapy	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Nov	<a href="#">Document assessment/review protocol.</a> <a href="#">Document assessment/review protocol.</a>	Dr. M.K. Krzyzanowska, lead author
<sup>4</sup>	Cancer Care Ontario	Gemcitabine in the Treatment of Cholangiocarcinoma and Gallbladder Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2005-Jun	<a href="#">Document assessment/review protocol.</a> *Guideline will no longer be updated	Dr. M. Brouwers, Lead Author
<sup>4</sup>	Cancer Care Ontario	Neoadjuvant or Adjuvant Therapy for Resectable Gastric Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Apr	<a href="#">Document assessment/review protocol.</a>	Dr. Rebecca Wong, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Systemic Therapy for Advanced Gastric Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-May	<a href="#">Document assessment/review protocol.</a>	Dr. Jim Biagi, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Sequence variants in hereditary	Specialty	Yes	<a href="#">More Details</a>	<a href="#">Guideline development</a>	ON Min of Health. Editorially	COI disclosed by	Date: 2017-Aug	<a href="#">Document assessment/re</a>	Dr. Harriet Feilotter

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		cancers guideline			<a href="#">...</a>	<a href="#">handbook.</a>	independent from its funding source.	authors.		<a href="#">view protocol.</a>	
<sup>4</sup>	Cancer Care Ontario	Temozolomide Monotherapy for the Treatment of Patients with Glioblastoma That Has Relapsed or Progressed Following Prior Therapy	Specialty	No	<a href="#">More Details.. »</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2011- Mar	<a href="#">Document assessment/re view protocol.</a>  *Guideline will no longer be updated	Dr. James Perry; Co-Chair, Neuro-oncology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Bevacizumab for the Treatment of Patients with Glioblastoma Multiforme That Has Relapsed or Progressed Following Prior Therapy	Specialty	No	<a href="#">More Details.. »</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2010	<a href="#">Document assessment/re view protocol.</a>  *Guideline will no longer be updated	Dr. James Perry; Co-Chair, Neuro-oncology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Gliadel ® Wafers in the Treatment of Malignant Glioma	Specialty	No	<a href="#">More Details.. »</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2013- Mar	<a href="#">Document assessment/re view protocol.</a>  *Guideline will no longer be updated	Dr. James Perry; Co-Chair, Neuro-oncology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Adjuvant Systemic Chemotherapy, Following Surgery and External Beam Radiotherapy,	Specialty	No	<a href="#">More Details.. »</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding	COI disclose d by authors.	Date: 2013- Nov	<a href="#">Document assessment/re view protocol.</a>  *Guideline will no longer be	Dr. James Perry; Co-Chair, Neuro-oncology Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		for Adults with Newly Diagnosed Malignant Glioma					source.			updated	
<sup>4</sup>	Cancer Care Ontario	Endolaryngeal surgery (with or without laser) versus radiotherapy in early (T1) glottic cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. Ralph Gilbert, Chair, Head and Neck Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Epidermal Growth Factor Receptor (EGFR) Targeted Therapy in Stage III and IV Head and Neck Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. Ralph Gilbert, Chair, Head and Neck Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	PET imaging in head and neck cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012	<a href="#">Document assessment/review protocol.</a>	Dr. John Yoo, Lead Author
<sup>4</sup>	Cancer Care Ontario	Symptomatic Treatment of Radiation-Induced Xerostomia in Head and Neck Cancer Patients	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2004-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. Ralph Gilbert, Chair, Head and Neck Cancer Disease Site Group
<sup>2</sup>	Cancer Care	Systemic therapy in the	Specialty	No	<a href="#">More Details</a>	<a href="#">Guideline development</a>	ON Min of Health.	COI disclosed	Date: 2016-	<a href="#">Document assessment/re</a>	Dr. Eric Winquist, Lead

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Ontario	curative treatment of head and neck squamous cell cancer			<a href="#">...</a>	<a href="#">handbook.</a>	Editorially independent from its funding source.	d by authors.	Aug	<a href="#">view protocol.</a>	Author
<sup>4</sup>	Cancer Care Ontario	Head and Neck Cancer	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009-Dec	<a href="#">Document assessment/review protocol.</a>	Dr. Ralph Gilbert, Chair, Head and Neck Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Amifostine as a Radioprotectant in Patients with Squamous Cell Head and Neck Cancer	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Apr	<a href="#">Document assessment/review protocol.</a>	Dr. Ralph Gilbert, Chair, Head and Neck Cancer Disease Site Group  *Guideline will no longer be updated
<sup>4</sup>	Cancer Care Ontario	Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Excluding Nasopharynx)	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Apr	<a href="#">Document assessment/review protocol.</a>	Dr. Ralph Gilbert, Chair, Head and Neck Cancer Disease Site Group  *Guideline will no longer be updated
<sup>4</sup>	Cancer Care Ontario	Post-operative Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2005-Feb	<a href="#">Document assessment/review protocol.</a>	Dr. Ralph Gilbert, Chair, Head and Neck Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	Cancer Care Ontario	Prophylactic Use of Filgrastim in Patients with Hematological Malignancies	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. C. Tom Kouroukis; Co-Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Amifostine to Ameliorate the Toxic Effects of Chemotherapy in the Treatment of Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-May	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Brent Zanke, Chair, Systemic Treatment Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Sorafenib for Advanced Hepatocellular Carcinoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2008-Feb	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Kelvin Chan, Lead Author
<sup>2</sup>	Cancer Care Ontario	Early-stage Hodgkin lymphoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Dec	<a href="#">Document assessment/review protocol.</a>	Dr. Matt Cheung, senior author
<sup>2</sup>	Cancer Care Ontario	Routine HPV testing in head and neck squamous cell carcinoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-May	<a href="#">Document assessment/review protocol.</a>	Dr. Ralph Gilbert, Chair, Head and Neck Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Self-collected Samples for Testing of	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development</a>	ON Min of Health. Editorially	COI disclosed by	Date: 2006-Apr	<a href="#">Document assessment/re</a>	Verna Mai; Chair, Screening Guidelines Steering

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Oncogenic Human Papillomavirus			<a href="#">+</a>	<a href="#">handbook.</a>	independent from its funding source.	authors.		<a href="#">view protocol.</a>  *Guideline will no longer be updated	Committee
<sup>4</sup>	Cancer Care Ontario	Liposomal Anthracyclines in Patients with HIV-positive Kaposi's Sarcoma	Specialty	No	<a href="#">More Details..</a> <a href="#">+</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Jun	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Brent Zanke, Chair, Systemic Treatment Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Alemtuzumab for the Treatment of T-cell Prolymphocytic Leukemia	Specialty	No	<a href="#">More Details..</a> <a href="#">+</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2007-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Alemtuzumab in Chronic Lymphocytic Leukemia	Specialty	No	<a href="#">More Details..</a> <a href="#">+</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Feb	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Dasatinib for the Treatment of Imatinib-Resistant or-Intolerant Chronic Myeloid Leukemia	Specialty	No	<a href="#">More Details..</a> <a href="#">+</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Jan	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Stem cell transplantation in myelodysplastic	Specialty	No	<a href="#">More Details..</a> <a href="#">+</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent	COI disclosed by	Date: 2012-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. Tom Kouroukis; Chair, Hematology Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		c syndromes and acute myeloid leukemia					from its funding source.	authors.			
<sup>2</sup>	Cancer Care Ontario	Stem cell transplantation in the treatment of acute lymphoblastic leukemia	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2016- Feb	<a href="#">Document assessment/re view protocol.</a>	Dr. Tom Kouroukis; Chair, Hematology Disease Site Group
<sup>2</sup>	Cancer Care Ontario	The prognostic value of the DNMT3A biomarker in cytogenetically normal patients with acute myeloid leukemia	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2013- Nov	<a href="#">Document assessment/re view protocol.</a>	Dr. Melissa Brouwers, Provincial Director, Program in Evidence-based Care
<sup>4</sup>	Cancer Care Ontario	Imatinib Mesylate (Gleevec) in Patients with Philadelphia Chromosome- positive Acute Lymphoblastic Leukemia	Specialty	No	<a href="#">More Details.. -</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2008- Sep	<a href="#">Document assessment/re view protocol.</a>  *Guideline will no longer be updated	Dr. Tom Kouroukis; Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Treatment of Acute Myeloid Leukemia in Older Patients	Specialty	No	<a href="#">More Details.. -</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2008- Dec	<a href="#">Document assessment/re view protocol.</a>  *Guideline will no longer be updated	Dr. Tom Kouroukis; Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care	Treatment of Chronic	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development</a>	ON Min of Health.	COI disclose	Date: 2013-	<a href="#">Document assessment/re</a>	Dr. Tom Kouroukis; Chair, Hematology Disease Site

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Ontario	Myeloid Leukemia with Imatinib			<a href="#">+</a>	<a href="#">handbook.</a>	Editorially independent from its funding source.	d by authors.	Dec	<a href="#">view protocol.</a>  *Guideline will no longer be updated	Group
<sup>2</sup>	Cancer Care Ontario	Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non- small-cell lung cancers	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2017- Apr	<a href="#">Document assessment/re view protocol.</a>	Frances A. Shepherd, Princess Margaret Cancer Centre
<sup>4</sup>	Cancer Care Ontario	Chemotherapy for Relapsed Small Cell Lung Cancer	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2013- May	<a href="#">Document assessment/re view protocol.</a>	Dr. Susanna Cheng. Lead Author
<sup>4</sup>	Cancer Care Ontario	Cross- Sectional Diagnostic Imaging in Lung Cancer	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2012-Apr	<a href="#">Document assessment/re view protocol.</a>  *Guideline will no longer be updated	Narinder Paul, radiology clinical lead
<sup>4</sup>	Cancer Care Ontario	Systemic Treatment of Advanced Non- Small Cell Lung Cancer	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclose d by authors.	Date: 2016- Nov	<a href="#">Document assessment/re view protocol.</a>	Dr. P. Ellis, lead author

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Cancer Care Ontario	Follow-up and surveillance of curatively treated lung cancer patients	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Aug	<a href="#">Document assessment/review protocol.</a>	Dr. Yee Ung, Lead Author
<sup>4</sup>	Cancer Care Ontario	Treatment of Patients with Stage III (N2 or N3) Non-Small Cell Lung Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2017-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. A. Swaminath, Lead Author
<sup>4</sup>	Cancer Care Ontario	Pemetrexed Monotherapy for the Maintenance Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Non-Squamous Histology	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Jan	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	PET Imaging in Small Cell Lung Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Postoperative Adjuvant Chemotherapy in Completely Resected Non-	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its	COI disclosed by authors.	Date: 2007-Dec	<a href="#">Document assessment/review protocol.</a>  *Guideline will	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Small Cell Lung Cancer: Guidance for Nurses					funding source.			no longer be updated	
<sup>4</sup>	Cancer Care Ontario	Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and Thoracic Radiotherapy and First-Line Chemotherapy	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2017-Oct	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Prophylactic Cranial Irradiation in Small Cell Lung Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2003-Nov	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Referral of Suspected Lung Cancer by Family Physicians and Other Primary Care Providers	Primary	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Aug	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Screening high-risk populations for lung cancer	Primary and Secondary	Yes	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Sept	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>4</sup>	Cancer Care	Second line or Subsequent	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development</a>	ON Min of Health.	COI disclosed	Date: 2012-Oct	<a href="#">Document assessment/re</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Ontario	Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer			<a href="#">+</a>	<a href="#">handbook.</a>	Editorially independent from its funding source.	d by authors.		<a href="#">view protocol.</a>  *Guideline will no longer be updated	Group
<sup>4</sup>	Cancer Care Ontario	High Dose Rate Brachytherapy in the Palliation of Patients with Non-small Cell Lung Cancer	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-May	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	IMRT in Lung Cancer	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2010-Nov	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Andrea Bezjak, Professor, Department of Radiation Oncology
<sup>4</sup>	Cancer Care Ontario	Photodynamic Therapy (PDT) in Patients with Non-Small Cell Lung Cancer	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Systemic treatment in the maintenance of patients with non-small cell lung Cancer	Specialty	No	<a href="#">More Details... ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Aug	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Treatment of patients with stage III (N2 or N3) non-small	Specialty	No	<a href="#">More Details... ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent	COI disclosed by	Date: 2017-Sept	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		cell lung cancer					from its funding source.	authors.			
<sup>2,4</sup>	<b>Cancer Care Ontario</b>	Epidermal growth factor receptor inhibitors, Gefitinib (Iressa®) Erlotinib (Tarceva®), Afatinib, Dacomitinib or Icotinib in non-small cell lung cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	<b>Date:</b> 2014-Apr	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>4</sup>	<b>Cancer Care Ontario</b>	PET Imaging in Lymphoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	<b>Date:</b> 2015-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. C. Tom Kouroukis, McMaster, Dept of Oncology
<sup>4</sup>	<b>Cancer Care Ontario</b>	Ibrutumomab Tiuxetan in Lymphoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	<b>Date:</b> 2013-Nov	<a href="#">Document assessment/review protocol.</a>	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group  *Guideline will no longer be updated
<sup>4</sup>	<b>Cancer Care Ontario</b>	Iodine-131 Tositumomab in Lymphoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	<b>Date:</b> 2007-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group  *Guideline will no longer be updated

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2,4</sup>	Cancer Care Ontario	Rituximab in lymphoma and chronic lymphocytic leukemia	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Colony-Stimulating Factor (CSF) in Patients Receiving Myelosuppressive Chemotherapy for the Treatment of Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-May	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Brent Zanke, Chair, Systemic Treatment Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Chemotherapy and Growth Factors in Older Patients with Newly Diagnosed, Advanced-Stage, Aggressive Histology Non-Hodgkin's Lymphoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Jun	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Follow-up of patients with cutaneous melanoma who were treated with curative intent	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Nov	<a href="#">Document assessment/review protocol.</a>	Sudha Rajagopal, lead author
<sup>4</sup>	Cancer Care	PET Imaging in	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development</a>	ON Min of Health.	COI disclosed	Date: 2009-Jan	<a href="#">Document assessment/re</a>	Dr. Teresa Petrella, Medical Oncologist, Odette Cancer

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Ontario	Melanoma			<a href="#">+</a>	<a href="#">handbook.</a>	Editorially independent from its funding source.	d by authors.		<a href="#">view protocol.</a>	Centre
<sup>4</sup>	Cancer Care Ontario	Screening for Skin Cancer	Primary	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2007-Jun	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Verna Mai; Chair, Screening Guidelines Steering Committee
<sup>4</sup>	Cancer Care Ontario	Single-Agent Interleukin-2 in the Treatment of Metastatic Melanoma	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Shail Verma, Co-Chair, Melanoma Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Surgical management of patients with lymph node metastases from cutaneous melanoma of the trunk or extremities	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Oct	<a href="#">Document assessment/review protocol.</a>	Dr. Shail Verma, Co-Chair, Melanoma Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2017-Dec	<a href="#">Document assessment/review protocol.</a>	Dr. Shail Verma, Co-Chair, Melanoma Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Temozolomide for the Treatment of	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development</a>	ON Min of Health. Editorially	COI disclosed by	Date: 2011-Sep	<a href="#">Document assessment/re</a>	Dr. Shailesh Verma, Co-Chair, Melanoma Disease

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Metastatic Melanoma			<a href="#">+</a>	<a href="#">handbook.</a>	independent from its funding source.	authors.		<a href="#">view protocol.</a>  *Guideline will no longer be updated	Site Group
<sup>2</sup>	<b>Cancer Care Ontario</b>	Adjuvant radiation therapy for curatively resected cutaneous melanoma	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Jan	<a href="#">Document assessment/review protocol.</a>	Alex Sun, lead author
<sup>2</sup>	<b>Cancer Care Ontario</b>	Indoor tanning devices and the risk of developing cutaneous malignant melanoma	Primary and Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Aug	<a href="#">Document assessment/review protocol.</a>	Elaine McWhirter, lead author
<sup>4</sup>	<b>Cancer Care Ontario</b>	Biochemotherapy for the Treatment of Metastatic Malignant Melanoma	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Shailendra Verma, Co-Chair, Melanoma Disease Site Group
<sup>4</sup>	<b>Cancer Care Ontario</b>	Radiation Therapy in Malignant Pleural Mesothelioma	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-May	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>4</sup>	<b>Cancer Care Ontario</b>	Chemotherapy in Patients with Advanced Malignant Pleural	Specialty	No	<a href="#">More Details... +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its	COI disclosed by authors.	Date: 2012-Nov	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Mesothelioma					funding source.				
<sup>4</sup>	Cancer Care Ontario	Surgical Management of Malignant Pleural Mesothelioma	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-May	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>2,4</sup>	Cancer Care Ontario	Bortezomib in multiple myeloma and lymphoma	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Jun	<a href="#">Document assessment/review protocol.</a>	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Optimal Therapy for Patients Diagnosed with Multiple Myeloma and High-Dose Chemotherapy and Stem Cell Support	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Stem cell transplantation in multiple myeloma	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. Tom Kouroukis; Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Thalidomide in Multiple Myeloma	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its	COI disclosed by authors.	Date: 2010-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
							funding source.			no longer be updated	
<sup>4</sup>	Cancer Care Ontario	Bisphosphonates in skeletal complications for patients with multiple myeloma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Oct	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Chemotherapy with Radiotherapy for Nasopharyngeal Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-May	<a href="#">Document assessment/review protocol.</a>	Dr. Ralph Gilbert, Chair, Head and Neck Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Radionuclide Therapy for Neuroendocrine Malignancies	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Aug	<a href="#">Document assessment/review protocol.</a>	Dr. Karen Y. Gulenchyn, Clinical Associate Professor Radiology & Medicine, McMaster University
<sup>4</sup>	Cancer Care Ontario	Neurokinin-1 Receptor Antagonists in the Prevention of Emesis due to High-dose Cisplatin	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2005-Apr	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Brent Zanke, Chair, Systemic Treatment Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Adjuvant Care for Stage I Ovarian Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-May	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung-Kee-Fung, Chair, Gynecology Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	Cancer Care Ontario	PET Imaging in Ovarian Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. Michel Prefontaine, London Health Sciences Centre
<sup>4</sup>	Cancer Care Ontario	Management of a suspicious adnexal mass	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung-Kee-Fung, Chair, Gynecology Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Intraperitoneal Chemotherapy in the First-line Treatment of Women with Stage III Epithelial Ovarian Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Jun	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Michael Fung-Kee-Fung, Chair, Gynecology Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Hyperbaric Oxygen Therapy for the Treatment and Prevention of Radionecrosis and Other Radiation-Induced Injuries in Cancer Patients	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Jul	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Melissa Brouwers, Director, Program in Evidence-based Care
<sup>4</sup>	Cancer Care Ontario	Cancer-related Pain Management	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its	COI disclosed by authors.	Date: 2008-Mar	<a href="#">Document assessment/review protocol.</a>  *Guideline will	Esther Green, Chair, Cancer-related Pain Management Working Panel

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
							funding source.			no longer be updated	
<sup>4</sup>	Cancer Care Ontario	Intraspinal Techniques for Pain Management in Cancer Patients	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009-May	<a href="#">Document assessment/review protocol.</a> *Guideline will no longer be updated	Dr. Jeff Myers, Head, Palliative Care Consult Team, Odette Cancer Centre
<sup>4</sup>	Cancer Care Ontario	Gabapentin and Tricyclic Antidepressants in the Treatment of Neuropathic Pain in Cancer Patients	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2006-Oct	<a href="#">Document assessment/review protocol.</a> *Guideline will no longer be updated	Melissa Brouwers, Director, Program in Evidence-based Care
<sup>2</sup>	Cancer Care Ontario	Guidelines for palliative care	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Jul	<a href="#">Document assessment/review protocol.</a>	Dr. N. Coakley, Corresponding Author
<sup>4</sup>	Cancer Care Ontario	Chemotherapy or Radiotherapy for Resectable Pancreatic Adenocarcinoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Oct	<a href="#">Document assessment/review protocol.</a> *Guideline will no longer be updated	Dr. Rebecca Wong, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	PET Imaging in Pancreatic Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding	COI disclosed by authors.	Date: 2009-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. Sindu Kanjeekal, Windsor Regional Cancer Centre

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
						source.					
<sup>4</sup>	Cancer Care Ontario	Locally Advanced Pancreatic Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Jan	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Rebecca Wong, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Folfirinox as first-line treatment for metastatic pancreatic Adenocarcinoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Jun	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Rebecca Wong, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Gemcitabine in the Treatment of Advanced Pancreatic Adenocarcinoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Rebecca Wong, Co-Chair, Gastrointestinal Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Adjuvant Radiotherapy Following Radical Prostatectomy for Pathologic T3 or Margin-Positive Prostate Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-May	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew洛blaw, Chair, Genitourinary Cancer Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Active surveillance for localized prostate cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding	COI disclosed by authors.	Date: 2014-Dec	<a href="#">Document assessment/review protocol.</a>	Dr. Chris Morash, author

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
						source.					
<sup>2</sup>	<b>Cancer Care Ontario</b>	Bone health and bone-targeted therapies for prostate cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Sept	<a href="#">Document assessment/review protocol.</a>	Dr. S. Alibhai, author
<sup>11</sup>	<b>Cancer Care Ontario</b>	Brachytherapy for patients with prostate cancer.	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2017 Mar	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew洛布, Chair, Genitourinary Cancer Disease Site Group
<sup>2</sup>	<b>Cancer Care Ontario</b>	Low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-Oct	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew洛布, Chair, Genitourinary Cancer Disease Site Group
<sup>2</sup>	<b>Cancer Care Ontario</b>	<u>Multiparametric magnetic resonance imaging in the diagnosis of prostate cancer</u>	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Aug	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew洛布, Chair, Genitourinary Cancer Disease Site Group
<sup>2</sup>	<b>Cancer Care Ontario</b>	Follow-up care and psychosocial needs of survivors of prostate cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-June	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew洛布, Chair, Genitourinary Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	Cancer Care Ontario	Surgical and Pathological Quality Performance in Radical Prostatectomy in Prostate Cancer	Specialty	No	<a href="#">More Details.. ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2017-Oct	<a href="#">Document assessment/review protocol.</a>	Dr. Joseph Chin, Chair Expert Panel on Prostate Cancer Surgery and Pathology
<sup>2</sup>	Cancer Care Ontario	Referral of patients with suspected prostate cancer by family physicians and other primary care providers	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2016-Dec	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew Loblaw, Chair, Genitourinary Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	High-intensity Focused Ultrasound for Prostate Cancer	Specialty	No	<a href="#">More Details.. ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009-Jul	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew Loblaw, Chair, Genitourinary Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer	Specialty	No	<a href="#">More Details.. ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Nov	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Andrew Loblaw, Chair, Genitourinary Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Cancer Care Ontario	Multiparametric magnetic resonance imaging for pre-treatment local staging of prostate cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	<b>Date:</b> 2016-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. M. Haider, Author
<sup>2</sup>	Cancer Care Ontario	Multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	<b>Date:</b> 2015-Aug	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew洛布, Chair, Genitourinary Cancer Disease Site Group
<sup>2,11</sup>	Cancer Care Ontario	Systemic therapy in men with metastatic castration-resistant prostate cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	<b>Date:</b> 2014-Oct	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew洛布, Chair, Genitourinary Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Bisphosphonates in Men with Hormone-Refractory Prostate Cancer	Specialty	No	<a href="#">More Details.. -</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	<b>Date:</b> 2012-Jun	<a href="#">Document assessment/review protocol.</a> *Guideline will no longer be updated	Dr. Andrew洛布, Chair, Genitourinary Cancer Disease Site Group
<sup>2,4</sup>	Cancer Care Ontario	Optimization of preoperative assessment in patients diagnosed with rectal cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	<b>Date:</b> 2014-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. Erin Kennedy, General Surgeon, Mount Sinai Hospital
<sup>4</sup>	Cancer Care Ontario	Preoperative or Postoperative Therapy for	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development</a>	ON Min of Health. Editorially	COI disclosed by	<b>Date:</b> 2013-Nov	<a href="#">Document assessment/re</a>	Dr. Rebecca Wong, Co-Chair, Gastrointestinal

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Patients with Stage II or III Rectal Cancer			<a href="#">+</a>	<a href="#">handbook.</a>	independent from its funding source.	authors.		<a href="#">view protocol.</a>	Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Interferon-alfa in the Treatment of Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Apr	<a href="#">Document assessment/review protocol.</a> *Guideline will no longer be updated	Dr. Andrew Loblaw, Chair, Genitourinary Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Interleukin-2 in the Treatment of Patients with Unresectable or Metastatic Renal Cell Cancer	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a> *Guideline will no longer be updated	Dr. Andrew Loblaw, Chair, Genitourinary Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2012-May	<a href="#">Document assessment/review protocol.</a> *Guideline will no longer be updated	Dr. Andrew Loblaw, Chair, Genitourinary Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer	Specialty	No	<a href="#">More Details.. +</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Dec	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew Loblaw, Chair, Genitourinary Cancer Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Cancer Care Ontario	Targeted therapies in patients with inoperable locally advanced or metastatic renal cell cancer	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2017-May	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew Loblaw, Chair, Genitourinary Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	The Prevention and Management of Acute Skin Reactions Related to Radiation Therapy	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2005-Feb	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Melissa Brouwers, Provincial Director, Program in Evidence-based Care
<sup>4</sup>	Cancer Care Ontario	Hyperfractionated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2003-Jan	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Ralph Gilbert, Chair, Head and Neck Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Imatinib Mesylate (GleevecTM) for the Treatment of Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumours	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-May	<a href="#">Document assessment/review protocol.</a>	Dr. Shailendra Verma, Chair, Sarcoma Disease Site Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	Cancer Care Ontario	Imatinib Mesylate in the Adjuvant Treatment of Gastrointestinal Stromal Tumours	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2010-Mar	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Shailendra Verma, Chair, Sarcoma Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Sunitinib Malate for Gastrointestinal Stromal Tumour (GIST) in Imatinib Mesylate Resistant Patients	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Oct	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Shailendra Verma, Chair, Sarcoma Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Management of Stage I Nonseminomatous Testicular Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2008-Feb	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Andrew Loblaw, Chair, Genitourinary Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Management of Stage I Seminoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Mar	<a href="#">Document assessment/review protocol.</a>	Dr. Andrew Loblaw, Chair, Genitourinary Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	PET Imaging in Testicular Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2009-Jan	<a href="#">Document assessment/review protocol.</a>	Dr. Peter Chung, Princess Margaret Hospital

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	Cancer Care Ontario	Malignant Thrombocytosis in Philadelphia Chromosome-Negative Myeloproliferative Disease	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2008-Jan	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. K. Imrie, Co-Chair, Hematology Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Thymoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Aug	<a href="#">Document assessment/review protocol.</a>	Dr. Yee C. Ung; Co-Chair, Lung Cancer Disease Site Group
<sup>4</sup>	Cancer Care Ontario	I-131 Remnant Ablation after Thyroidectomy for Papillary or Follicular Thyroid Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2005-Jul	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Glenn Bauman, Chair, Therapeutic Radiopharmaceutical Guidelines Group
<sup>4</sup>	Cancer Care Ontario	Recombinant Humanized Thyroid Stimulating Hormone (rhTSH) Preparation Prior to Radioiodine Ablation in Patients Who Have Undergone Thyroidectomy for Papillary or Follicular Thyroid Cancer	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2007-May	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. John Yoo, Author

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>4</sup>	Cancer Care Ontario	Adjuvant Chemotherapy Following Complete Resection of Soft Tissue Sarcoma in Adults	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Oct	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Shailendra Verma, Chair, Sarcoma Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Doxorubicin-Based Chemotherapy for the Palliative Treatment of Adult Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-Oct	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Shailendra Verma, Chair, Sarcoma Disease Site Group
<sup>4</sup>	Cancer Care Ontario	Ifosfamid-based Combination Chemotherapy in Advanced Soft Tissue Sarcoma	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2011-Sep	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Shailendra Verma, Chair, Sarcoma Disease Site Group
<sup>2</sup>	Cancer Care Ontario	Surgical margins and handling of soft-tissue sarcoma in extremities	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-Oct	<a href="#">Document assessment/review protocol.</a>  *Guideline will no longer be updated	Dr. Shailendra Verma, Chair, Sarcoma Disease Site Group
<sup>4</sup>	Cancer Care Ontario	IMRT in Soft-Tissue Sarcomas	Specialty	No	<a href="#">More Details..</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its	COI disclosed by authors.	Date: 2010-Oct	<a href="#">Document assessment/review protocol.</a>  *Guideline will	Dr. Charles Catton, Associate Professor Department of Radiation Oncology - University of Toronto

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
						funding source.			no longer be updated		
<sup>2</sup>	<b>Cancer Care Ontario</b>	Sentinel lymph node biopsy in vulvar cancer	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2014-July	<a href="#">Document assessment/review protocol.</a>	Dr. Michael Fung Kee Fung, Chair, Gynecology Disease Site Group
<sup>4</sup>	<b>College of Dental Surgeons of British Columbia</b> <i>686 West Broadway, Suite 500 Vancouver, BC, V5Z 1G1</i>	Oral Cancer CPG	Specialty	No	<a href="#">More Details..</a>	Based on BC Cancer Agency Methods <a href="#">Guidelines &amp; Protocols Advisory Committee Process Doc</a>	Not disclosed.	Author COI not disclosed.	Date: 2008-Mar	Regular updates	Dr. Michele Williams Co-Chair, Oral Medicine Leader, BC Cancer Agency
<sup>2,4</sup>	<b>Lymphoma Canada Scientific Advisory Board</b> <i>6860 Century Avenue, Suite 202 Mississauga, ON L5N 2W5</i>	First-Line Treatment of Follicular Lymphoma	Specialty	No	<a href="#">More Details..</a>	NCCN categories of evidence and consensus	Lymphoma Canada.	No COI to disclose by authors.	Date: 2015-Feb	Cycle not indicated.	Joseph Connors, Division of Medical Oncology
<sup>4</sup>	<b>National Advisory Committee on Immunization</b>	Update On human papillomavirus (HPV) vaccines	Primary	No	<a href="#">More Details..</a>	<a href="#">Methods</a>	Gov't of Canada.	No COI to disclose by	Date: 2012	Regular updates. Schedule not indicated.	Dr. S Deeks, Chair, HPV Working Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	n  130 Colonnade Road A.L. 6501H Ottawa, Ontario K1A 0K9							authors.			
<sup>4</sup>	<b>New Brunswick Cancer Network</b>  <b>HSBC Place</b> P. O. Box 5100 Fredericton, NB E3B 5G8	New Brunswick Cervical Cancer Prevention and Screening	Primary	No	<a href="#">More Details.. ...</a>	CAN-ADAPTE process to adapt existing guidelines.	Gov't of NB.	Author COI not disclose d.	Date: 2011-Jun	Update schedule not indicated.	Dr. Ed Reardon, Chair CPG Working Group
<sup>4</sup>	<b>Pediatric Oncology Group of Ontario</b>  480 University Avenue, Suite 1014 Toronto, ON	Emetogenicity Classification Guidelines	Specialty	No	<a href="#">More Details.. ...</a>	<a href="#">GRADE methodology</a>	POGO and Ministry of Health and LTC ON.	No COI to disclose by authors.	Date: 2010-Aug	3 year cycle.	L. Lee Dupuis MScPhm, ACPR, FCSHP
<sup>2,11</sup>	<b>Pediatric Oncology Group of Ontario</b>	Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing	Specialty	No	<a href="#">More Details ...</a>	<a href="#">GRADE methodology</a>	POGO.	No COI to disclose by authors.	Date: 2015-Mar	Updated schedule not indicated.	Lillian Sung, MD, PhD, FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		haematopoietic stem cell transplantation									
<sup>2,11</sup>	<b>Pediatric Oncology Group of Ontario</b>	Prevention and Treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients.	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">GRADE methodology</a>	POGO and Ministry of Health and LTC ON.	No COI to disclose by authors.	Date: 2014 Apr	3 year cycle.	L. Lee Dupuis, pediatric oncology pharmacist (chair)
<sup>11</sup>	<b>Pediatric Oncology Group of Ontario</b>	Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients.	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">GRADE methodology</a>	POGO.	No COI to disclose by authors.	Date: 2017 Oct	3 year cycle.	Priya Patel, Department of Pharmacy, The Hospital for Sick Children, Toronto
<sup>2,11</sup>	<b>Pediatric Oncology Group of Ontario</b>	Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer	Specialty	Yes	<a href="#">More Details ...</a>	<a href="#">GRADE methodology</a>	POGO.	No COI to disclose by authors.	Date: 2016-Mar	Formal update in 5 years.	Jacqueline Flank, BScPhm, ACPR, MS
<sup>4</sup>	<b>Saskatchewan Cancer Agency 200-4545 Parliament</b>	Breast cancer treatment guidelines	Specialty	No	<a href="#">More Details..</a>	Multidisciplinary consensus.	No outside funding.	Author COI not disclosed.	Date: 2012-Mar	Cycle not indicated.	Dr. Haji Chalchal

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Avenue Regina, SK S4W 0G3										
<sup>4</sup>	<b>Saskatchewan Cancer Agency</b>	Provincial Central Nervous System Cancer Treatment Guidelines	Specialty	No	<a href="#">More Details..</a>	Multidisciplinary consensus.	No outside funding.	Author COI not disclosed.	Date: 2011	Cycle not indicated.	Dr. Mohammad Khan
<sup>2,4</sup>	<b>Saskatchewan Cancer Agency</b>	Provincial colorectal cancer treatment guidelines	Specialty	No	<a href="#">More Details ...</a>	Multidisciplinary consensus.	No outside funding.	Author COI not disclosed.	Date: 2013-Oct	Cycle not indicated.	Dr. Vamsee Torri
<sup>4</sup>	<b>Saskatchewan Cancer Agency</b>	Esophageal Cancer and Gastro-esophageal junction Cancer Treatment guidelines	Specialty	No	<a href="#">More Details..</a>	Multidisciplinary consensus.	No outside funding.	Author COI not disclosed.	Date: 2014-Jun	Cycle not indicated.	Dr. Arbind Dubey
<sup>4</sup>	<b>Saskatchewan Cancer Agency</b>	Prostate Cancer Guidelines	Specialty	No	<a href="#">More Details..</a>	Multidisciplinary consensus.	No outside funding.	Author COI not disclosed.	Date: 2008	Cycle not indicated.	Dr. Ali El-Gayed, Radiation Oncologist
<sup>4</sup>	<b>SickKids</b> 555 University Avenue Toronto, Ontario Canada M5G 1X8	Postoperative Fevers in Surgical Oncology Patients	Specialty	Yes	<a href="#">More Details..</a>	<a href="#">Development Process</a>	Internal funding.	Author COI not disclosed.	Date: 2017-July	Annual cycle.	Eleanor Hendershot RN, MN, ACNP, APN Hematology/Oncology
<sup>4</sup>	<b>SickKids</b>	Guidelines for Supportive Care	Specialty	No	<a href="#">More Details..</a>	<a href="#">Development Process</a>	Internal funding.	Author COI not disclosed.	Date: 2017-Jun	Bi-Annual cycle	Lillian Sung MD, FRCP(C)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Management for Patients with Newly Diagnosed Acute Myeloid Leukemia			<a href="#">More Details..</a>			d.			
<sup>4</sup>	SickKids	Children with Acute Leukemia and an Elevated WBC at Diagnosis	Specialty	No	<a href="#">More Details..</a>	<a href="#">Development Process</a>	Internal funding.	Author COI not disclose d.	Date: 2017-Jun	Annual cycle.	Oussama Abla, MD, Division of Haematology/Oncology/BMT
<sup>4</sup>	SickKids	Prevention of Tumour Lysis Syndrome	Specialty	No	<a href="#">More Details..</a>	<a href="#">Development Process</a>	Internal funding.	Author COI not disclose d.	Date: 2016-Sep	3 year cycle.	L. Lee Dupuis, R.Ph., ACPR, M.Sc.Phm., FCSHP, PhD
<sup>4</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>  2781 Lancaster Road, Suite 200, Ottawa, ON K1B 1A7	Cervical Cancer Prevention in Low-Resource Settings	Specialty	No	<a href="#">More Details..</a>	<a href="#">Method details..</a>	SOGC.	No COI to disclose by authors.	Date: 2011-Mar	5 year cycle.	Laurie Elit, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Epidemiology and investigations for suspected endometrial cancer	Specialty	No	<a href="#">More Details ...</a>	<a href="#">Method details..</a>	SOGC.	No COI to disclose by authors.	Date: 2013-Apr	5 year cycle.	Marie-Claude Renaud, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
					to guidelin es dated post 2016- Jan						
<sup>2</sup>	<b>Society of Obstetrician s and Gynaecolog ists of Canada</b>	Adjuvant therapy in endometrial cancer	Specialty	No	<a href="#">More Details ...</a>  Member s only access to guidelin es dated post 2016- Jan	<a href="#">Method details.</a>	SOGC.	No COI to disclose by authors.	<b>Date:</b> 2013-Apr	5 year cycle.	Rachel Kupets, MD
<sup>2</sup>	<b>Society of Obstetrician s and Gynaecolog ists of Canada</b>	Uterine leiomyomas	Specialty	No	<a href="#">More Details ...</a>  Member s only access to guidelin es dated post 2016- Jan	<a href="#">Method details.</a>	SOGC.	No COI to disclose by authors.	<b>Date:</b> 2015- Feb	5 year cycle.	George A.Vilos, MD, London ON
<sup>2</sup>	<b>Thrombosis Canada</b>  <i>128 Halls Road</i>	Cancer and thrombosis	Specialty	Yes	<a href="#">More Details ...</a>	Consensus. Details not included.	Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Leo,	Author COI not disclose d.	<b>Date:</b> 2017	Cycle not indicated	Jeffrey Habert, MD, CCFP, FCFP

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	<i>Whitby, ON L1P 1Y8</i>						Pfizer, Sanofi, Servier.				
1,2	<b>Toward Optimized Practice</b> <i>#200, 12315 Stony Plain Road Edmonton, AB T5N 3Y8</i>	Breast cancer screening	Primary	No	<a href="#">More Details ...</a>	<a href="#">CPG Process</a>	AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2013-Sep	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
1,2,4	<b>Toward Optimized Practice</b>	Cervical cancer screening	Primary	No	<a href="#">More Details ...</a>	<a href="#">CPG Process</a>	AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2016-May	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
1,2,4,10	<b>Toward Optimized Practice</b>	Colorectal cancer screening	Primary	No	<a href="#">More Details ...</a>	<a href="#">CPG Process</a>	AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2015-Jun	2-5 year cycle. .	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>

## Circulatory and Respiratory Health

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/ Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2,3</sup>	<u><a href="#">BC Guidelines</a></u> <i>PO Box 9642 STN PROV GOVT Victoria BC</i>	<u>Ambulatory ECG monitoring (Holter monitor and other devices)</u>	Primary and Specialty	Yes	<u>More Details...</u>	<u>Guidelines and Protocols Advisory Committee Handbook</u>	BC Ministry of Health	No COI to disclose by authors.	<u>Date:</u> 2013-Apr	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2,3</sup>	<u><a href="#">BC Guidelines</a></u>	Asthma in adults - recognition, diagnosis and management	Primary	Yes	<u>More Details...</u>	<u>Guidelines and Protocols Advisory Committee Handbook</u>	BC Ministry of Health	No COI to disclose by authors.	<u>Date:</u> 2015-Oct	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2,3</sup>	<u><a href="#">BC Guidelines</a></u>	<u>Atrial fibrillation - diagnosis and management</u>	Primary and Specialty	Yes	<u>More Details...</u>	<u>Guidelines and Protocols Advisory Committee Handbook</u>	BC Ministry of Health	No COI to disclose by authors.	<u>Date:</u> 2015-Apr	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2,3</sup>	<u><a href="#">BC Guidelines</a></u>	<u>Cardiovascular disease - primary prevention</u>	Primary	Yes	<u>More Details...</u>	<u>Guidelines and Protocols Advisory Committee Handbook</u>	BC Ministry of Health	No COI to disclose by authors.	<u>Date:</u> 2014-Apr	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2,3</sup>	<u><a href="#">BC Guidelines</a></u>	<u>Chronic heart failure - diagnosis and management</u>	Primary and Specialty	Yes	<u>More Details...</u>	<u>Guidelines and Protocols Advisory Committee Handbook</u>	BC Ministry of Health	No COI to disclose by authors.	<u>Date:</u> 2015-Oct	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2,3,7</sup>	<u><a href="#">BC Guidelines</a></u>	Chronic obstructive pulmonary disease (COPD): diagnosis and management	Primary and Specialty	Yes	<u>More Details...</u>	<u>Guidelines and Protocols Advisory Committee Handbook</u>	BC Ministry of Health	No COI to disclose by authors.	<u>Date:</u> 2017-Apr	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>

<sup>23</sup>	<a href="#"><b>BC Guidelines</b></a>	Hypertension - diagnosis and management	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2016-Jun	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<a href="#"><b>BC Guidelines</b></a>	Sleep complaints in Adults – Primary Care	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2004-Nov	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>

<sup>2,3</sup>	<a href="#"><u>BC Guidelines</u></a>	<u>Stroke and transient ischemic attack - acute and long-term management</u>	<u>Primary and Specialty</u>	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>Guidelines and Protocols Advisory Committee Handbook</u></a>	<u>BC Ministry of Health</u>	<u>No COI to disclose by authors.</u>	<u>Date:</u> 2015-Apr	<u>3-5 year cycle.</u>	<u>GPAC Working Group</u> <a href="mailto:hlth.guidelines@gov.bc.ca"><u>hlth.guidelines@gov.bc.ca</u></a>
<sup>2,3</sup>	<a href="#"><u>BC Guidelines</u></a>	<u>Use of non-vitamin K antagonist oral anticoagulants (NOAC) in non-valvular atrial fibrillation</u>	<u>Primary and Specialty</u>	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>Guidelines and Protocols Advisory Committee Handbook</u></a>	<u>BC Ministry of Health</u>	<u>No COI to disclose by authors.</u>	<u>Date:</u> 2015-Nov	<u>3-5 year cycle.</u>	<u>GPAC Working Group</u> <a href="mailto:hlth.guidelines@gov.bc.ca"><u>hlth.guidelines@gov.bc.ca</u></a>
<sup>2,3</sup>	<a href="#"><u>BC Guidelines</u></a>	<u>Warfarin therapy - management during invasive procedures and surgery</u>	<u>Specialty</u>	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>Guidelines and Protocols Advisory Committee Handbook</u></a>	<u>BC Ministry of Health</u>	<u>No COI to disclose by authors.</u>	<u>Date:</u> 2015-Apr	<u>3-5 year cycle.</u>	<u>GPAC Working Group</u> <a href="mailto:hlth.guidelines@gov.bc.ca"><u>hlth.guidelines@gov.bc.ca</u></a>
<sup>2,3</sup>	<a href="#"><u>BC Guidelines</u></a>	<u>Warfarin therapy management</u>	<u>Primary</u>	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>Guidelines and Protocols Advisory Committee Handbook</u></a>	<u>BC Ministry of Health</u>	<u>No COI to disclose by authors.</u>	<u>Date:</u> 2015-Apr	<u>3-5 year cycle.</u>	<u>GPAC Working Group</u> <a href="mailto:hlth.guidelines@gov.bc.ca"><u>hlth.guidelines@gov.bc.ca</u></a>
<sup>2</sup>	<b>Cdn Action Network for the Advancement, Dissemination &amp; Adoption of Practice-informed Tobacco Treatment (CAN-ADAPTT)</b>  175 College Street Toronto, ON	<u>Smoking cessation clinical practice guideline</u>	<u>Primary</u>	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>Adapted GRADE process</u></a>	<u>Funded by Health Canada</u>	<u>No COI to disclose by authors.</u>	<u>Date:</u> 2012	<u>Update not scheduled.</u>	Peter Selby, MBBS, CCFP, FCFP, MHSc, Dip ABAM

<sup>2</sup>	<u><a href="#">Canadian Association of Cardiac Rehabilitation</a></u> <u>20 Crown Steel</u> <u>Dr. Unit #6</u> <u>Markham, ON</u>	Aerobic exercise intensity assessment and prescription in cardiac rehabilitation	Primary and Specialty	<u>Yes</u>	<u>More Details...</u>	Consensus.	No outside funding	No COI to disclose by authors.	<b>Date:</b> 2012-Dec	Cycle not specified.	James A. Stone MD, PhD
<sup>2</sup>	<u><a href="#">Canadian Association of Gastroenterology</a></u> <u>189 Queen Street</u> <u>East, Suite 1,</u> <u>Toronto, ON</u>	Risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease	Specialty	<u>Yes</u>	<u>More Details..</u>	<u>GRADE methodology</u>	AbbVie Canada and Warner Chilcott	COI disclosed by authors.	<b>Date:</b> 2014-Mar	Updated when approved by committee.	Geoffrey C. Nguyen, MD, PhD, FRCP(C)
<sup>2</sup>	<u><a href="#">Canadian Cardiovascular Society</a></u> <u>222 Queen Street,</u> <u>Suite 1100</u> <u>Ottawa, ON</u>	Diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult	Primary and Specialty	<u>Yes</u>	<u>More Details..</u>	<u>CCS Guideline process</u>	CCS operating budget.	<u>Link to COI disclosures.</u>	<b>Date:</b> 2016-Nov	Updates determined by Guidelines Committee .	Todd J. Anderson, MD
<sup>2</sup>	<u><a href="#">Canadian Cardiovascular Society</a></u>	Management of atrial fibrillation	Primary and Specialty	<u>Yes</u>	<u>More Details...</u>	<u>CCS Guideline process</u>	CCS operating budget.	<u>Link to COI disclosures.</u>	<b>Date:</b> 2016-Oct	Updates determined by Guidelines Committee .	Laurent Macle, MD (Co-chair)
<sup>2</sup>	<u><a href="#">Canadian Cardiovascular Society</a></u>	Management of heart failure	Primary and Specialty	<u>Yes</u>	<u>More Details...</u>	<u>CCS Guideline process</u>	CCS operating budget.	<u>Link to COI disclosures.</u>	<b>Date:</b> 2017-Nov	Updates determined by Guidelines Committee .	Justin A. Ezekowitz, MBBCh (Chair, Primary Panel)

<sup>‡</sup>	<u><a href="#">Canadian Cardiovascular Society</a></u>	Antiplatelet therapy	Primary and Specialty	<u>Yes</u>	<u>More Details...</u>	<u>CCS Guideline process</u>	<u>CCS operating budget.</u>	<u>Link to COI disclosures.</u>	<b>Date:</b> 2018-Jan	Updates determined by Guidelines Committee .	Shamir R. Mehta, MD (co-chair)
<sup>‡</sup>	<u><a href="#">Canadian Cardiovascular Society</a></u>	Fitness following left ventricular assist device implantation	Specialty	<u>Yes</u>	<u>More Details...</u>	<u>CCS Guideline process</u>	<u>CCS operating budget.</u>	<u>Link to COI disclosures.</u>	<b>Date:</b> 2012-Mar	Updates determined by Guidelines Committee .	Roger Basket, MD
<sup>‡</sup>	<u><a href="#">Canadian Cardiovascular Society</a></u>	Cardiac risk assessment before the use of stimulant medications in children and youth	Specialty	<u>Yes</u>	<u>More Details...</u>	Consensus among group of physicians: cardiology; paediatrics; child and adolescent psychiatry	<u>Funding not disclosed.</u>	<u>Author COI not disclosed.</u>	<b>Date:</b> 2009-Nov	Updates determined by Guidelines Committee .	AE Warren MD MSc FRCPC
<sup>‡</sup>	<u><a href="#">Canadian Cardiovascular Society</a></u>	Cardiovascular complications of cancer therapy	Specialty	<u>Yes</u>	<u>More details...</u>	<u>CCS Guideline process</u>	<u>CCS operating budget.</u>	<u>Link to COI disclosures.</u>	<b>Date:</b> 2016-Jun	Updates determined by Guidelines Committee .	Sean A. Virani, MD, MSc, MPH, FRCPC (Co-Chair, Primary Panel)
<sup>‡</sup>	<u><a href="#">Canadian cardiovascular society</a></u>	Diagnosis and management of stable ischemic heart disease	Primary and Specialty	<u>Yes</u>	<u>More Details...</u>	<u>CCS Guideline process</u>	<u>Funded through CCS operating budget.</u>	<u>Link to COI disclosures.</u>	<b>Date:</b> 2014-Aug	Updates determined by Guidelines Committee .	G.B. John Mancini, MD (Co-Chair)
<sup>‡</sup>	<u><a href="#">Canadian Cardiovascular Society</a></u>	Heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications	Primary and Specialty	<u>Yes</u>	<u>More Details...</u>	<u>CCS Guideline process</u>	<u>Funded through CCS operating budget.</u>	<u>Link to COI disclosures.</u>	<b>Date:</b> 2015-Jan	Updates determined by Guidelines Committee .	Gordon W. Moe, MD, MSc, FRCPC (Chair)

<sup>‡</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Heart failure management guidelines update: focus on rehabilitation and exercise and surgical coronary revascularization	Primary and Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2014-Mar	Updates determined by Guidelines Committee .	Gordon W. Moe, MD, MSc, FRCPC (Chair)
<sup>‡</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Heart failure management: Focus on acute and chronic heart failure	Primary and Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2013-Feb	Updates determined by Guidelines Committee .	Gordon W. Moe, MD, MSc, FRCPC (Chair)
<sup>‡</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Management of patients with refractory angina	Primary and Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2012-Mar	Updates determined by Guidelines Committee .	Michael McGillion, RN, PhD (Chair)
<sup>‡</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Syncope in the pediatric patient	Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2017-Feb	Updates determined by Guidelines Committee .	Shubhayan Sanatani, MD, FRCPC (Chair)
<sup>‡</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Management of thoracic aortic disease	Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2014-Jun	Updates determined by Guidelines Committee .	Munir Boodhwani, MD, MMSc (Co-Chair)
<sup>‡</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Open and endovascular surgery for thoracic aortic disease	Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2016-May	Updates determined by Guidelines Committee .	Jehangir J. Appoo, MDCM (Co-chair)

<sup>2</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Optimal care of the post-arrest patient	Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2017-Jan	Updates determined by Guidelines Committee .	Graham C. Wong, MD, MPH (Co-chair)
<sup>2</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery	Specialty	<u>Yes</u>	<a href="#"><u>More Details..</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2017-Jan	Updates determined by Guidelines Committee .	Joel Parlow, MD, MSc (Co-chair)
<sup>2</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Perioperative management of patients with implanted pacemakers, defibrillators, and neurostimulating devices	Specialty	<u>Yes</u>	<a href="#"><u>More Details..</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2012-Mar	Updates determined by Guidelines Committee .	Jeff S. Healey, MD (Co-chair)
<sup>2</sup>	<a href="#"><u>Canadian cardiovascular society</u></a>	Presentation, diagnosis, and medical management of heart failure in children: guidelines	Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2013-Dec	Updates determined by Guidelines Committee .	Paul F. Kantor, MBBCh
<sup>2</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Pulse oximetry screening in newborns to enhance detection of critical congenital heart disease	Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2017-Feb	Updates determined by Guidelines Committee .	Kenny K. Wong, MD (Co-Chair)
<sup>2</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Radiation exposure from cardiac imaging and interventional procedures	Specialty	<u>Yes</u>	<a href="#"><u>More Details..</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2013-Nov	Updates determined by Guidelines Committee .	Madhu K. Natarajan, MD, MSc (Co-chair)

<sup>2.11</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Remote monitoring for cardiovascular implantable electronic device follow-up	Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2013-Apr	Updates determined by Guidelines Committee .	Raymond Yee, MD (Chair, Primary Writing Panel)
<sup>2</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Transcatheter aortic valve implantation	Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2012-Jun	Updates determined by Guidelines Committee .	John Webb, MD, FRCPC
<sup>2</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Cardiac resynchronization therapy	Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2013-Feb	Updates determined by Guidelines Committee .	Derek V. Exner, MD, MPH'
<sup>2</sup>	<a href="#"><u>Canadian Cardiovascular Society</u></a>	Cardiac resynchronization therapy: Implementation	Specialty	Specialty	<a href="#"><u>More Details..</u></a>	<a href="#"><u>CCS Guideline process</u></a>	Funded through CCS operating budget.	<a href="#"><u>Link to COI disclosures.</u></a>	<b>Date:</b> 2013-Nov	Updates determined by Guidelines Committee .	Ratika Parkash, MD, MSc
<sup>2</sup>	<a href="#"><u>Canadian Society for Cardiovascular Magnetic Resonance</u> FMC, SSB Suite 0700 1403 - 29th St. NW Calgary AB</a>	Cardiovascular magnetic resonance image analysis and reporting	Specialty	<u>Yes</u>	<a href="#"><u>More Details...</u></a>	Consensus generated through task force.	Funding not indicated.	COI disclosed by authors.	<b>Date:</b> 2013-Mar	Cycle not indicated.	Matthias G. Friedrich, MD

<sup>2</sup>	<u><a href="#">Canadian Critical Care Society (CCCS)</a></u> <u>20 Crown Steel Dr. Unit #6, Markham, ON</u>	<u>Targeted temperature management (therapeutic hypothermia) after cardiac arrest</u>	<u>Specialty</u>	<u>Yes</u>	<u>More Details...</u>	<u>Methods</u>	<u>Unrestricted grant from the Kingston Resuscitation Institute.</u>	<u>COI disclosed by working group.</u>	<u>Date:</u> 2016-Jan  Determined by KT Committee	<u>Daniel W. Howes, MD, FRCPC</u>
<sup>2</sup>	<u><a href="#">Canadian Heart Rhythm Society and Canadian Association of Radiologists</a></u> <u>University of Toronto, Suite 602, 581 Davis Dr, Newmarket, ON</u>	<u>Magnetic resonance imaging with cardiac implantable electronic devices</u>	<u>Specialty</u>	<u>Yes</u>	<u>More Details...</u>	<u>GRADE methodology</u>	<u>Overall funding not indicated.</u>	<u>COI declared</u>	<u>Date:</u> 2014-Oct  Cycle not indicated.	<u>Atul Verma, MD</u>
<sup>2</sup>	<u><a href="#">Canadian Hereditary Angioedema Network</a></u> <u>20 Carlton Street, Suite 123, Toronto, ON</u>	<u>Angioedema guideline</u>	<u>Specialty</u>	<u>Yes</u>	<u>More Details...</u>	<u>Consensus</u>	<u>CSL Behring, Shire, and ViroPharma.</u>	<u>COI disclosed by working group.</u>	<u>Date:</u> 2014-Oct  Cycle not indicated.	<u>Stephen Betschel, MD, FRCPC</u>
<sup>2,11</sup>	<u><a href="#">Canadian Interventional Radiology Association</a></u> <u>1370, Notre-Dame W, Montreal, QC</u>	<u>Intraarterial catheter-directed treatment of acute ischemic stroke</u>	<u>Specialty</u>	<u>Yes</u>	<u>More Details...</u>	<u>Consensus among working group (international)</u>	<u>CIRA is funded by medical device companies.</u>	<u>COI disclosed by working group.</u>	<u>Date:</u> 2013-Jan  3 year cycle.	<u>Kieran J. Murphy, MD</u>
<sup>2</sup>	<u><a href="#">Canadian Interventional Radiology Association</a></u>	<u>Diagnosis and management of iliofemoral deep vein thrombosis</u>	<u>Specialty</u>	<u>Yes</u>	<u>More Details...</u>	<u>American Heart Association clinical practice methodology; GRADE methodology</u>	<u>CIRA is funded by medical device companies.</u>	<u>No COI to disclose by authors.</u>	<u>Date:</u> 2015-Sep  2 year cycle.	<u>David Liu MD</u>

<sup>2</sup>	<b>Canadian Paediatric Society</b> <u>2305 St Laurent Blvd, Ottawa, ON</u>	Assessment of cardiorespiratory stability using the infant car seat challenge before discharge in preterm infants (<37 weeks' gestational age)	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Apr	3 year cycle.	Michael R Narvey MD (Fetus and Newborn Committee)
<sup>2</sup>	<b>Canadian Paediatric Society</b>	NRP providers: a case-based review	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI declared by working group.	<b>Date:</b> 2017-Aug	5 year cycle	Emer Finan MD (principal author)
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Pulse oximetry screening in newborns to enhance detection of critical congenital heart disease	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Jul	3 year cycle	Michael R Narvey MD (Fetus and Newborn Committee)
<sup>2</sup>	<b>Canadian Sleep Society</b>  305 Rue St-Vallier, Chicoutimi, QC	Role of different health care professionals in managing obstructive sleep apnea and snoring with oral appliances	Primary and Specialty	Yes	<a href="#">More Details...</a>	Consensus	CSS receives funding from medical device companies.	COI and funding not disclosed.	<b>Date:</b> 2012-Sep	Cycle not indicated.	Luc Gauthier DMD MSc

<sup>2</sup>	<b>Canadian Task Force on Preventive Health Care</b> 3280 Hospital Drive Northwest, Calgary, AB	Screening for abdominal aortic aneurysm in primary care	Primary	<u>Yes</u>	<a href="#">More Details...</a>	<a href="#">Procedure Manual</a>	PHAC.	No COI to disclose by authors.	<b>Date:</b> 2017-Sep	Update: not indicated. Topic Selection Working Group to determine updates.	Harminder Singh MD MPH
<sup>2</sup>	<b>Canadian Task Force on Preventive Health Care</b>	Screening for high blood pressure in Canadian adults	Primary	<u>Yes</u>	<a href="#">More Details...</a>	<a href="#">Procedure Manual</a>	PHAC.	No COI to disclose by authors.	<b>Date:</b> 2013-Sep	Update: due 2018. Topic Selection Working Group to determine updates.	Patrice Lindsay, PhD
<sup>2</sup>	<b>Canadian Thoracic Society</b>  30 Concourse Gate, Unit 27  Ottawa, ON	Diagnosis and management of asthma in preschoolers, children and adults	Primary	Yes	<a href="#">More Details...</a>	Consensus update.	Unrestricted funding from Canadian Institutes of Health Research, AstraZeneca Canada, Boehringer Ingelheim Canada, GlaxoSmithKline Inc, Pfizer and Talecris.	<a href="#">COI disclosed by authors.</a>	<b>Date:</b> 2012-Apr	Cycle not declared.	M Diane Lougheed MD MSc
<sup>11</sup>	<b>Canadian Thoracic Society</b>	Prevention of acute exacerbations of COPD.	Primary	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a> and American College of Chest Physicians Grading System	CTC and CHEST.	COI disclosed by authors.	<b>Date:</b> 2015-Apr	Cycle not declared.	Darcy D. Marciniuk, MD, FCCP

<sup>2</sup>	<b>Canadian Thoracic Society</b>	Spirometry in primary care	Primary	Yes	<a href="#">More Details...</a>	Consensus	CTC.	COI disclosed by authors.	<b>Date:</b> 2013-Jan	Cycle not declared.	Allan L. Coates MD
<sup>2</sup>	<b>Canadian Thoracic Society</b>	Tuberculosis standards	Primary and Specialty	Yes	<a href="#">More Details...</a>	Chapter consensus.	PHAC, CTC, others.	Author COI not disclosed.	<b>Date:</b> 2014-Feb	Cycle not declared.	Dick Menzies, MD, MSc

<sup>2</sup>	<u><a href="#">Cardiometabolic Risk Working Group</a></u> <u>30 Bond St.</u> <u>Toronto, ON</u>	Managing cardiometabolic risk in primary	Primary	<u>Yes</u>	<u>More Details...</u>	Synthesis of consensus statement.	Funding not declared.	COI disclosed by authors.	<b>Date:</b> 2012-Apr	Cycle not declared.	Ananda Chatterjee MD
<sup>2</sup>	<u><a href="#">C-CHANGE</a></u> <u>40 Ruskin St.</u> <u>Ottawa, ON</u>	Canadian Cardiovascular Harmonized National Guidelines	Primary	<u>Yes</u>	<u>More Details...</u>	Guideline review and harmonization.	Funding from <u>ON Ministry of Health.</u>	COI disclosed by authors.	<b>Date:</b> 2014-Nov	Cycle pending major changes to incorporated guidelines.	Peter P. Liu MD
<sup>2</sup>	<u><a href="#">Diabetes Canada</a></u> <u>1400-522 University Ave</u> <u>Toronto ON</u>	Dyslipidemia	Primary and Specialty	<u>Yes</u>	<u>More Details..</u>	<u>Methods</u>	<u><a href="#">Diabetes Canada</a></u>	COI disclosed by authors.	<b>Date:</b> 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	<u><a href="#">Diabetes Canada</a></u>	Management of acute coronary syndromes	Primary and Specialty	<u>Yes</u>	<u>More Details..</u>	<u>Methods</u>	<u><a href="#">Diabetes Canada</a></u>	COI disclosed by authors.	<b>Date:</b> 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	<u><a href="#">Diabetes Canada</a></u>	Physical activity and diabetes	Primary	<u>Yes</u>	<u>More Details...</u>	<u>Methods</u>	Funding: <u><a href="#">Diabetes Canada</a></u>	COI disclosed by authors.	<b>Date:</b> 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	<u><a href="#">Diabetes Canada</a></u>	Screening for the presence of coronary artery disease	Primary and Specialty	<u>Yes</u>	<u>More Details...</u>	<u>Methods</u>	Funding: <u><a href="#">Diabetes Canada</a></u>	COI disclosed by authors.	<b>Date:</b> 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>

<sup>2</sup>	<a href="#">Diabetes Canada</a>	Treatment of diabetes in people with heart failure	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	<a href="#">Diabetes Canada</a>	Treatment of hypertension	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>

<sup>2</sup>	<a href="#">Diabetes Canada</a>	<a href="#">Cardiovascular protection in people with diabetes</a>	<a href="#">Primary and Specialty</a>	<a href="#">Yes</a>	<a href="#">More Details...</a>	<a href="#">Methods</a>	<a href="#">Funding: Diabetes Canada</a>	<a href="#">COI disclosed by authors.</a>	<a href="#">Date: 2018-Apr</a>	<a href="#">Annual cycle.</a>	<a href="#">Ms. Jovita Sundaramoorthy, Vice President, Research and Education</a> <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	<a href="#">Heart and Stroke Foundation of Canada 110-1525 Carling Ave. Ottawa, ON</a>	<a href="#">Acute inpatient stroke care guidelines</a>	<a href="#">Specialty</a>	<a href="#">Yes</a>	<a href="#">More Details...</a>	<a href="#">Methodology</a>	<a href="#">No commercial interests.</a>	<a href="#">Author COI disclosures.</a>	<a href="#">Date: 2015-Oct</a>	<a href="#">Thematic annual updates.</a>	<a href="#">Leanne Casaubon MD, MSc, FRCPC, DABPN(VascNeurol)</a>
<sup>2</sup>	<a href="#">Heart and Stroke Foundation of Canada</a>	<a href="#">Managing stroke transitions of care</a>	<a href="#">Primary and Specialty</a>	<a href="#">Yes</a>	<a href="#">More Details...</a>	<a href="#">Methodology</a>	<a href="#">No commercial interests.</a>	<a href="#">Author COI disclosures.</a>	<a href="#">Date: 2015</a>	<a href="#">Thematic annual updates.</a>	<a href="#">Jill Cameron PhD</a>
<sup>2</sup>	<a href="#">Heart and Stroke Foundation of Canada</a>	<a href="#">Telestroke</a>	<a href="#">Primary and Specialty</a>	<a href="#">Yes</a>	<a href="#">More Details...</a>	<a href="#">Methodology</a>	<a href="#">No commercial interests.</a>	<a href="#">Author COI disclosures.</a>	<a href="#">Date: 2017</a>	<a href="#">Thematic annual updates.</a>	<a href="#">Frank Silver, MD, FRCPC</a>
<sup>2</sup>	<a href="#">Heart and Stroke Foundation of Canada</a>	<a href="#">Stroke rehabilitation</a>	<a href="#">Primary and Specialty</a>	<a href="#">Yes</a>	<a href="#">More Details...</a>	<a href="#">Methodology</a>	<a href="#">No commercial interests.</a>	<a href="#">Author COI disclosures.</a>	<a href="#">Date: 2013-Jul</a>	<a href="#">Thematic annual updates.</a>	<a href="#">Debbie Hebert, OT</a>
<sup>2</sup>	<a href="#">Heart and Stroke Foundation of Canada</a>	<a href="#">Hyperacute stroke care</a>	<a href="#">Specialty</a>	<a href="#">Yes</a>	<a href="#">More Details...</a>	<a href="#">Methodology</a>	<a href="#">No commercial interests.</a>	<a href="#">Author COI disclosures.</a>	<a href="#">Date: 2015-Jun</a>	<a href="#">Thematic annual updates.</a>	<a href="#">Leanne Casaubon MD, MSc, FRCPC, DABPN(VascNeurol)</a>

<sup>2</sup>	<b>Heart and Stroke Foundation of Canada</b>	Mood and cognition in patients following stroke	Primary and Specialty	<u>Yes</u>	<a href="#">More Details...</a>	<a href="#">Methodology</a>	No commercial interests.	<a href="#">Author COI disclosures.</a>	<b>Date:</b> 2015-Jun	Thematic annual updates.	Gail A. Eskes Ph.D, R. Psych.
<sup>2</sup>	<b>Heart and Stroke Foundation of Canada</b>	Stroke prevention	Primary	<u>Yes</u>	<a href="#">More Details...</a>	<a href="#">Methodology</a>	No commercial interests.	<a href="#">Author COI disclosures.</a>	<b>Date:</b> 2017-Oct	Thematic annual updates.	Theodore Wein, MD, FRCPC
<sup>2</sup>	<u><a href="#">Heart Rhythm Society (Canadian)</a></u> <u>222 Queen Street,</u> <u>Suite 1100 Ottawa ON</u>	<u>Arrhythmias in adult congenital heart disease</u>	Primary and Specialty	<u>Yes</u>	<a href="#">More Details...</a>	<u>Consensus of international writing group.</u>	<u>International partnership.</u>	Author COI disclosed.	<b>Date:</b> 2014-Oct	Cycle not indicated.	Louise Harris, MBChB, FHRS
<sup>2</sup>	<u><a href="#">Heart Rhythm Society (Canadian)</a></u>	<u>Asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern</u>	Specialty	<u>Yes</u>	<a href="#">More Details...</a>	<u>Consensus of international writing group.</u>	<u>International partnership.</u>	Author COI disclosed.	<b>Date:</b> 2012-Jun	Cycle not indicated	George J. Klein, MD, FRCP(C)
<sup>2</sup>	<u><a href="#">Hypertension Canada</a></u> <u>3780 14th Avenue, Suite 211 Markham, ON</u>	<u>Blood pressure measurement, diagnosis, and assessment of risk of pediatric hypertension</u>	Primary and Specialty	<u>Yes</u>	<a href="#">More Details...</a>	<a href="#">Process</a>	<u>Funded by Hypertension Canada, free from external influence.</u>	Author COI disclosed by authors.	<b>Date:</b> 2017	Annual cycle.	Janis M. Dionne, MD
<sup>2</sup>	<u><a href="#">Hypertension Canada</a></u>	<u>Blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension</u>	Primary	<u>Yes</u>	<a href="#">More Details...</a>	<a href="#">Process</a>	<u>Funded by Hypertension Canada, free from external influence.</u>	Author COI disclosed by authors.	<b>Date:</b> 2017	Annual cycle.	Alexander A. Leung, MD MPH

<sup>2</sup>	<u>Hypertension Canada</u>	Hypertension Education Program guidelines for pharmacists	Primary	<u>Yes</u>	<u>More Details...</u>	<u>Process</u>	Funded by Hypertension Canada, free from external influence.	No COI to disclose by authors.	<b>Date:</b> 2016-Nov	Annual cycle.	Yazid N. Al Hamarneh, BSc(Pharm), PhD
<sup>2</sup>	<u>Hypertension Canada</u>	Management of hypertension	Primary	<u>Yes</u>	<u>More Details...</u>	<u>Process</u>	Funded by Gov't of Canada and unrestricted support from Servier Canada Inc.	COI disclosed by working group.	<b>Date:</b> 2017	Annual cycle.	Doreen Rabi, MD, MSc (Chair)
<sup>2</sup>	<b>Ontario Association of Medical Laboratories</b> <u>1802, 5000 Yonge St, North York, ON</u>	Lipid testing in adults	Primary and Specialty	<u>Yes</u>	<u>More Details...</u>	Committee consensus	Funding not disclosed.	Author COI not disclosed.	<b>Date:</b> 2013-Nov	5 year cycle	Todd Anderson, MD, FRCP(C)
<sup>2</sup>	<b>Ontario Association of Medical Laboratories</b>	Testing of lower respiratory tract specimens	Primary	Yes	<u>More Details...</u>	Committee consensus	Funding not disclosed.	Author COI not disclosed.	<b>Date:</b> 2015-Jun	5 year cycle	Julius Kapala Ph.D. , RSM (CCM), SM (ASCP)
<sup>2</sup>	<b>Ontario Association of Medical Laboratories</b>	Transition from the MDRD to the CKD-EPI equation for the calculation of an estimated glomerular filtration rate (eGFR), and its interpretation in concert with the urine albumin/creatinine ratio (ACR)	Specialty	Yes	<u>More Details...</u>	Committee consensus	Funding not disclosed.	Author COI not disclosed.	<b>Date:</b> 2015-Apr	5 year cycle	Judy Ash, MPPAL, BSc, ART, CQMgr, CQA (ASQ)

<sup>8</sup>	Registered Nurses' Association of Ontario (RNAO) <i>158 Pearl Street, Toronto, ON</i>	Adult Asthma Promoting Control	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2017-May	3 year cycle	Megan Bamford, RN, BScN, MScN
<sup>8</sup>	RNAO	Assessment and Management of Venous Leg Ulcers	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2004-Mar	3 year cycle	Kathryn Kozell, RN, BA, BScN, MScN, ACNP/CNS, ET
<sup>8</sup>	RNAO	Integrating Smoking Cessation into Daily Nursing Practice	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2017-Jun	3 year cycle	Sheila John, RN, BScN, MScN
<sup>8</sup>	RNAO	Nursing Care of Dyspnea – in patients with COPD	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2005-Mar	3 year cycle	Pat Hill Bailey, RN, PhD
<sup>8</sup>	RNAO	Nursing management of high blood pressure	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2005-Oct	3 year cycle	Tazim Virani, RN, MScN, PhD(candidate)
<sup>8</sup>	RNAO	Stroke assessment across the continuum of care: nursing	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2005-Jun	3 year cycle	Tazim Virani, RN, MScN, PhD(candidate)

<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>  <i>2781 Lancaster Road, Suite 200, Ottawa, ON K1B 1A7</i>	<u>Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy</u>	<u>Primary and Specialty</u>	<u>Yes</u>	<u>More Details...</u> Members only access to guidelines dated post 2016-Jan	<u>Method details.</u>	Funded by SOGC.	No COI to disclose by authors.	<b>Date:</b> 2014-May	5 year cycle.	Laura A. Magee, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	<u>Venous thromboembolism and antithrombotic therapy in pregnancy</u>	<u>Specialty</u>	<u>Yes</u>	<u>More Details...</u>	<u>Method details.</u>	Funded by SOGC.	No COI to disclose by authors.	<b>Date:</b> 2014-Jun	5 year cycle.	Wee-Shian Chan, MD
<sup>2</sup>	<b>Thrombosis Canada</b>  <i>128 Halls Road Whitby, ON</i>	<u>Acetylsalicylic acid (ASA)</u>	<u>Primary and Specialty</u>	<u>Yes</u>	<u>More Details...</u>	Consensus. Details not included.	Independent from commercial interests.	Author COI not disclosed by authors.	<b>Date:</b> 2017-Jun	Cycle not indicated.	Jeffrey Habert, MD, CCFP, FCFP
<sup>2</sup>	<b>Thrombosis Canada</b>	<u>Apixaban (Eliquis)</u>	<u>Primary and Specialty</u>	<u>Yes</u>	<u>More Details...</u>	Consensus. Details not included.	Independent from commercial interests.	Author COI not disclosed by authors.	<b>Date:</b> 2017-Sep	Cycle not indicated.	Jeffrey Habert, MD, CCFP, FCFP
<sup>2</sup>	<b>Thrombosis Canada</b>	<u>Cancer and thrombosis</u>	<u>Specialty</u>	<u>Yes</u>	<u>More Details...</u>	Consensus. Details not included.	Independent from commercial interests.	Author COI not disclosed by authors.	<b>Date:</b> 2017-Aug	Cycle not indicated.	Jeffrey Habert, MD, CCFP, FCFP
<sup>2</sup>	<b>Thrombosis Canada</b>	<u>Central venous catheter-related deep vein thrombosis</u>	<u>Specialty</u>	<u>Yes</u>	<u>More Details...</u>	Consensus. Details not included.	Independent from commercial interests.	Author COI not disclosed by authors.	<b>Date:</b> 2017-Jun	Cycle not indicated.	Jeffrey Habert, MD, CCFP, FCFP

<sup>2</sup>	<b>Thrombosis Canada</b>	Cerebral venous thrombosis	Specialty	<u>Yes</u>	<a href="#">More Details...</a>	Consensus. Details not included.	Independent from commercial interests.	Author COI not disclosed by authors.	<b>Date:</b> 2017-Dec	Cycle not indicated.	Jeffrey Habert, MD, CCFP, FCFP
<sup>2</sup>	<b>Thrombosis Canada</b>	Deep vein thrombosis (DVT): diagnosis	Primary	<u>Yes</u>	<a href="#">More Details...</a>	Consensus. Details not included.	Independent from commercial interests.	Author COI not disclosed by authors.	<b>Date:</b> 2017-May	Cycle not indicated.	Jeffrey Habert, MD, CCFP, FCFP
<sup>2</sup>	<b>Thrombosis Canada</b>	Deep vein thrombosis (DVT): treatment	Specialty	<u>Yes</u>	<a href="#">More Details...</a>	Consensus. Details not included.	Independent from commercial interests.	Author COI not disclosed by authors.	<b>Date:</b> 2017-Nov	Cycle not indicated.	Jeffrey Habert, MD, CCFP, FCFP
<sup>1</sup>	<b>Toward Optimal Practice</b>  #200, 12315 Stony Plain Road Edmonton, AB	Diagnosis and Management of Croup	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	Author COI disclosed by authors.	<b>Date:</b> 2015-Jun	2-5 year cycle	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1,2</sup>	<b>Toward Optimal Practice</b>	Prevention and Management of Cardiovascular Disease	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	Author COI disclosed by authors.	<b>Date:</b> 2017-Apr	2-5 year cycle	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	<b>Toward Optimal Practice</b>	<b>Red Blood and Plasma Transfusion</b>	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	Author COI disclosed by authors.	<b>Date:</b> 2009-Jan	2-5 year cycle	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>10</sup>	<b>Winnipeg Regional Health Authority (WRHA)</b>  650 Main St, Winnipeg, MB	Administration of Intravenous Push Antiarrhythmic Agents (Adult)	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2017-Nov	Cycle not indicated.	Dr. Lorraine Avery, CNS, Cardiac Sciences Program, WRHA

<sup>10</sup>	<b>WRHA</b>	Inpatient Care for Patients Following an Acute Stroke	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2013-Dec	Cycle not indicated.	Alan Jackson BA, MD, FAAN, FRCPC
<sup>10</sup>	<b>WRHA</b>	Management of Tobacco Use and Dependence	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2013-Jul	Cycle not indicated.	Catherine Cook, Vice President, Population and Aboriginal Health, WRHA
<sup>10</sup>	<b>WRHA</b>	Use of a pacemaker magnet for adult patients with a pacemaker or implantable cardioverter defibrillator undergoing operative or other procedures	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2015-Nov	Cycle not indicated.	Dr. Colette Seifer, director of the cardiology section of the Cardiac Sciences Program

## Gender and Health / Women's Health

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<u><a href="#">BC Guidelines</a></u> <u><a href="#">PO Box 9642</a></u> <u><a href="#">STN PROV</a></u> <u><a href="#">GOVT</a></u> <u><a href="#">Victoria BC</a></u>	Hormone testing – indications and appropriate use	Primary	Yes	<u><a href="#">More Details...</a></u>	<u><a href="#">Guidelines and Protocols Advisory Committee Handbook</a></u>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2016-May	3-5 year cycle	<u><a href="#">GPAC Working Group</a></u> <u><a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a></u>
<sup>2</sup>	<b>British Columbia Centre for Excellence in HIV/AIDS</b>  <i>4500 Oak Street Vancouver, BC</i>	Care of HIV positive pregnant women and interventions to reduce perinatal transmission guidelines	Specialty	Yes	<u><a href="#">More Details...</a></u>	Adapted from Cdn Task Force on Preventive Health Care.	BC Women's Hospital and Health Centre	Author COI not disclosed.	<b>Date:</b> 2013-Jul	Cycle not indicated.	Deborah Money, MD, FRCSC
<sup>2</sup>	<b>Canadian Association of Radiologists</b> <i>294 Albert St Suite 600, Ottawa, ON</i>	<u><a href="#">Breast imaging and intervention</a></u>	Specialty	Yes	<u><a href="#">More Details...</a></u>	<u><a href="#">Consensus. Not stated.</a></u>	<u><a href="#">Not stated</a></u>	Author COI not disclosed.	<b>Date:</b> 2016-Sep	Cycle not indicated.	<u><a href="#">Shiela Appavoo, MD (Chair)</a></u>
<sup>2</sup>	<b>Canadian Paediatric Society</b> <i>2305 St Laurent Blvd, Ottawa, ON</i>	Counselling and management for anticipated extremely preterm birth	Specialty	Yes	<u><a href="#">More Details...</a></u>	<u><a href="#">Position statement process</a></u>	<u><a href="#">CPS receives unrestricted sponsorship.</a></u>	COI disclosed by working group.	<b>Date:</b> 2017-Mar	3 year cycle	Brigitte Lemyre MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Emergency contraception	Primary	No	<u><a href="#">More Details...</a></u>	<u><a href="#">Position statement process</a></u>	<u><a href="#">CPS receives unrestricted sponsorship.</a></u>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Debra K Katzman MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Vitamin D supplementation: mothers and infants	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	John C Godel, MD
<sup>2</sup>	<b>Canadian Task Force on Preventive Health Care</b> <i>3280 Hospital Drive Northwest, Calgary, AB</i>	Recommendations on routine screening pelvic examination	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Procedure Manual</a> SNAP-IT (Smooth National Adaptation and Presentation of Guidelines to Improve Thrombosis Treatment)	Provided by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2016-Mar	Topic Selection Working Group to determine updates.	Marcello A. Tonelli, M.D., SM, FRCPC
<sup>2</sup>	<a href="#">Diabetes Canada</a> <i>1400-522 University Ave Toronto ON</i>	Diabetes and pregnancy	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	<b>Date:</b> 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	<b>Ontario Association of Medical Laboratories</b> <i>1802, 5000 Yonge St, North York, ON</i>	Investigation of genital tract infections	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Committee consensus</a>	Funding not disclosed.	Author COI not disclosed.	<b>Date:</b> 2015-Nov	5 year cycle	Huda Almohri, M.D., FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Perinatal Services BC</b>  555 W 12th Ave, Vancouver, BC	Antidepressant use during pregnancy: considerations for the newborn exposed to SSRIs/SNRIs	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Provincial Health Services Authority.	No COI to disclose by authors.	<b>Date:</b> 2013-May	Cycle not indicated.	Dr. Catherine Cronin Neonatologist, Interior Health Region
<sup>2</sup>	<b>Perinatal Services BC</b>	Breastfeeding healthy term infant	Primary	No	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Provincial Health Services Authority.	No COI to disclose by authors.	<b>Date:</b> 2015-Mar	Cycle not indicated.	Roberta Hewat, PhD
<sup>2</sup>	<b>Perinatal Services BC</b>  BC Mental Health and Substance Use Services	Mental health disorders in the perinatal period	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Provincial Health Services Authority.	No COI to disclose by authors.	<b>Date:</b> 2014-Mar	Cycle not indicated.	Deirdre Ryan MB, FRCPC
<sup>2</sup>	<b>Perinatal Services BC</b>	Population and public health prenatal care pathway	Primary	Yes	<a href="#">More Details...</a>	Consensus and opinion.	Provincial Health Services Authority.	No COI to disclose by authors.	<b>Date:</b> 2014-Mar	Cycle not indicated.	Carolyn Solomon Committee Co-Chair, Manager-Maternal and Women's Health
<sup>2</sup>	<b>Perinatal Services BC</b>	<u>Standards for obstetrical ultrasound assessments</u>	Primary and Specialty	<u>Yes</u>	<a href="#">More Details...</a>	<u>Working group consensus.</u>	Provincial Health Services Authority.	No COI to disclose by authors.	<b>Date:</b> 2015-Dec	not indicated.  Cycle	Dr. Jason Burrows (MFM)
<sup>2</sup>	<b>Public Health Agency of Canada</b>	Sexually transmitted infections Section 1	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by	<b>Date:</b> 2016	Chapters updated as new evidence	Tom Wong, MD, MPH, FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	130 Colonnade Road  A.L. 6501H  Ottawa, ON						authors.		available.		
<sup>8</sup>	<b>Registered Nurses' Association of Ontario (RNAO)</b>  158 Pearl Street, Toronto, ON	Breastfeeding	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2003-Sep	3 year cycle	Monique Stewart, RN, BNSc, MN
<sup>8</sup>	<b>RNAO</b>	Interventions for Postpartum Depression	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2005-Apr	3 year cycle	Tazim Virani, RN, MScN, PhD(candidate)
<sup>8</sup>	<b>RNAO</b>	Woman Abuse: screening, identification and initial response	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2005-Mar	3 year cycle	Tazim Virani, RN, MScN, PhD(candidate)
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>  2781 Lancaster Road, Suite 200, Ottawa, ON K1B 1A7	Prenatal screening for fetal aneuploidy, fetal anomalies, and adverse pregnancy outcomes	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan	<a href="#">Method details.</a>	Funded by SOGC.	No COI to disclose by authors.	<b>Date:</b> 2011-Jul	5 year cycle.	David Chitayat, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Abnormal uterine bleeding in pre-menopausal women	Primary and Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2013-May	5 year cycle.	Sukhbir Singh, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Advanced reproductive age and fertility	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.  (2017 update published)	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2011-Nov	5 year cycle.	Kimberly Liu, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Alcohol use and pregnancy consensus clinical guidelines	Primary and Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.  (2017 update published)	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2010-Aug	5 year cycle.	George Carson, MD, FRCSC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Amniotic fluid: technical update on physiology and measurement	Specialty	Yes	<a href="#">More Details...</a> Members only access to guidelines dated post 2016-Jan. (full article not available)	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2016-Apr	5 year cycle.	Sari Kives, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Antibiotic prophylaxis in obstetric procedures	Specialty	Yes	<a href="#">More Details...</a> Members only access to guidelines dated post 2016-Jan. (2017 update published)	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2010-Sep	5 year cycle.	Julie van Schalkwyk, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Canadian contraception consensus Chapter 1 Contraception in Canada	Primary	No	<a href="#">More Details...</a> Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2015-Oct	5 year cycle.	Amanda Black, MD (Co-chair)
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Canadian contraception consensus Chapter 2 Contraceptive care and access	Primary	No	<a href="#">More Details...</a> Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2015-Oct	5 year cycle.	Amanda Black, MD (Co-chair)
<sup>2</sup>	Society of Obstetricians and	Canadian contraception consensus Chapter 3	Primary	No	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by	Date: 2015-	5 year cycle.	Amanda Black, MD (Co-chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Gynaecologists of Canada	Emergency contraception			Members only access to guidelines dated post 2016-Jan.			authors.	Oct		
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Canadian contraception consensus Chapter 4 Natural family planning	Primary	No	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2015- Nov	5 year cycle.	Amanda Black, MD (Co- chair)
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Canadian contraception consensus Chapter 5 Barrier methods	Primary	No	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2015- Nov	5 year cycle.	Amanda Black, MD (Co- chair)
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Canadian contraception consensus Chapter 6 Permanent contraception	Primary	No	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2015- Nov	5 year cycle.	Amanda Black, MD (Co- chair)
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Canadian contraception consensus Chapter 7 intrauterine contraception	Specialty	No	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2016- Feb	5 year cycle.	Amanda Black, MD (Co- chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
					available)						
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Canadian contraception consensus Chapter 8 progestin-only contraception	Primary	No	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2016- Mar	5 year cycle.	Amanda Black, MD (Co-chair)
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Care of pregnant women living with hiv and interventions to reduce perinatal transmission	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014- Aug	5 year cycle.	Deborah Money, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Cervical insufficiency and cervical cerclage	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2013- Dec	5 year cycle.	Richard Brown, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Determination of gestational age by ultrasound	Primary and Specialty	No	More Details... Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2014-Feb	5 year cycle.	Kimberly Butt, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Diabetes in pregnancy	Primary and Specialty	Yes	More Details... Members only access to guidelines dated post 2016-Jan. (full article not avail.)	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2016-Jul	5 year cycle.	Howard Berger, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy	Primary and Specialty	Yes	More Details... Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2014-May	5 year cycle.	Laura A. Magee, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Endometrial ablation in the management of abnormal uterine bleeding	Specialty	Yes	More Details... Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2015-Apr	5 year cycle.	Philippe Laberge, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Evaluation and treatment of recurrent urinary incontinence following pelvic floor surgery	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan. (2017 update not avail.)	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2010-Sep	5 year cycle.	Danny Lovatsis, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Female genital cosmetic surgery	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2013-Dec	5 year cycle.	Dorothy Shaw, MBChB
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Female genital cutting	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2013-Nov	5 year cycle.	Liette Perron, MSW
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Female nutrition: adolescence, reproduction, menopause, and beyond	Primary	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan. (full article not avail.)	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2016-Jun	5 year cycle.	Deborah L. O'Connor, PhD, RD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Female sexual health	Primary	No	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan. (2017 update not avail.)	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2012-Aug	5 year cycle.	John Lamont, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Induction of labour	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2013-Sep	5 year cycle.	Dean Leduc, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Intrauterine growth restriction: screening, diagnosis, and management	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2013-Aug	5 year cycle.	Andrea Lausman, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Investigation and management of non-immune fetal hydrops	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2013-Oct	5 year cycle.	Valérie Désilets, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Magnetic resonance imaging in the obstetric patient	Specialty	Yes	<a href="#">More Details...</a> Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014-Apr	5 year cycle.	<a href="#">Yves Patenaude, MD</a>
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Management of a pregnant trauma patient	Specialty	Yes	<a href="#">More Details...</a> Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2015-Jun	5 year cycle.	Venu Jain, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Management of uterine fibroids in women with otherwise unexplained infertility	Specialty	No	<a href="#">More Details...</a> Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2015-Mar	5 year cycle.	Belina Carranza-Mamane, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Management of uterine leiomyomas	Specialty	Yes	<a href="#">More Details...</a> Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2015-Feb	5 year cycle.	George A. Vilos, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Managing menopause Ch 1-9	Primary and Specialty	Yes	<a href="#">More Details...</a> Members only access to guidelines dated post	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014-Sep	5 year cycle.	Robert Reid, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
					2016-Jan.						
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Maternity leave in normal pregnancy	Primary	No	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan. (2017 update not avail.)	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2011- Aug	5 year cycle.	Dean Leduc, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Medical abortion	Primary and Specialty	No	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan. (full article not avail.)	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2016- Apr	5 year cycle.	Dustin Costescu, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Menstrual suppression in special circumstances	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014- Oct	5 year cycle.	Yolanda A. Kirkham, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Minimize risk of infection with intrauterine device insertion	Specialty	Yes	<a href="#">More Details..</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014-Mar	5 year cycle.	Sheila Caddy, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Obstetrical anal sphincter injuries (OASIS): prevention, recognition, and repair	Specialty	No	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2015-Dec	5 year cycle.	Marie-Andrée Harvey, MD, MSc
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Osteoporosis in menopause	Primary	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014-Sep	5 year cycle.	Aliya Khan, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Parvovirus B19 infection in pregnancy	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014-Dec	5 year cycle.	Joan Crane, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital	Primary	No	<a href="#">More Details...</a>  Members only access to guidelines dated post	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2015-May	5 year cycle.	R. Douglas Wilson, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		anomalies			2016-Jan.						
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Pregnancy outcomes after assisted human reproduction	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014- Jan	5 year cycle.	Nanette Okun, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Prenatal diagnosis procedures and techniques to obtain a diagnostic fetal specimen or tissue: maternal and fetal risks and benefits	Specialty	No	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2015- Jul	5 year cycle.	R. Douglas Wilson, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Prenatal invasive procedures in women with hepatitis b, hepatitis c, and/or human immunodeficiency virus infections	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014- Jul	5 year cycle.	Alain Gagnon, MD, FRCSC
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Prenatal screening, diagnosis, and pregnancy management of fetal neural tube defects	Specialty	No	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014- Oct	5 year cycle.	R. Douglas Wilson, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Prevention of ovarian hyperstimulation syndrome	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014-Nov	5 year cycle.	Shannon Corbett, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Surgical safety checklist in obstetrics and gynaecology	Specialty	No	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2013-Jan	5 year cycle.	Sukhbir S. Singh, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Technical update on pessary use	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2013-Jul	5 year cycle.	Magali Robert, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Technical update on tissue morcellation during gynaecologic surgery: its uses, complications and risks of unsuspected malignancy	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2015-Jan	5 year cycle.	Sukhbir S. Singh, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Toxoplasmosis in pregnancy: Prevention, screening, and treatment	Specialty	No	<a href="#">More Details...</a>  Members only access to guidelines dated post	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2013-Jan	5 year cycle.	Caroline Paquet, RM

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
					2016-Jan.						
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Umbilical cord blood banking : implications for perinatal care providers	Specialty	No	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2015- Sep	5 year cycle.	B. Anthony Armon, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Venous thromboembolism and antithrombotic therapy in pregnancy	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2014- Jun	5 year cycle.	Wee-Shian Chan, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	<b>Date:</b> 2015- Mar	5 year cycle.	Julie van Schalkwyk, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada Canadian Association of Radiologists	Non-medical use of fetal ultrasound	Specialty	No	<a href="#">More Details...</a> Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2014-Feb	5 year cycle.	Shia Salem, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada Canadian Paediatric Society	Prevention of early-onset neonatal group B streptococcal disease	Specialty	No	<a href="#">More Details...</a> Members only access to guidelines dated post 2016-Jan.	<a href="#">Method details.</a>	Funded by SOGC.	COI disclosed by authors.	Date: 2013-Oct	5 year cycle.	Deborah Money, MD
<sup>1</sup>	Toward Optimized Practice #200, 12315 Stony Plain Road Edmonton, AB	Laboratory Endocrine Testing Guidelines: Amenorrhea (without Hirsutism) and Menopause	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	Author COI declared.	Date: 2008-Jan	2-5 year cycle	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>2</sup>	Toward Optimized Practice	Third trimester fetal well-being studies: criteria and managing results	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	Author COI declared.	Date: 2017-Jun	2-5 year cycle	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>2</sup>	Toward Optimized Practice	Ultrasound for twin and multiple pregnancies	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	Author COI declared.	Date: 2017-Jun	2-5 year cycle	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>10</sup>	Winnipeg Regional Health Authority	Breastfeeding	Primary	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health	Author COI not	Date: 2013-	Cycle not	Kathy Hamelin, Clinical Nurse Specialist

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	(WHRA) 650 Main St, Winnipeg, MB						Authority	disclosed.	Jun	indicated.	

## Genetics / Genetic Disorders

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>BC Guidelines</b> <u>PO Box 9642 STN PROV GOVT Victoria BC</u>	HFE-associated hereditary hemochromatosis investigations and management	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2013-Apr	3-5 year cycle	GPAC Working Group <a href="mailto:hth.guidelines@gov.bc.ca">hth.guidelines@gov.bc.ca</a>
<sup>2</sup>	<b>Canadian Paediatric Society</b> <u>2305 St Laurent Blvd, Ottawa, ON</u>	Genetic testing of healthy children	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2015-Jan	3 year cycle.	Laura Arbour MD
<sup>2</sup>	<b>Canadian Pharmacogenomics Network for Drug Safety</b>  950 West 28th Avenue 3rd Floor Vancouver, BC	CYP2D6 genotyping for safe and efficacious codeine therapy	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	CIHR Meeting, Planning and Dissemination Grant – KT Supplement.	Author COI not disclosed.	<b>Date:</b> 2013-Nov	Cycle not indicated.	Bruce Carleton, B.Pharm, Pharm.D.
<sup>2</sup>	<b>Canadian Psoriasis Guidelines Committee</b>  135 Union Street East, Waterloo, ON	Plaque psoriasis	Specialty	Yes	<a href="#">More Details...</a>	CMA Handbook on CPGs (2007)	Funding: AbbVie Canada Inc, Amgen Canada Inc, LEO Pharma Inc, Novartis Canada, Pfizer Canada	COI disclosed by authors.	<b>Date:</b> 2016-May	Cycle not indicated.	Kim Alexander Papp, MD, PhD, FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Cancer Care Ontario  620 University Avenue  Toronto, ON	Sequence variants in hereditary cancers guideline	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2017-Aug	<a href="#">Document assessment/review protocol.</a>	Harriet Feilotter  Molecular Geneticist, Chair Molecular Oncology and Testing Advisory Committee
<sup>2</sup>	Cancer Care Ontario	DNMT3A biomarker in cytogenetically normal patients with acute myeloid leukemia	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Nov	<a href="#">Document assessment/review protocol.</a>	Harriet Feilotter  Molecular Geneticist, Chair Molecular Oncology and Testing Advisory Committee
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada  2781 Lancaster Road, Suite 200, Ottawa, ON	Investigation and management of non-immune fetal hydrops	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan	<a href="#">Method details.</a>	Funded by SOGC.	No COI to disclose by authors.	Date: 2013-Oct	5 year cycle.	Valérie Désilets, MD
<sup>2</sup>	Society of Obstetricians and Gynaecologists of Canada	Preimplantation genetic diagnosis and screening	Specialty	Yes	<a href="#">More Details...</a>  Members only access to guidelines dated post 2016-Jan	<a href="#">Method details.</a>	Funded by SOGC.	No COI to disclose by authors.	Date: 2015-May	5 year cycle.	Elias M. Dahdouh, MD
<sup>1</sup>	Toward Optimal Practice  #200, 12315 Stony Plain Road Edmonton, AB	Diagnosis and Management of Hemochromatosis	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2010-Feb	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>

## Health Services and Policy Research

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Alberta Health Services – Cancer Care  Seventh Street Plaza 14th Floor, North Tower 10030 – 107 Street NW Edmonton, Alberta T5J 3E4	Organization and delivery of healthcare services for head and neck cancer patients	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	No direct industry involvement.	Some members of the AB Provincial Head and Neck Tumour Team are involved in research funded by industry or have other potential conflicts of interest.	Date: 2015-Nov	Annual cycle.	AB Provincial Head and Neck Tumour Team: medical oncologists, radiation oncologists, surgical oncologists, nurses, pathologists, and pharmacists.  <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	BC Guidelines  PO Box 9642 STN PROV GOVT  Victoria BC	Ambulatory ECG monitoring (Holter monitor and other devices)	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	Date: 2013-Apr	3-5 year cycle.	GPAC Working Group  <a href="mailto:hth.guidelines@gov.bc.ca">hth.guidelines@gov.bc.ca</a>
<sup>2</sup>	Canadian Anesthesiologists' Society  1 Eglinton Avenue East, Suite 208  Toronto, ON	Practice of anesthesia	Specialty	Yes	<a href="#">More Details...</a>	Method not indicated.	Funded by CAS.	No COI to disclose by authors.	Date: 2018	Annual cycle.	Gregory Dobson, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Association of Emergency Physicians <i>180 Elgin St, Suite # 808 Ottawa, ON</i>	Emergency Department Triage and Acuity Scale (CTAS)	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement instructions</a>	Funding not disclosed.	Author COI not disclosed.	Date: 2014-Apr	4 year cycle.	Michael J. Bullard, MD
<sup>2</sup>	Canadian Association of Emergency Physicians	Vasopressor and inotrope use in Canadian emergency departments	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement instructions</a>	No industry funding.	No COI to disclose by authors.	Date: 2015-Feb	Cycle not disclosed.	Dennis Djogovic, MD, FRCPC
<sup>2</sup>	Canadian Association of Gastroenterology <i>189 Queen Street East, Suite 1, Toronto, ON</i>	Safety and quality indicators in endoscopy	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Cdn Partnership Against Cancer; CIHR.	COI disclosed by authors.	Date: 2012-Jan	Updated when approved by committee.	David Armstrong MB BChir
<sup>2</sup>	Canadian Association of Pathologists <i>4 Cataraqui Street, Suite 310 Kingston, ON</i>	Telepathology service for anatomic pathology using whole-slide imaging	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Process</a>	Not disclosed.	Author COI not disclosed.	Date: 2014-Mar	5 year cycle.	Bernard Têtu MD
<sup>2</sup>	Canadian Association of Radiologists <i>294 Albert St Suite 600, Ottawa, ON</i>	Prevention of contrast-induced nephropathy	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funding not disclosed.	No COI to disclose by authors.	Date: 2014-May	Cycle not indicated.	Richard J. Owen, MBBCh, MRCP, FRCR

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Council of Motor Transport Administrators <i>1111 Prince of Wales Dr, Ottawa, ON</i>	Determining driver fitness in Canada	Primary	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Provincial governments.	No COI to disclose by authors.	Date: 2015-Dec	Cycle not indicated.	Terry Wallace (Chair) Executive Director Driver Programs Alberta Transportation
<sup>2</sup>	Canadian Institutes of Health Research <i>190 Elgin St. Ottawa, ON</i>	HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE</a>	CIHR funded.	COI disclosed by authors.	Date: 2017-Nov	5 year cycle	Darrell H. S. Tan MD PhD
<sup>2</sup>	Canadian Paediatric Society <i>2305 St Laurent Blvd, Ottawa, ON</i>	Interfacility transport of critically ill newborns	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2015-Jun	3 year cycle.	Hilary EA Whyte MD, Fetus and Newborn Committee
<sup>2</sup>	Canadian Paediatric Society	Needle stick injuries in the community	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2017-Jan	3 year cycle.	Robert Bortolussi MD (Chair)
<sup>2</sup>	Canadian Paediatric Society	Read, speak, sing : promoting literacy in the physician's office	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2017-Jan	3 year cycle.	John LeBlanc MD (chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	School and daycare exclusion policies for chickenpox: a rational approach	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2016-Feb	3 year cycle.	Gilles Delage MD (Chair)
<sup>2</sup>	Canadian Paediatric Society	Special considerations for the health supervision of children and youth in foster care	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2016-Feb	3 year cycle.	Mark Feldman MD (chair)
<sup>2</sup>	Canadian Paediatric Society	Health care standards for youth in custodial facilities	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2016-Feb	3 year cycle.	Jean-Yves Frappier MD
<sup>2</sup>	Canadian Paediatric Society	Transracial adoption	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2017-Jan	3 year cycle.	Michelle Ponti MD (chair)
<sup>2</sup>	Cancer Care Ontario <i>620 University Avenue Toronto, Ontario Canada M5G 2L7</i>	Colonoscopy quality assurance in Ontario	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Sep	<a href="#">Document assessment/review protocol.</a>	Dr. Jill Timmouth, Chair, Colonoscopy Quality Assurance Guideline Working Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Cancer Care Ontario	Effective use of advanced practice nurses in the delivery of adult cancer services in Ontario	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-May	<a href="#">Document assessment/review protocol.</a>	Denise Bryant-Lukosius, RN, CON(C) PhD, former oncology CNS (lead)
<sup>2</sup>	Cancer Care Ontario	Safe handling of cytotoxics	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2013-Dec	<a href="#">Document assessment/review protocol.</a>	Susan Dent MD FRCPC, Safe Handling of Cytotoxics Expert Panel
<sup>2</sup>	Cancer Care Ontario	Advanced practice nurses in the delivery of adult cancer services in Ontario	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	Date: 2015-May	<a href="#">Document assessment/review protocol.</a>	Denise Bryant-Lukosius, RN, CON(C) PhD, former oncology CNS (lead)
<sup>2</sup>	College of Dental Hygienists of British Columbia  Suite 600, 3795 Carey Road  Victoria, BC	Infection prevention and control guidelines	Specialty	Yes	<a href="#">More Details...</a>	Working group consensus.	Funding not disclosed.	COI not disclosed.	Date: 2012-Jul	Cycle not indicated.	Rebecca Chisholm  Director of Policy and  Dental Hygiene Practice

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	College of Family Physicians of Canada  2630 Skymark Avenue  Mississauga, ON	Rural maternity care	Primary and Specialty	No	<a href="#">More Details...</a>	Working group consensus.	Funding not disclosed.	COI not disclosed.	Date: 2017-Dec	3 year cycle.	Katherine J. Miller, MD
<sup>5</sup>	College of Physicians and Surgeons of Ontario  80 College Street Toronto, ON	Chronic Kidney Disease and Dialysis	Primary and Specialty	Yes	<a href="#">More Details...</a>	Task force consensus.	College funded.	Author COI not disclosed.	Date: 2010-Jul	5 year cycle.	Dr. Arif Manuel, Chair
<sup>5</sup>	College of Physicians and Surgeons of ON	Diagnostic Imaging	Specialty	Yes	<a href="#">More Details...</a>	Task force consensus.	College funded.	Author COI not disclosed.	Date: 2013-May	5 year cycle.	Dr. Paul Voorheis, Chair Diagnostic Imaging Task Force
<sup>5</sup>	College of Physicians and Surgeons of ON	Infection Prevention and Control for Clinical Office Practice	Primary and Specialty	Yes	<a href="#">More Details...</a>	Advisory Committee Consensus.	Public Health ON	Author COI not disclosed.	Date: 2015-Apr	Updated as new evidence available.	Dr. Matthew Muller, Chair, Provincial Infectious Diseases Advisory Council.
<sup>5</sup>	College of Physicians and Surgeons of ON	Laser Treatment for Benign Vascular Lesions	Specialty	Yes	<a href="#">More Details...</a>	Task force consensus.	College funded.	Author COI not disclosed.	Date: 2009-Mar	5 year cycle.	Dr. Neil Shear, Chair, Dermatology Task Force
<sup>5</sup>	College of Physicians and	Magnetic Resonance Imaging &	Specialty	Yes	<a href="#">More Details...</a>	Task force consensus.	College funded.	Author COI not	Date: 2015-	5 year cycle.	Dr. Paul Voorheis, Chair, MRI and CT Task Force

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Surgeons of ON	Computed Tomography						disclosed.	Oct		
<sup>5</sup>	College of Physicians and Surgeons of ON	Managing Disruptive Physician Behaviour	Primary and Specialty	No	<a href="#">More Details...</a>	Steering Committee consensus.	College funded.	Author COI not disclosed.	Date: 2008-Apr	Cycle not indicated.	Dr. Ken Harris, Steering Committee
<sup>5</sup>	College of Physicians and Surgeons of ON	Nuclear Medicine	Specialty	Yes	<a href="#">More Details...</a>	Task force consensus.	College funded.	Author COI not disclosed.	Date: 2011-Aug	5 year cycle.	Dr. Christopher O'Brien, Chair, PET Task Force
<sup>5</sup>	College of Physicians and Surgeons of ON	Ophthalmology	Specialty	Yes	<a href="#">More Details...</a>	Task force consensus.	College funded.	Author COI not disclosed.	Date: 2012-Oct	5 year cycle.	Dr. E. Rand Simpson, Chair, Ophthalmology Task Force
<sup>5</sup>	College of Physicians and Surgeons of ON	Out-of-Hospital Premises Standards	Primary and Specialty	Yes	<a href="#">More Details...</a>	Summary of standards and regulations	College funded.	Author COI not disclosed.	Date: 2016-Dec	5 year cycle.	Shandelle Johnson Manager, Practice Assessment and Enhancement
<sup>2,5</sup>	College of Physicians and Surgeons of ON	Pulmonary Function Studies	Specialty	Yes	<a href="#">More Details...</a>	Task force consensus.	College funded.	Author COI not disclosed.	Date: 2014-Jun	5 year cycle.	Kenneth Chapman MD, M.Sc., FRCPC, FACP

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Diabetes Canada  1400-522 University Ave  Toronto ON	Diabetes and driving	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	In-hospital management of diabetes	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Organization of diabetes care	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>6</sup>	Ontario Association of Medical Laboratories  1802, 5000 Yonge St, North York, ON	Collection and Testing of Stool Specimens for Ova and Parasites in Symptomatic Patients	Primary and Specialty	Yes	<a href="#">More Details...</a>	Committee consensus	Funded through OAML.	Author COI not disclosed.	Date: 2015-May	5 year cycle.	Anu Rebbapragada Ph.D., CIC
<sup>6</sup>	OAML	Indications for Urine Culture	Primary	Yes	<a href="#">More Details...</a>	Committee consensus	Funded through OAML.	Author COI not disclosed.	Date: 2001-May	5 year cycle.	Andrew Baines, MD, Ph.D., FRCPC
<sup>6</sup>	OAML	Laboratory Monitoring of Oral Anticoagulation	Primary	Yes	<a href="#">More Details...</a>	Committee consensus	Funded through OAML.	Author COI not disclosed.	Date: 2008-Sep	5 year cycle.	Judy Ash BSc, MLT, ART, CQMgr, CQA (ASQ)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		(Warfarin)									
<sup>6</sup>	OAML	Laboratory Tests to Detect Thyroid Dysfunction	Primary	Yes	<a href="#">More Details...</a>	Committee consensus	Funded through OAML.	Author COI not disclosed.	Date: 2007-Jul	5 year cycle.	Judy Ash BSc, MLT, ART, CQMgr, CQA (ASQ)
<sup>6</sup>	OAML	Ordering of Erythrocyte Sedimentation Rate (ESR)	Primary	Yes	<a href="#">More Details...</a>	Committee consensus	Funded through OAML.	Author COI not disclosed.	Date: 2001-Mar	5 year cycle.	Judy Ash BSc, MLT, ART, CQMgr, CQA (ASQ)
<sup>6</sup>	OAML	Ordering of Microscopic Urinalysis	Primary	Yes	<a href="#">More Details...</a>	Committee consensus	Funded through OAML.	Author COI not disclosed.	Date: 2012-Jun	5 year cycle.	Judy Ash BSc, MLT, ART, CQMgr, CQA (ASQ)
<sup>6</sup>	OAML	Ordering Serum Levels of Gonadotropins (FSH, LH) and Prolactin CLP-021	Primary	Yes	<a href="#">More Details...</a>	Committee consensus	Funded through OAML.	Author COI not disclosed.	Date: 2008-Jun	5 year cycle.	Judy Ash BSc, MLT, ART, CQMgr, CQA (ASQ)
<sup>6</sup>	OAML	Ordering Urine Testing for Drugs of Abuse: Targeted and Screening Tests	Primary	Yes	<a href="#">More Details...</a>	Committee consensus	Funded through OAML.	Author COI not disclosed.	Date: 2013-Mar	5 year cycle.	Judy Ash BSc, MLT, ART, CQMgr, CQA (ASQ)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>6</sup>	OAML	Pre-Analytical Laboratory Procedures for Medical Office Staff	Primary	Yes	<a href="#">More Details...</a>	Committee consensus	Funded through OAML.	Author COI not disclosed.	Date: 2007-Mar	5 year cycle.	Judy Ash BSc, MLT, ART, CQMgr, CQA (ASQ)
<sup>6</sup>	OAML	Rejection of Specimens	Specialty	Yes	<a href="#">More Details...</a>	Committee consensus	Funded through OAML.	Author COI not disclosed.	Date: 2007-Mar	5 year cycle.	Judy Ash BSc, MLT, ART, CQMgr, CQA (ASQ)
<sup>6</sup>	OAML	Retention of Laboratory Records & Materials	Specialty	n/a	<a href="#">More Details...</a>	Committee consensus	Funded through OAML.	Author COI not disclosed.	Date: 2006-Jun	5 year cycle.	Judy Ash BSc, MLT, ART, CQMgr, CQA (ASQ)
<sup>6</sup>	OAML	Serum Tests to Detect Renal Dysfunction	Primary and Specialty	Yes	<a href="#">More Details...</a>	Committee Consensus	Funded through OAML.	Author COI not disclosed.	Date: 1996	5 year cycle.	Judy Ash BSc, MLT, ART, CQMgr, CQA (ASQ)
<sup>6</sup>	OAML	Collection and Storage of Bacteriology Specimens for Testing	Primary	Yes	<a href="#">More Details...</a>	Committee Consensus	Funded through OAML.	Author COI not disclosed.	Date: 2004-Apr	5 year cycle.	Judy Ash BSc, MLT, ART, CQMgr, CQA (ASQ)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Ontario Agency for Health Protection and Promotion <i>480 University Avenue, Suite 300 Toronto ON</i>	Cleaning, disinfection and sterilization of medical equipment/devices in all health care settings	Primary and Specialty	n/a	<a href="#">More Details...</a>	Advisory Committee Consensus	Public Health Ontario.	Author COI not disclosed.	Date: 2013-May	Updated as required.	Dr. Mary Vearncombe, Chair, Provincial Infectious Diseases Advisory Committee on Infection Prevention and Control
<sup>2</sup>	Perinatal Services BC <i>555 W 12th Ave, Vancouver, BC</i>	Maternal newborn transfer network: principles and processes	Specialty	Yes	<a href="#">More Details...</a>	Working group consensus.	Provincial Health Services Authority.	No COI to disclose by authors.	Date: 2014-Apr	Cycle not indicated.	Peter Beresford, MD, FRCSC
<sup>7</sup>	Public Health Agency of Canada	Environmental Sanitation Practices to Control the Spread of Communicable Disease in Passenger Conveyances and Terminals	n/a	n/a	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	Date: 2014-Jun	Cycle not indicated.	Travelling Public Program
<sup>7</sup>	Public Health Agency of Canada	Infection Prevention and Control Guideline for Flexible Gastrointestinal Endoscopy and Flexible Bronchoscopy	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	Date: 2011	Cycle not indicated.	Jonathan Love, MD, FRCPC
<sup>7</sup>	Public Health Agency of Canada	Prevention and Control of Measles Outbreaks in	n/a	n/a	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by	Date: 2013	Cycle not indicated.	Gaston DeSerres, Measles and Rubella Elimination Working Group

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Canada						authors.			
<sup>7</sup>	Public Health Agency of Canada	Routine Practices and Additional Precautions for Preventing the Transmission of Infection in Healthcare Settings	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	Date: 2014	Cycle not indicated.	Geoffrey Taylor, MD, FRCPC, FACP
<sup>7</sup>	Public Health Agency of Canada	Vaccine Storage and Handling	Primary	n/a	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	Date: 2015	Cycle not indicated.	Julie Laroche, Vaccine and Immunization Program Surveillance Division (PHAC)
<sup>2</sup>	Registered Nurses' Association of Ontario (RNAO) <i>158 Pearl Street, Toronto, ON</i>	Care transitions	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2014-Apr	3 year cycle.	Nancy Pearce, RN, PhD
<sup>2</sup>	RNAO	Engaging clients who use substances	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2015-Mar	3 year cycle.	Wayne Skinner, MSW, RSW Panel Co-Chair
<sup>8</sup>	RNAO	Assessment and Device Selection for Vascular Access	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2004-May	3 year cycle.	Julia Johnston, RN, BScN, MN, CINA(c)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>8</sup>	RNAO	Care and Maintenance to Reduce Vascular Access Complications	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2005-Apr	3 year cycle.	Tazim Virani, RN, MScN, PhD(candidate)
<sup>8</sup>	RNAO	Crisis Intervention for Adults Using a Trauma-Informed Approach	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2017-Dec	3 year cycle.	Sabrina Merali, RN, MN
<sup>8</sup>	RNAO	Establishing Therapeutic Relationships	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2002-Jul	3 year cycle.	Ruth Gallop, RN, PhD
<sup>8</sup>	RNAO	Facilitating Client Centred Learning	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2012-Sep	3 year cycle.	Audrey Friedman, RTT, MSW
<sup>8</sup>	RNAO	Person-and Family-Centred Care	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2015-May	3 year cycle.	Eleanor Rivoire, RN, BScN, MSc (Pediatrics) Expert Panel Co-Chair
<sup>8</sup>	RNAO	Strategies to Support Self-Management in Chronic	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and	No COI to disclose by	Date: 2010-Sep	3 year cycle.	Patrick McGowan, PhD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Conditions: Collaboration with Clients				LTC.	authors.				
<sup>8</sup>	RNAO	Supporting and Strengthening Families Through Expected and Unexpected Life Events	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	Date: 2002- Jul	3 year cycle.	Claire Mallette, RN, PhD(cand.)
<sup>1,2</sup>	TOP Alberta Doctors <i>#200, 12315 Stony Plain Road Edmonton, AB</i>	Doctors Opposing Violence Everywhere (DOVE)	Primary and Specialty	n/a	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2015- Jan	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>10</sup>	Winnipeg Regional Health Authority (WRHA) <i>650 Main St, Winnipeg, MB</i>	Advance Care Planning (Operating Room and Immediate Postoperative Period)	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority.	Author COI not disclosed.	Date: 2011- Dec	Cycle not indicated.	Carol Knudson: WRHA Perioperative and MDR Nurse Educator
<sup>10</sup>	WRHA	Intranasal Medication Administration	Primary and Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority.	Author COI not disclosed.	Date: 2017- Nov	Cycle not indicated.	Lisa Streeter RN MN CHPCN(c)
<sup>10</sup>	WRHA	Management of throat packs during surgical procedures	Specialty	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority.	Author COI not disclosed.	Date: 2014- Sep	Cycle not indicated.	Lanette Siragusa, Director, WRHA Surgery Program

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>10</sup>	WRHA	Observation and Therapeutic Engagement Levels	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority.	Author COI not disclosed.	Date: 2017-Nov	Cycle not indicated.	Dr. Jitender Sareen, WRHA Regional Medical Director, Mental Health
<sup>10</sup>	WRHA	Patient Positioning for Surgical Procedures	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority.	Author COI not disclosed.	Date: 2011-Dec	Cycle not indicated.	Carol Knudson: WRHA Perioperative & MDR Nurse Educator
<sup>10</sup>	WRHA	Preoperative Fasting (Adult)	Specialty	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority.	Author COI not disclosed.	Date: 2013-Sep	Cycle not indicated.	Dr. Fahd Al Gurashi; Site Medical Manager Obstetrical Anesthesia
<sup>10</sup>	WRHA	Sedation for Palliative Purposes	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority.	Author COI not disclosed.	Date: 2017-Jul	Cycle not indicated.	Dr. Mike Harlos, Medical Director, WRHA Adult and Pediatric Palliative Care
<sup>10</sup>	WRHA	Surgical Skin Preparation	Specialty	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority.	Author COI not disclosed.	Date: 2011-May	Cycle not indicated.	Carol Knudson: WRHA Perioperative & MDR Nurse Educator
<sup>10</sup>	WRHA	Telemetry	Specialty	Yes	<a href="#">More</a>	Summary of guidelines.	Winnipeg Regional	Author COI not	Date: 2012-	Cycle not indicated.	Dr. Roger Philipp, WHRA

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Guidelines			<a href="#">Details...</a>	Consensus.	Health Authority.	disclosed.	Oct		Cardiac Services

## Human Development, Child and Youth Health

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Academy of Sport and Exercise Medicine <i>55 Metcalfe Street Suite 300 Ottawa, ON</i>	Physical activity prescription: a critical opportunity to address a modifiable risk factor for the prevention and management of chronic disease	Primary	Yes	<a href="#">More Details...</a>	Consensus.	Funding not declared.	No COI to disclose by authors.	<b>Date:</b> 2016-Jul	Cycle not indicated.	Jane Thornton, BScKin(H), MSc, MD, PhD
<sup>2</sup>	Active Healthy Kids Canada <i>401 Smyth Road, Ottawa, ON</i>	Active video games for children and youth	Primary	No	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Active Healthy Kids Canada	Author COI not disclosed.	<b>Date:</b> 2013-Dec	Cycle not indicated.	Jean-Philippe Chaput PhD
<sup>2,3</sup>	<a href="#"><u>BC Guidelines</u></a> <i>PO Box 9642 STN PROV GOVT Victoria BC</i>	Asthma in children - diagnosis and management	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	<a href="#">BC Ministry of Health</a>	No COI to disclose by authors.	<b>Date:</b> 2015-Oct	3-5 year review cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Anxiety and Depression in Children and Youth - Diagnosis and Treatment	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	<a href="#">BC Ministry of Health</a>	No COI to disclose by authors.	<b>Date:</b> 2010-Jan	3-5 year review cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Oral Rehydration Therapy (ORT) in Children	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	<a href="#">BC Ministry of Health</a>	No COI to disclose by authors.	<b>Date:</b> 2010-Sep	3-5 year review cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>3</sup>	<b>BC Guidelines</b>	Otitis Media - Acute Otitis Media & Otitis Media with Effusion	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2010-Jan	3-5 year review cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Febrile Seizures	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2010-Sep	3-5 year review cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2</sup>	<b>British Columbia Centre for Disease Control</b>  655 West 12th Avenue Vancouver, BC	Sexually transmitted infections in adolescents and adults	Primary	Yes	<a href="#">More Details...</a>	Methods not declared.	Provincial Health Services Authority.	Author COI not disclosed.	<b>Date:</b> 2014-Aug	Regular updates.	Richard Lester, MD, FRCP(C)
<sup>2</sup>	<b>British Columbia Centre for Excellence in HIV/AIDS</b>  4500 Oak Street Vancouver, BC	HIV infected and exposed children	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	BC Women's Hospital and Health Centre	Author COI not disclosed.	<b>Date:</b> 2014	Cycle not indicated.	Neora Pick, MD, FRCPC
<sup>2</sup>	<b>British Columbia Centre for Excellence in HIV/AIDS</b>	HIV positive pregnant women and interventions to reduce perinatal transmission guidelines	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	BC Women's Hospital and Health Centre	Author COI not disclosed.	<b>Date:</b> 2013-Jul	Cycle not indicated.	Deborah Money, MD, FRCSC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canada Fetal Alcohol Spectrum Disorder Research Network</b>  PO Box 11364 Wessex PO  Vancouver, BC	Fetal alcohol spectrum disorder: a guideline for diagnosis across the lifespan	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Public Health Agency funding.	COI disclosed by authors.	<b>Date:</b> 2015-Dec	Re-evaluated based on new evidence.	Jocelynn L. Cook PhD
<sup>2</sup>	<b>Canadian Academy of Child and Adolescent Psychiatry</b>  141 Laurier Ave W, Ottawa, ON	SSRIs and SNRIs with children and adolescents in clinical practice	Specialty	Yes	<a href="#">More Details...</a>	Data review.	CACAP funded.	No COI to disclose by authors.	<b>Date:</b> 2016-Feb	Re-evaluated based on new evidence.	E. Jane Garland MD, FRCPC
<sup>2</sup>	<b>Canadian Cardiovascular Society</b>  222 Queen Street, Suite 1100 Ottawa, ON	Cardiac risk assessment before the use of stimulant medications in children and youth	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">CCS Guideline process</a>	<u>Funded through CCS operating budget.</u>	No COI to disclose by authors.	<b>Date:</b> 2009-Nov	Updates determined by Guidelines Committee.	AE Warren MD MSc FRCPC
<sup>2,11</sup>	<b>Canadian Cardiovascular Society</b>	Presentation, diagnosis, and medical management of heart failure in children: guidelines	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">CCS Guideline process</a>	<u>Funded through CCS operating budget.</u>	<a href="#">Link to COI disclosures.</a>	<b>Date:</b> 2013-Dec	Updates determined by Guidelines Committee.	Paul F. Kantor, MBBCh
<sup>2,11</sup>	<b>Canadian Cardiovascular Society</b>	Syncope in the pediatric patient	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">CCS Guideline process</a>	<u>Funded through CCS operating budget.</u>	<a href="#">Link to COI disclosures.</a>	<b>Date:</b> 2017-Feb	Updates determined by Guidelines	Shubhayan Sanatani, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
										Committee.	
<sup>2</sup>	<b>Canadian Paediatric Society</b> <i>2305 St Laurent Blvd, Ottawa, ON</i>	Air travel and children's health issues	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Mark Feldman MD (chair), Community Paediatrics Committee
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Sexual abuse of young people with a disability or chronic health condition	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Miriam Kaufman MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Healthy active living: Physical activity guidelines for children and adolescents	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2012-Apr	3 year cycle.	Stan Lipnowski MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Dietary exposures and allergy prevention in high-risk infants	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Edmond S Chan MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Emergency treatment of anaphylaxis in infants and children	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Adam Cheng MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Family-based treatment of children and adolescents with anorexia nervosa	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Sheri M Findlay MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Antimicrobial stewardship in daily practice: managing an important resource	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2014-May	3 year cycle.	Nicole Le Saux MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Preventing and treating infections in children with asplenia or hypoplasia	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Marina I Salvadori MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Managing the paediatric patient with an acute asthma exacerbation	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Oliva Ortiz-Alvarez MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Extended-release medications for children and adolescents with attention-deficit hyperactivity disorder	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Mark Feldman MD
<sup>2</sup>	Canadian Paediatric Society	A bite in the playroom: managing human bites in child care settings	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Dorothy L Moore MD
<sup>2</sup>	Canadian Paediatric Society	Minimizing blood loss and the need for transfusions in very premature infants	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2015-Dec	3 year cycle.	Brigitte Lemyre MD
<sup>2</sup>	Canadian Paediatric Society	Red blood cell transfusion in newborn infants	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Robin K Whyte MD
<sup>2</sup>	Canadian Paediatric Society	Ankyloglossia and breastfeeding	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2015-May	3 year cycle.	Anne Rowan-Legg MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Baby-friendly Initiative: Protecting, promoting and supporting breastfeeding	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Catherine M Pound MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Weaning from the breast	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Barbara Grueger MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Bronchiolitis: recommendations for diagnosis, monitoring and management of children one to 24 months of age	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2018-Jan	3 year cycle.	Jeremy N Friedman MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Cannabis and Canada's children and youth	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-May	3 year cycle.	Christina N. Grant MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Medical use of cannabis a therapeutic option for children?	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Michael J Rieder MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Assessment of cardiorespiratory stability using the infant car seat challenge before discharge in preterm infants (<37 weeks' gestational age)	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Apr	3 year cycle.	Michael R Narvey MD
<sup>2</sup>	Canadian Paediatric Society	Health implications of children in child care centres: Part A: Canadian trends in child care, behaviour and developmental outcomes	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle	Mia Lang MD
<sup>2</sup>	Canadian Paediatric Society	Health implications of children in child care centres: Part B: Injuries and infections	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Mia Lang MD
<sup>2</sup>	Canadian Paediatric Society	Chiropractic care for children : controversies and issues	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Linda Spigelblatt MD
<sup>2</sup>	Canadian Paediatric Society	Care of adolescents with chronic conditions	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Jorge Pinzon MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Neonatal male circumcision	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2015-Sep	3 year cycle.	S Todd Sorokan MD
<sup>2</sup>	Canadian Paediatric Society	Clostridium difficile in paediatric populations	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Upton D Allen MD
<sup>2</sup>	Canadian Paediatric Society	Sport-related concussion: evaluation and management	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2014-Mar	3 year cycle.	Laura K Purcell MD
<sup>2</sup>	Canadian Paediatric Society	Emergency management of the paediatric patient with generalized convulsive status epilepticus	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Jeremy N Friedman MD
<sup>2</sup>	Canadian Paediatric Society	Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Ann L Jefferies MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Acute management of croup in the emergency department	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-May	3 year cycle.	Oliva Ortiz-Alvarez MD
<sup>2</sup>	Canadian Paediatric Society	Maternal depression and child development	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2015-Jan	3 year cycle.	Anne-Claude Bernard-Bonnin MD
<sup>2</sup>	Canadian Paediatric Society	Type 1 diabetes in school	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2015-Feb	3 year cycle.	Sarah E Lawrence MD
<sup>2</sup>	Canadian Paediatric Society	Dieting in adolescence	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Sheri M Findlay MD
<sup>2</sup>	Canadian Paediatric Society	Fetal alcohol syndrome	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	John Godel MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Youth and firearms in Canada	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2018-Feb	3 year cycle.	Katherine Austin MD
<sup>2</sup>	Canadian Paediatric Society	Folate and neural tube defects: The role of supplements and food fortification	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Apr	3 year cycle.	Mark Bernstein MD
<sup>2</sup>	Canadian Paediatric Society	Special considerations for the health supervision of children and youth in foster care	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Michelle Ponti MD
<sup>2</sup>	Canadian Paediatric Society	Gambling in children and adolescents	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Rina Gupta PhD
<sup>2</sup>	Canadian Paediatric Society	Ethical approach to genital examination in children	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Sandra Woods MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Harm reduction: An approach to reducing risky health behaviours in adolescents	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Karen Mary Leslie MD
<sup>2</sup>	Canadian Paediatric Society	Management of the paediatric patient with acute head trauma	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Catherine A Farrell MD
<sup>2</sup>	Canadian Paediatric Society	Universal newborn hearing screening	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Hema Patel MD
<sup>2</sup>	Canadian Paediatric Society	Pulse oximetry screening in newborns to enhance detection of critical congenital heart disease	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Nov	3 year cycle.	Michael Narvey MD
<sup>2</sup>	Canadian Paediatric Society	Prevention and management of neonatal herpes simplex virus infections	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Upton D Allen MBBS

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Homeopathy in the paediatric population	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Linda Spigelblatt MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Issues of care for hospitalized youth	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Mar	3 year cycle.	Sheri M Findlay MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Human papillomavirus vaccine for children and adolescents	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Lindy M Samson MD
<sup>2,11</sup>	<b>Canadian Paediatric Society</b>	Risk of acute hyponatremia in hospitalized children and youth receiving maintenance intravenous fluids.	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Jeremy N Friedman MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Increasing the use of influenza vaccines in children with egg allergy	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2014-Dec	3 year cycle.	Charles PS Hui MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Preventing playground injuries	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2012-Jun	3 year cycle.	Natalie L Yanchar MD
<sup>2</sup>	Canadian Paediatric Society	Head lice infestations : a clinical update	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2018-Feb	3 year cycle.	Carl Cummings MD
<sup>2</sup>	Canadian Paediatric Society	Lyme disease in Canada: focus on children	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Heather Onyett MD
<sup>2</sup>	Canadian Paediatric Society	Immunization for meningococcal serogroup B - what does the practitioner need to know?	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Joan L Robinson MD
<sup>2</sup>	Canadian Paediatric Society	Invasive meningococcal vaccination for Canadian children and youth	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2018-Feb	3 year cycle.	Joan L. Robinson MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Suspected and confirmed bacterial meningitis in Canadian children older than one month of age	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Nicole Le Saux MD
<sup>2</sup>	Canadian Paediatric Society	Mental health problems in children with neuromotor disabilities	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Mar	3 year cycle.	Benjamin Klein MD
<sup>2</sup>	Canadian Paediatric Society	Supporting the mental health of children and youth of separating parents	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	mental
<sup>2</sup>	Canadian Paediatric Society	Primary nocturnal enuresis	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Mark Feldman MD
<sup>2</sup>	Canadian Paediatric Society	NRP providers: a case-based review	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Aug	3 year cycle.	Emer Finan MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Nutrition for healthy term infants, birth to six months: an overview	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Jeffrey N Critch MD
<sup>2</sup>	Canadian Paediatric Society	Nutrition for healthy term infants, six to 24 months: an overview	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Jeffrey N Critch MD
<sup>2</sup>	Canadian Paediatric Society	Sport nutrition for young athletes	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2013-Apr	3 year cycle.	Laura K Purcell MD
<sup>2</sup>	Canadian Paediatric Society	Vegetarian diets in children and adolescents	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Minoli Amit MD
<sup>2</sup>	Canadian Paediatric Society	Preventing ophthalmia neonatorum	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2015-Mar	3 year cycle.	Dorothy L Moore MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Acute otitis media in children six months of age and older	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Nicole Le Saux MD
<sup>2</sup>	Canadian Paediatric Society	Recommendations for the use of pacifiers	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Michelle Ponti MD
<sup>2</sup>	Canadian Paediatric Society	Treatment decisions regarding infants, children and adolescents	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Christine Harrison PhD
<sup>2</sup>	Canadian Paediatric Society	Prevention and management of pain and stress in the neonate	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Keith J Barrington MD (chair)
<sup>2</sup>	Canadian Paediatric Society	Advance care planning for paediatric patients	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Ellen Tsai MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Uncomplicated pneumonia in healthy Canadian children and youth	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2015-Dec	3 year cycle.	Nicole Le Saux MD
<sup>2</sup>	Canadian Paediatric Society	Adolescent pregnancy	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Karen Mary Leslie MD
<sup>2</sup>	Canadian Paediatric Society	Counselling and management for anticipated extremely preterm birth	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Aug	3 year cycle.	Brigitte Lemyre MD
<sup>2</sup>	Canadian Paediatric Society	Facilitating discharge of the preterm infant	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Ann L Jefferies MD
<sup>2</sup>	Canadian Paediatric Society	Probiotics in the paediatric population	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2015-Feb	3 year cycle.	Valérie Marchand MD (past Chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Retinopathy of prematurity: an update on screening and management	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Mar	3 year cycle.	Ann L Jefferies MD
<sup>2</sup>	Canadian Paediatric Society	Rotavirus vaccines in infants	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Jun	3 year cycle.	Nicole Le Saux MD
<sup>2</sup>	Canadian Paediatric Society	Prevention of congenital rubella syndrome	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Mar	3 year cycle.	Joan L Robinson MD
<sup>2</sup>	Canadian Paediatric Society	Scabies	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2015-Oct	3 year cycle.	Anna Banerji MD
<sup>2</sup>	Canadian Paediatric Society	Screen time and young children: Promoting health and development in a digital world	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Nov	3 year cycle.	Michelle Ponti MD
<sup>2</sup>	Canadian Paediatric Society	Management of term infants at increased risk for early onset bacterial sepsis	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Ann L Jefferies MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Adolescent sexual orientation	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Mar	3 year cycle.	Miriam Kaufman MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	E-cigarettes: children and youth in Canada	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2015-Mar	3 year cycle.	Richard Stanwick MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Selective serotonin reuptake inhibitor medications for the treatment of child and adolescent mental illness	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Daphne J Korczak MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Sexually transmitted infections in adolescents: Maximizing opportunities for optimal care	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Upton D Allen MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Meeting the health care needs of street-involved youth	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	April S Elliott MD
<sup>2</sup>	Canadian Paediatric Society	Suicidal ideation and behaviour	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2015-Jun	3 year cycle.	Daphne J Korczak MD
<sup>2</sup>	Canadian Paediatric Society	Preventing hospitalizations respiratory syncytial virus infections	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-May	3 year cycle.	Joan L Robinson MD
<sup>2</sup>	Canadian Paediatric Society	Banning children and youth under the age of 18 years from commercial tanning facilities	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Danielle Taddeo MD
<sup>2</sup>	Canadian Paediatric Society	Temperature measurement in paediatrics	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Mark Feldman MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Toilet learning : anticipatory guidance with a child-oriented approach	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Fabian P Gorodzinsky MD
<sup>2</sup>	Canadian Paediatric Society	Trampoline use in homes and playgrounds	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2013-Jan	3 year cycle.	Laura Purcell MD
<sup>2</sup>	Canadian Paediatric Society	Transition to adult care for youth with special health care needs	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Miriam Kaufman MD
<sup>2</sup>	Canadian Paediatric Society	Interfacility transport of critically ill newborns	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2015-Jun	3 year cycle.	Hilary EA Whyte MD
<sup>2</sup>	Canadian Paediatric Society	Transracial adoption	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Cecilia Baxter MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Prophylactic antibiotics for children with recurrent urinary tract infections	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2015-Feb	3 year cycle.	Noni E MacDonald MD
<sup>2</sup>	Canadian Paediatric Society	Urinary tract infections in infants and children: diagnosis and management	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Joan L Robinson MD
<sup>2</sup>	Canadian Paediatric Society	Benefits of influenza vaccine in pregnancy for the fetus and the infant younger than six months of age	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Noni E MacDonald MD
<sup>2</sup>	Canadian Paediatric Society	Vision screening in infants, children and youth	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Minoli Amit MD
<sup>2</sup>	Canadian Paediatric Society	Vitamin D supplementation: recommendations for Canadian mothers and infants	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	John C Godel, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Zika virus: what does a physician caring for children in Canada need to know?	Specialty	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Mar	3 year cycle.	Joan L Robinson MD
<sup>2</sup>	<b>Canadian pDCD Guideline Development Committee</b>  1800 Alta Vista Drive  Ottawa, ON	Controlled pediatric donation after circulatory determination of death-	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Canadian Blood Services.	COI disclosed by authors.	<b>Date:</b> 2017-Nov	Cycle not indicated.	Matthew J. Weiss, MD, FRCPC
<sup>2</sup>	<b>Canadian Society for Exercise Physiology</b>  18 Louisa St., Suite 370  Ottawa, ON	24 hour movement guidelines (aged 0–4 year)	Primary	No	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	CIHR Grant; HALO (CHEO).	No COI to disclose by authors.	<b>Date:</b> 2017-Nov	Cycle not indicated.	Mark Tremblay, MSc, PhD
<sup>2</sup>	<b>Canadian Task Force on Preventive Health Care</b>  3280 Hospital Drive Northwest, Calgary, AB	Screening for developmental delay	Primary	No	<a href="#">More Details...</a>	<a href="#">Procedure Manual</a>	PHAC and CIHR.	No COI to disclose by authors.	<b>Date:</b> 2016-May	5 year cycle.	Marcello Tonelli MD MS
<sup>11</sup>	<b>Canadian Task Force on Preventive Health Care</b>	Growth monitoring, and prevention and management of overweight and obesity in children and youth in primary care.	Primary	No	<a href="#">More Details...</a>	<a href="#">Procedure Manual</a>	PHAC and CIHR.	No COI to disclose by authors.	<b>Date:</b> 2015-Apr	5 year cycle.	Patricia Parkin MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>11</sup>	<b>Canadian Task Force on Preventive Health Care</b>	Behavioural interventions for the prevention and treatment of cigarette smoking among school-aged children and youth.	Primary	No	<a href="#">More Details...</a>	<a href="#">Procedure Manual</a>	PHAC and CIHR.	No COI to disclose by authors.	<b>Date:</b> 2015-Apr	5 year cycle.	Brett D. Thombs PhD
<sup>2</sup>	<b>Canadian Thoracic Society</b>  30 Concourse Gate, Unit 27  Ottawa, ON	Asthma in preschoolers	Primary	No	<a href="#">More Details...</a>	Consensus.	Editorially independent from CTS funders.	<a href="#">COI declared.</a>	<b>Date:</b> 2015-May	Cycle not indicated.	Francine M Ducharme MD MSc
<sup>2</sup>	<b>Canadian Urological Association</b>  Avenue, Suite 401 Dorval, QC	Cryptorchidism diagnosis, management and follow-up	Specialty	No	<a href="#">More Details...</a>	<a href="#">CUA Guideline methods</a>	Funding not indicated.	No COI to disclose by authors.	<b>Date:</b> 2017-Jul	5 year cycle.	Luis H. Braga, MD
<sup>2</sup>	<b>Canadian Urological Association</b>	Sports and the solitary kidney: what parents of a young child with a solitary kidney should know	Primary	No	<a href="#">More Details...</a>	<a href="#">CUA Guideline methods</a>	Funding not indicated.	No COI to disclose by authors.	<b>Date:</b> 2014-Aug	5 year cycle.	Karen Psooy, MD, FRCSC
<sup>2</sup>	<b>Canadian Urological Association</b>	Multicystic dysplastic kidney (MCDK) in the neonate: the role of the urologist	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">CUA Guideline methods</a>	Funding not indicated.	No COI to disclose by authors.	<b>Date:</b> 2016-Feb	5 year cycle.	Karen Psooy, MD, FRCSC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Centre for Addiction and Mental Health</b> <i>150 Isabella St, Ottawa, ON</i>	Mental health promotion programs: children (7-12) & youth (13-19)	Primary	No	<a href="#">More Details...</a>	Update to previous work.	CAMH, Dalla Lana School of Public Health, Toronto Public Health funding.	Author COI not disclosed.	<b>Date:</b> 2014-Oct	Cycle not indicated.	Suzanne F. Jackson, Ph.D.
<sup>2</sup>	<b>Diabetes Canada</b> <i>1400-522 University Ave Toronto ON</i>	Type 1 diabetes in children and adolescents	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	<b>Date:</b> 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	<b>Diabetes Canada</b>	Type 2 diabetes in children and adolescents	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	<b>Date:</b> 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	<b>Health Canada</b> <i>70 Colombine Dr Way, Ottawa, ON</i>	Nutrition for healthy term infants: recommendations from birth to six months	Primary	No	<a href="#">More Details...</a>	Evidence review and consensus.	Government of Canada.	Author COI not disclosed.	<b>Date:</b> 2013	Cycle not indicated.	Alison Barrett, Infant Feeding Expert Advisory Committee
<sup>2</sup>	<b>Health Canada</b>	Nutrition for healthy term infants: recommendations from six to 24 Months	Primary	No	<a href="#">More Details...</a>	Evidence review and consensus.	Government of Canada.	Author COI not disclosed.	<b>Date:</b> 2014-Apr	Cycle not indicated.	Gisèle Conway, Infant Feeding Expert Advisory Committee

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Help ELiminate Pain in KIDS</b>  555 University Ave,  Toronto, ON	Reducing pain during vaccine injections: clinical practice guideline	Primary	No	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	CIHR	COI disclosed by authors.	<b>Date:</b> 2015- Aug	5 year cycle.	Anna Taddio MSc PhD
<sup>2</sup>	<b>Hypertension Canada</b>  3780 14th Avenue, Suite 211  Markham, ON	Blood pressure measurement, diagnosis, and assessment of risk of pediatric hypertension	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Process</a>	Funded by <a href="#">Hypertension Canada, free from external influence.</a>	COI disclosed by authors.	<b>Date:</b> 2017	Annual review.	<a href="#">Janis M. Dionne, MD</a>
<sup>2</sup>	<b>McMaster University</b>  1280 Main St W, Hamilton, ON	Allergic disease prevention (GLAD-P): prebiotics	Primary	No	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Funded by World Allergy Organization.	COI disclosed by authors.	<b>Date:</b> 2016- Mar	Cycle not indicated.	Holger J. Schünemann MD PhD
<sup>2</sup>	<b>Ontario Neurotrauma Foundation</b>  90 Eglinton St E, Toronto, ON	Pediatric concussion	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Essential Evidence Plus</a>	Gov't of ON.	Author COI not disclosed.	<b>Date:</b> 2014- Jun	Cycle not indicated.	Richard Riopelle, MD
<sup>2</sup>	<b>Pediatric Oncology Group of Ontario</b>  480 University Avenue, Suite 1014 Toronto, ON	Prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	POGO.	No COI to disclose by authors.	<b>Date:</b> 2015- Mar	Cycle not indicated.	Lillian Sung, MD, PhD, FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Pediatric Oncology Group Of Ontario	Anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients	Specialty	Yes	<a href="#">More Details...</a>	GRADE methodology	Funded by POGO and Ministry of Health and LTC ON.	No COI to disclose by authors.	Date: 2014 Apr	To be reviewed every 3 years.	L. Lee Dupuis, pediatric oncology pharmacist (chair)
<sup>2</sup>	Perinatal Services BC  555 W 12th Ave, Vancouver, BC	Breastfeeding healthy term infant	Primary	No	<a href="#">More Details...</a>	Adapted from CTFPHC	Provincial Health Services Authority.	No COI to disclose by authors.	Date: 2015-Mar	Cycle not indicated.	Roberta Hewat, PhD
<sup>2</sup>	Perinatal Services BC	Population and public health prenatal care pathway	Primary	Yes	<a href="#">More Details...</a>	Consensus and opinion.	Provincial Health Services Authority.	No COI to disclose by authors.	Date: 2014-Mar	Cycle not indicated.	Carolyn Solomon Committee Co-Chair, Manager-Maternal and Women's Health
<sup>2</sup>	Perinatal Services BC	Neonatal resuscitation	Specialty	Yes	<a href="#">More Details...</a>	Adapted from CTFPHC	Provincial Health Services Authority.	No COI to disclose by authors.	Date: 2017-Sep	Cycle not indicated.	Gustavo Pelligrina, MD
<sup>2</sup>	Perinatal Services BC	Antidepressant use during pregnancy: considerations for the newborn exposed to SSRIs/SNRIs	Primary and Specialty	Yes	<a href="#">More Details...</a>	Adapted from CTFPHC	Provincial Health Services Authority.	No COI to disclose by authors.	Date: 2013-May	Cycle not indicated.	Dr. Catherine Cronin Neonatologist, Interior Health Region

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Public Health Agency of Canada</b> <i>130 Colonnade Road A.L. 6501H Ottawa, ON</i>	Immunization guide	Primary	No	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	<b>Date:</b> 2016	Chapters updated as new evidence available.	Bryna Warshawsky, MDCM (Chair, NACI)
<sup>2,8</sup>	<b>Registered Nurses' Association of Ontario (RNAO)</b> <i>158 Pearl Street, Toronto, ON</i>	Primary prevention of childhood obesity	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2014-May	3 year cycle.	Lorraine Telford, RN, MN, CCHN(C)
<sup>2,8</sup>	<b>RNAO</b>	Working with families to promote safe Sleep for infants 0-12 months of age	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2014-Feb	3 year cycle.	Leigh Baetz-Craft, RN, BScN, MN, IBCLC, PNC(C)
<sup>8</sup>	<b>RNAO</b>	Promoting Asthma Control in Children	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2004-May	3 year cycle.	Jennifer Olajos-Clow, RN, BA/BPHE, BNSc, MSc, CAE
<sup>8</sup>	<b>RNAO</b>	Enhancing Healthy Adolescent Development	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2010-Dec	3 year cycle.	Joyce Fox RN, BScN, MHS

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>  <i>2781 Lancaster Road, Suite 200, Ottawa, ON</i>	Pregnancy outcomes after assisted human reproduction	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	No COI to disclose by authors.	<b>Date:</b> 2014-Jan	5 year cycle.	Nanette Okun, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Adolescent pregnancy guidelines	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	No COI to disclose by authors.	<b>Date:</b> 2015-Aug	5 year cycle.	Nathalie Fleming, MD
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>	Umbilical cord blood banking : implications for perinatal care providers	Specialty	No	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	No COI to disclose by authors.	<b>Date:</b> 2015-Sep	5 year cycle.	B. Anthony Arsmson, MD
<sup>1</sup>	<b>Toward Optimal Practice</b>  <i>#200, 12315 Stony Plain Road Edmonton, AB</i>	Third Trimester Fetal Well-Being Studies: Criteria and Managing Results	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding..	COI disclosed by authors.	<b>Date:</b> 2017-Jun	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	<b>Toward Optimal Practice</b>	Determination of Gestational Age by Ultrasound	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding..	COI disclosed by authors.	<b>Date:</b> 2014-Sep	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>1</sup>	<b>Toward Optimal Practice</b>	Ultrasound for Twin and Multiple Pregnancies	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2017-Jun	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>10</sup>	<b>Winnipeg Regional Health Authority (WHRA) 650 Main St, Winnipeg, MB</b>	Emergency Department Pediatric Asthma Care Map	Specialty	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2012-Apr	Cycle not indicated.	Hans Pasterkamp, MD, FRCPC
<sup>10</sup>	<b>WHRA</b>	Pediatric Asthma Inpatient Care Map	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2007-Oct	Cycle not indicated.	Hans Pasterkamp, MD, FRCPC
<sup>10</sup>	<b>WHRA</b>	Pediatric Diabetic Ketacidosis guideline and Standard Order Sheet	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2014-Jul	Cycle not indicated.	Brandy Wicklow MD, MSC, FRCPC
<sup>10</sup>	<b>WHRA</b>	Child Health Falls Prevention and Treatment Guidelines	Specialty	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2016-Feb	Cycle not indicated.	Child Health Standards Committee
<sup>10</sup>	<b>WHRA</b>	Prevention and Treatment of Newborn Infant Falls	Specialty	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2016-Dec	Cycle not indicated.	Lisa Merrill, Clinical Nurse Specialist
<sup>10</sup>	<b>WHRA</b>	Child Health Pediatric Confirmation of Nasally or Orally Inserted Gastric Tube for Feeding or Drainage	Specialty	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2017-Jul	Cycle not indicated.	Child Health Standards Committee
<sup>10</sup>	<b>WHRA</b>	Fetal Heart Rate Assessment and Documentation in the OR Theatre	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2017-Jul	Cycle not indicated.	Elizabeth Reddoch, Quality and Process Improvement Officer
<sup>10</sup>	<b>WHRA</b>	Child Health Identification Guideline	Specialty	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2015-Sep	Cycle not indicated.	Child Health Standards Committee

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>10</sup>	<b>WHRA</b>	Neonatal Clinical Practice Guidelines	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2015	Cycle not indicated.	Michael Narvey, MD, FRCPC, FAAP
<sup>10</sup>	<b>WHRA</b>	Newborn: Prophylaxis with Erythromycin Eye Ointment	Specialty	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2015-May	Cycle not indicated.	Margaret Morris, MD, FRCSC, M. ED
<sup>10</sup>	<b>WHRA</b>	Fetal Scalp Sampling	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2016-Apr	Cycle not indicated.	Michael Narvey, MD, FRCPC, FAAP
<sup>10</sup>	<b>WHRA</b>	Vitamin K for the Prevention of Vitamin K Deficiency Bleeding (VKDB) in Newborns	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2014-Feb	Cycle not indicated.	Fabiana Postolow, MD

## Infection and Immunity

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Alberta Health Services – Cancer Care</b>  <i>Seventh Street Plaza 14th Floor, North Tower 10030 – 107 Street NW Edmonton, Alberta T5J 3E4</i>	Pneumococcal vaccination in adult and pediatric patients undergoing cancer treatment	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guideline Utilization Resource Unit Handbook – Methodology</a>	No direct industry involvement.	Some members of the AB Provincial Tumour Council are involved in research funded by industry or have other potential conflicts of interest.	<b>Date:</b> 2017-Oct	3 year cycle.	AB Provincial Tumour Council <a href="mailto:GURU@albertahealthservices.ca">GURU@albertahealthservices.ca</a>
<sup>2</sup>	<b>Association of Medical Microbiology and Infectious Disease Canada</b>  <i>192 Bank St, Ottawa, ON</i>	Antiviral drugs for influenza: a foundation document for practitioners	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	PHAC funding.	COI disclosed by authors.	<b>Date:</b> 2013	Cycle not indicated.	Fred Y Aoki MD
<sup>2</sup>	<b>Association of Medical Microbiology and Infectious Disease Canada</b>	Early antiretroviral therapy in HIV infected persons	Specialty	Yes	<a href="#">More Details...</a>	Evidence review and working group consensus.	PHAC funding.	Author COI not disclosed.	<b>Date:</b> 2016-Oct	Cycle not indicated.	Marissa Becker, MD, MSc, FRCPC
<sup>2,3</sup>	<b>BC Guidelines</b>  <i>PO Box 9642 STN PROV GOVT Victoria BC</i>	Antinuclear antibody (ANA) testing for connective tissue disease	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2013-Jun	3-5 year cycle.	GPAC Working Group <a href="mailto:hlt.hguidelines@gov.bc.ca">hlt.hguidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Erythrocyte Sedimentation	Specialty	Yes	<a href="#">More</a>	<a href="#">Guidelines and Protocols</a>	BC Ministry of Health	No COI to disclose by	<b>Date:</b> 2007-	3-5 year	GPAC Working Group <a href="mailto:hlt.hguidelines@gov.bc.ca">hlt.hguidelines@gov.bc.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
		Rate (ESR)			<a href="#">Details...</a>	<a href="#">Advisory Committee Handbook</a>		authors.	Apr	cycle.	
<sup>2,3</sup> ,	<b>BC Guidelines</b>	Hepatitis - Viral Hepatitis Testing	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	Date: 2012-Jan	3-5 year cycle.	GPAC Working Group <a href="mailto:hth.guidelines@gov.bc.ca">hth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Infectious Diarrhea - Guideline for Ordering Stool Specimens)	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	Date: 2009-Mar	3-5 year cycle.	GPAC Working Group <a href="mailto:hth.guidelines@gov.bc.ca">hth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Macroscopic and Microscopic Urinalysis and the Investigation of Urinary Tract Infections	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	Date: 2009-Apr	3-5 year cycle.	GPAC Working Group <a href="mailto:hth.guidelines@gov.bc.ca">hth.guidelines@gov.bc.ca</a>
<sup>2</sup>	<b>British Columbia Centre for Excellence in HIV/AIDS</b>  4500 Oak Street  Vancouver, BC	Antiretroviral (ARV) treatment of adult HIV infection	Specialty	Yes	<a href="#">More Details...</a>	Adapted from Cdn Task Force on Preventive Health Care.	BC Women's Hospital and Health Centre	Author COI not disclosed.	Date: 2015-Sep	Cycle not indicated.	Julio S. G. Montaner, OC, M.D., OBC D.Sc., FRCPC, FCCP, FACP, FRSC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>British Columbia Centre for Excellence in HIV/AIDS</b>	HIV positive pregnant women and interventions to reduce perinatal transmission guidelines	Specialty	Yes	<a href="#">More Details...</a>	Adapted from Cdn Task Force on Preventive Health Care.	BC Women's Hospital and Health Centre	Author COI not disclosed.	<b>Date:</b> 2013-Jul	Cycle not indicated.	Deborah Money, MD, FRCSC
<sup>2</sup>	<b>British Columbia Centre for Excellence in HIV/AIDS</b>	HIV/AIDS in British Columbia	Primary	Yes	<a href="#">More Details...</a>	Adapted from Cdn Task Force on Preventive Health Care.	BC Women's Hospital and Health Centre	Author COI not disclosed.	<b>Date:</b> 2015-Aug	Cycle not indicated.	Rolando Barrios, MD, MCFP, FRCPC (Co-Chair)
<sup>2</sup>	<b>Canadian Institutes of Health Research</b> <i>160 Elgin St; Ottawa ON</i>	Hepatitis C infection in HIV-hepatitis C coinfected adults	Specialty	Yes	<a href="#">More Details...</a>	Guideline update. Consensus.	CIHR Grant; unrestricted funding: Gilead Canada; Merck, Abbvie and BMS.	COI disclosed by working group.	<b>Date:</b> 2016	Cycle not indicated.	Mark W. Hull, MD, MHSc, FRCPC
<sup>2</sup>	<b>Canadian Paediatric Society</b> <i>2305 St Laurent Blvd, Ottawa, ON</i>	'Nosodes' are no substitute for vaccines	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Michael J Rieder MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Antimicrobial stewardship in daily practice: managing an important resource	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	<b>Date:</b> 2017-Jan	3 year cycle.	Nicole Le Saux MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Immunization for meningococcal serogroup B	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2017-Jan	3 year cycle.	Joan L Robinson MD
<sup>2</sup>	Canadian Paediatric Society	Invasive meningococcal vaccines for children/youth in Canada	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2018-Feb	3 year cycle.	Joan L. Robinson MD
<sup>2</sup>	Canadian Paediatric Society	Influenza vaccine benefits in pregnancy for the fetus and the infant younger than six months of age	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2017-Jan	3 year cycle.	Noni E MacDonald MD
<sup>2</sup>	Canadian Paediatric Society	Neonatal herpes simplex virus infections	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2017-Jan	3 year cycle.	Upton D Allen MBBS
<sup>2</sup>	Canadian Paediatric Society	Preventing hospitalizations respiratory syncytial virus infections	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2016-May	3 year cycle.	Joan L Robinson MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Paediatric Society	Preventing mosquito and tick bites: a Canadian update	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2017-Jan	3 year cycle.	Heather Onyett MD
<sup>2</sup>	Canadian Paediatric Society	Scabies	Primary	No	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2015-Oct	3 year cycle.	Anna Banerji MD
<sup>2</sup>	Canadian Paediatric Society	Management of HIV exposed and HIV positive children.	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2016-Feb	3 year cycle.	Joan L Robinson MD
<sup>2</sup>	Canadian Paediatric Society	Testing for HIV infection in pregnancy	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	CPS receives unrestricted sponsorship.	COI disclosed by working group.	Date: 2017-Jan	3 year cycle.	Joan L Robinson MD
<sup>2</sup>	Canadian Pain Society  250 Consumers Road, Suite 301  Toronto, ON	Zoster vaccine to prevent postherpetic neuralgia (Safety and Effectiveness)	Primary	No	<a href="#">More Details...</a>	Consensus: CPS Study Day.	Unrestricted grant: Merck. CIHR research grant.	Author COI not disclosed.	Date: 2015-Feb	Cycle not indicated.	Gilles Lavigne DMD PhD FRCD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2,11</sup> ,	<b>Canadian Task Force on Preventive Health Care</b> <i>3280 Hospital Drive Northwest, Calgary, AB</i>	Hepatitis C screening for adults	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Procedure Manual</a>	Provided by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2017-Apr	Topic Selection Working Group to determine updates.	Roland Grad MDCM MSc
<sup>2</sup>	<b>Committee to Advise on Tropical Medicine and Travel (CATMAT)</b> 130 Colonnade Road A.L. 6501H Ottawa, ON	Disseminated strongyloidiasis: prevention, assessment and management	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funded by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2016-Jan	Cycle not indicated.	Ann McCarthy MD (Chair)
<sup>2</sup>	<b>Committee to Advise on Tropical Medicine and Travel (CATMAT)</b>	Malaria issues in special hosts	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Funded by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2015-May	Cycle not indicated.	Ann McCarthy MD (Chair)
<sup>2</sup>	<b>Committee to Advise on Tropical Medicine and Travel (CATMAT)</b>	Malaria: diagnosis and treatment	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Funded by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2014-Apr	Cycle not indicated.	Ann McCarthy MD (Chair)
<sup>2</sup>	<b>Committee to Advise on Tropical Medicine and Travel (CATMAT)</b>	Malaria: prevention	Specialty	No	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Funded by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2014-Apr	Cycle not indicated.	Ann McCarthy MD (Chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Committee to Advise on Tropical Medicine and Travel (CATMAT)	Viral hepatitis: prevention during travel	Primary	No	<a href="#">More Details...</a>	Consensus.	Funded by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2014-Jul	Cycle not indicated.	Ann McCarthy MD (Chair)
<sup>2</sup>	Committee to Advise on Tropical Medicine and Travel (CATMAT)	Meningococcal disease and the international traveler	Primary	No	<a href="#">More Details...</a>	Consensus.	Funded by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2015-May	Cycle not indicated.	Ann McCarthy MD (Chair)
<sup>2</sup>	Committee to Advise on Tropical Medicine and Travel (CATMAT)	Poliovirus and the international traveler	Primary	No	<a href="#">More Details...</a>	Consensus.	Funded by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2014-Jul	Cycle not indicated.	Ann McCarthy MD (Chair)
<sup>2</sup>	Committee to Advise on Tropical Medicine and Travel (CATMAT)	Travelers and yellow fever	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Funded by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2013-Mar	Cycle not indicated.	Ann McCarthy MD (Chair)
<sup>2</sup>	Committee to Advise on Tropical Medicine and Travel (CATMAT)	Travelers' diarrhea	Primary	No	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Funded by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2015-Nov	Cycle not indicated.	Ann McCarthy MD (Chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Committee to Advise on Tropical Medicine and Travel (CATMAT)</b>	Travelers who intend to visit friends and relatives (international)	Primary	Yes	<a href="#">More Details...</a>	Consensus.	Funded by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2015-Apr	Cycle not indicated.	Ann McCarthy MD (Chair)
<sup>2</sup>	<b>Committee to Advise on Tropical Medicine and Travel (CATMAT)</b>	Zika virus	Primary and Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funded by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2016-May	Cycle not indicated.	Ann McCarthy MD (Chair)
<sup>2</sup>	<b>Diabetes Canada</b> <u>1400-522 University Ave</u> <u>Toronto ON</u>	Influenza, pneumococcal, hepatitis B and herpes zoster immunization	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	<b>Date:</b> 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	<b>Manitoba Health and Healthy Living</b>  <i>300 Carlton St, Winnipeg, MB</i>	Syphilis	Specialty	Yes	<a href="#">More Details...</a>	Expert opinion.	Gov't Of MB	Author COI not disclosed.	<b>Date:</b> 2014-Jul	Cycle not indicated.	Richard Rusk, DVM, MD, CCFP, MPH
<sup>2</sup>	<b>National Advisory Committee on Immunization (PHAC)</b>  <i>130 Colonnade Road A.L. 6501H Ottawa, ON</i>	Conjugate pneumococcal vaccine - 13 valent in adults (Pneu-C-13)	Primary	No	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	<b>Date:</b> 2013-Oct	Updated as new evidence available.	Bryna Warshawsky, MDCM (Chair, NACI)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	National Advisory Committee on Immunization	Hepatitis A vaccine	Primary	No	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	<b>Date:</b> 2016-May	Updated as new evidence available.	Bryna Warshawsky, MDCM (Chair, NACI)
<sup>2</sup>	National Advisory Committee on Immunization	Hepatitis B vaccine	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	<b>Date:</b> 2017-May	Updated as new evidence available.	Bryna Warshawsky, MDCM (Chair, NACI)
<sup>2</sup>	National Advisory Committee on Immunization	Human Papillomavirus (HPV) vaccines	Primary	No	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	<b>Date:</b> 2016-Jul	Updated as new evidence available.	Bryna Warshawsky, MDCM (Chair, NACI)
<sup>2</sup>	National Advisory Committee on Immunization	Quadrivalent conjugate meningococcal vaccines	Primary	No	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	<b>Date:</b> 2013-Jan	Updated as new evidence available.	Bryna Warshawsky, MDCM (Chair, NACI)
<sup>2</sup>	New Brunswick Provincial Advisory Working Group on Chronic Hepatitis C Virus Infection  135 MacBeath Avenue, Moncton,	Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funding: Abbvie.	Author COI not disclosed.	<b>Date:</b> 2014-Nov	Cycle not indicated.	Daniel J Smyth MD FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	NB										
<sup>2</sup>	<b>Ontario Agency for Health Protection and Promotion</b> <i>480 University Avenue, Toronto, ON</i>	Testing and treatment of gonorrhea in Ontario	Primary	Yes	<a href="#">More Details...</a>	Infectious Diseases Society of America/U.S. Public Health Service Grading System	Public Health ON.	Author COI not disclosed.	<b>Date:</b> 2013-Apr	Cycle not indicated.	Dr. Erika Bontovics (chair)
<sup>2</sup>	<b>Ontario Association of Medical Laboratories</b> <i>1802, 5000 Yonge St, North York, ON</i>	Collection and testing for ova and parasites in symptomatic patients	Primary	Yes	<a href="#">More Details...</a>	Committee consensus	Funding not disclosed.	Author COI not disclosed.	<b>Date:</b> 2015-May	5 year cycle.	Anu Rebbapragada Ph.D., CIC
<sup>2</sup>	<b>Ontario Association of Medical Laboratories</b>	Genital tract infections	Primary	No	<a href="#">More Details...</a>	Committee consensus	Funding not disclosed.	Author COI not disclosed.	<b>Date:</b> 2015-Nov	5 year cycle.	Judy Ash M.PP.A.L, B.Sc., ART, CQMgr, CQA (ASQ)
<sup>27</sup>	<b>Public Health Agency of Canada</b>	Immunization guide	Primary	No	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	<b>Date:</b> 2016	Chapters updated as new evidence available.	Bryna Warshawsky, MDCM (Chair, NACI)
<sup>2</sup>	<b>Public Health Agency of Canada</b>	Measles outbreaks in Canada	Primary and Specialty	No	<a href="#">More Details...</a>	Committee consensus	Government of Canada	No COI to disclose by authors.	<b>Date:</b> 2013-Oct	Cycle not indicated.	Dr. Gaston DeSerres

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>27</sup>	Public Health Agency of Canada	Sexually transmitted infections	Primary	No	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Government of Canada	No COI to disclose by authors.	<b>Date:</b> 2016-Dec	Updated as new evidence available.	Tom Wong, MD, MPH, FRCPC
<sup>2</sup>	Public Health Agency of Canada Canadian Lung Association Canadian Thoracic Society	Tuberculosis standards	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Funding: PHAC; CLA, CTS.	No COI to disclose by authors.	<b>Date:</b> 2014-Feb	Cycle not indicated.	Dick Menzies, MD, MSc
<sup>2</sup>	<b>Society of Obstetricians and Gynaecologists of Canada</b>  <i>2781 Lancaster Road, Suite 200, Ottawa, ON K1B 1A7</i>	Prevention of early-onset neonatal group B streptococcal disease	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Method details.</a>	Funded by SOGC.	No conflicts indicated.	<b>Date:</b> 2013-Oct	5 year cycle.	Deborah Money, MD
<sup>1</sup>	<b>Toward Optimal Practice #200, 12315 Stony Plain Road Edmonton, AB</b>	<b>Diagnosis and Management of Nursing Home Acquired Pneumonia (NHAP)</b>	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2015-Mar	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	<b>Toward Optimal Practice</b>	<b>Diagnosis and Management of Active Tuberculosis</b>	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2014-May	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>1</sup>	Toward Optimal Practice	Diagnosis and Management of Urinary Tract Infection in Long Term Care Facilities	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2015-Jan	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	Toward Optimal Practice	Multiple Sclerosis and Management of Urinary Tract Infection	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2017-Mar	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	Toward Optimal Practice	Ordering Stool Test for Investigation of Suspected Infectious Diarrhea	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2014-Apr	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	Toward Optimal Practice	Serological Testing for Suspected Viral Hepatitis	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2014-Apr	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>2</sup>	Toward Optimal Practice	Helicobacter pylori infection in adults	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2017-Mar	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>10</sup>	Winnipeg Regional Health Authority (WHRA) 650 Main St,	Wound Care & Skin Tears	Primary and Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	Date: 2014-Jan	Cycle not indicated.	John Embil, MD, FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Winnipeg, MB										

## Musculoskeletal Health and Arthritis

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2,3</sup>	<b>BC Guidelines</b> <i>PO Box 9642 STN PROV GOVT Victoria BC</i>	Ankle Injury - X-Ray for Acute Injury of the Ankle or Mid-Foot	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2014-Mar	3-5 year cycle.	GPAC Working Group <a href="mailto:hith.guidelines@gov.bc.ca">hith.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Antinuclear Antibody (ANA) Testing for Connective Tissue Disease	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2013-Jun	3-5 year cycle.	GPAC Working Group <a href="mailto:hith.guidelines@gov.bc.ca">hith.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Osteoarthritis in Peripheral Joints - Diagnosis and Treatment	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2009-Dec	3-5 year cycle.	GPAC Working Group <a href="mailto:hith.guidelines@gov.bc.ca">hith.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Osteoporosis: Diagnosis, Treatment and Fracture Prevention	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2012-Oct	3-5 year cycle.	GPAC Working Group <a href="mailto:hith.guidelines@gov.bc.ca">hith.guidelines@gov.bc.ca</a>
<sup>2,3,7</sup>	<b>BC Guidelines</b>	Rheumatoid Arthritis- Diagnosis and Management	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2012-Sep	3-5 year cycle.	GPAC Working Group <a href="mailto:hith.guidelines@gov.bc.ca">hith.guidelines@gov.bc.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Association of Gastroenterology</b> <i>189 Queen Street East, Suite 1, Toronto, ON</i>	Hip fracture and proton pump inhibitor therapy	Primary	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	AbbVie Canada and Warner Chilcott funding.	COI disclosed by authors.	<b>Date:</b> 2013-Oct	Updated when approved by committee.	Paul Moayyedi, Bsc, MB ChB, PhD, MPH, FRCP, FRCPC, AGAF, FACG
<sup>2</sup>	<b>Canadian Association of Radiologists</b> <i>294 Albert St Suite 600, Ottawa, ON</i>	Bone mineral densitometry reporting	Primary	Yes	<a href="#">More Details...</a>	Consensus. Not stated.	Not stated.	Author COI not disclosed.	<b>Date:</b> 2013-Jan	Cycle not indicated.	Kerry Siminoski, MD, FRCPC
<sup>11</sup>	<b>Canadian Chiropractic Guideline Initiative</b> <i>186 Spadina Ave. Suite 6 Toronto, ON</i>	Neck pain-associated disorders and whiplash-associated disorders	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Funding: provincial and national chiropractic associations, regulatory boards and the CCPA.	No COI to disclose by authors.	<b>Date:</b> 2016-Oct	Cycle not indicated.	André E. Bussières, DC, PhD
<sup>2</sup>	<b>Canadian Dental Association (Canadian Orthopaedic Association Association of Medical Microbiology and Infectious Disease Canada)</b> <i>1815 Alta Vista Dr, Ottawa, ON</i>	Dental patients with total joint replacement	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funding not disclosed.	Author COI not disclosed.	<b>Date:</b> 2016-Nov	Cycle not indicated.	Cynthia Vezina (COA)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Rheumatology Association</b> <i>12-16715 Yonge Street Suite 244 Newmarket, ON</i>	Pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: Part II Safety	Specialty	Yes	<a href="#">More Details...</a>	Systematic review and Consensus.	No industry funding.	COI declared by authors.	<b>Date:</b> 2012-Aug	Cycle not indicated.	C. Bombardier, MD, FRCPC
	<b>Osteoporosis Canada</b> <i>1200 Eglinton Ave East, Suite 500 Toronto, ON</i>	Diagnosis and Management of Osteoporosis	Primary	No	<a href="#">More Details...</a>	Modified RAND/University of California, LA Delphi Method	Funded by OC.	COI declared by authors.	<b>Date:</b> 2010-Nov	Scheduled for update in 2019.	Alexandra Papaioannou MD MSc
<sup>2</sup>	<b>Ottawa Panel</b> <i>451 Smyth Rd, Ottawa, ON</i>	Foot care in the management of juvenile idiopathic arthritis	Specialty	Yes	<a href="#">More Details...</a>	Systematic Review and Delphi consensus.	University of Ottawa, Arthritis Health Professional Association grant.	COI declared by authors.	<b>Date:</b> 2016-Jul	Cycle not indicated.	Lucie Brosseau PT, PhD
<sup>2</sup>	<b>Ottawa Panel</b>	Physical activity in the management of juvenile idiopathic arthritis	Specialty	Yes	<a href="#">More Details...</a>	Systematic Review and Delphi consensus.	Arthritis Health Professionals Association, Arthritis Society	COI declared by authors.	<b>Date:</b> 2017-May	Cycle not indicated.	Sabrina Cavallo, OT, PhD
<sup>1,2</sup>	<b>Toward Optimized Practice</b> <i>#200, 12315 Stony Plain Road Edmonton, AB</i>	<b>Low Back Pain</b>	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI declared by authors.	<b>Date:</b> 2017-Jul	2-5 year cycle.	Guideline committee <a href="mailto:cpq@topalbertadoctors.org">cpq@topalbertadoctors.org</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>1</sup>	Toward Optimized Practice	Osteoporosis	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI declared by authors.	<b>Date:</b> 2016-Feb	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	Toward Optimized Practice	Radiography of the Ankle and Foot (Ottawa Ankle Rules) (Guideline)	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI declared by authors.	<b>Date:</b> 2014-Mar	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>10</sup>	Winnipeg Regional Health Authority (WHRA) 650 Main St, Winnipeg, MB	Osteoporosis	Primary	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2014-Oct	Cycle not indicated.	Kristin Anderson, , Chair, MB Health, Director, Primary Health Care

## Neurosciences, Mental Health and Addiction

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Anxiety Disorders Association of Canada  311 - 409 Granville St  Vancouver, BC	Anxiety, posttraumatic stress and obsessive-compulsive disorders	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Unrestricted grants: Astra Zeneca Canada, Eli Lilly Canada, Janssen, Lundbeck Canada, Pfizer, Purdue, Servier, Shire, Valeant.	COI disclosed by authors.	Date: 2014	Cycle not indicated.	Martin Katzman, MDFRCP(C)
<sup>2</sup>	<a href="#"><u>BC Guidelines</u></a> <u>PO Box 9642</u> <u>STN PROV</u> <u>GOVT</u> <u>Victoria BC</u>	Cognitive impairment: recognition, diagnosis and management in primary care	Primary	Yes	<a href="#">More Details...</a>	<a href="#"><u>Guidelines and Protocols Advisory Committee Handbook</u></a>	<a href="#"><u>BC Ministry of Health</u></a>	No COI to disclose by authors.	Date: 2016-Jun	3-5 year cycle.	GPAC Working Group <a href="mailto:hith.guidelines@gov.bc.ca">hith.guidelines@gov.bc.ca</a>
<sup>2</sup>	<b>BC Guidelines</b>	Major depressive disorder in adults: diagnosis & management	Primary	No	<a href="#">More Details...</a>	<a href="#"><u>Guidelines and Protocols Advisory Committee Handbook</u></a>	<a href="#"><u>BC Ministry of Health</u></a>	No COI to disclose by authors.	Date: 2013-Dec	3-5 year cycle.	GPAC Working Group <a href="mailto:hith.guidelines@gov.bc.ca">hith.guidelines@gov.bc.ca</a>
<sup>2</sup>	<b>BC Guidelines</b>	Problem drinking	Primary	No	<a href="#">More Details...</a>	<a href="#"><u>Guidelines and Protocols Advisory Committee Handbook</u></a>	<a href="#"><u>BC Ministry of Health</u></a>	No COI to disclose by authors.	Date: 2013-Apr	3-5 year cycle.	GPAC Working Group <a href="mailto:hith.guidelines@gov.bc.ca">hith.guidelines@gov.bc.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>British Columbia Centre on Substance Use</b> <i>625 Powell St, Vancouver, BC</i>	Opioid use disorders	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	College of Pharmacists BC; CIHR Grant; Province of BC.	COI disclosed by authors.	<b>Date:</b> 2017-Feb	Annual cycle.	Evan Wood (Committee Chair), MD, PhD, ABIM, FRCPC, Dip. ABAM, FASAM
<sup>2</sup>	<b>Canadian Academy of Child and Adolescent Psychiatry</b> <i>141 Laurier Ave W, Ottawa, ON</i>	SSRIs and SNRIs with children and adolescents	Specialty	Yes	<a href="#">More Details...</a>	Systematic review and consensus.	Funding not disclosed.	Author COI not disclosed.	<b>Date:</b> 2016-Feb	Updated as new evidence available.	E. Jane Garland MD, FRCPC
<sup>2</sup>	<b>Canadian Coalition for Seniors' Mental Health</b> <i>20 Crown Steel Dr. Unit #6 Markham, ON</i>	Seniors' mental health : the assessment and treatment of delirium	Primary and Specialty	yes	<a href="#">More Details...</a>	Evidence update. Consensus.	CIHR grant; PHAC. Unrestricted grant: AstraZeneca; Lilly; Janssen; Organon, RBC Foundation.	COI disclosed by authors.	<b>Date:</b> 2014	Cycle not indicated.	David B. Hogan, MD, FACP, FRCPC
<sup>2</sup>	<b>Canadian Headache Society</b> <i>1403 – 29th Street NW Calgary, AB</i>	Migraine headache	Primary	No	<a href="#">More Details...</a>	Guideline adaptation process.	Alberta Health.	COI disclosed by authors.	<b>Date:</b> 2015	Cycle not indicated.	Werner J. Becker MD FRCP(C)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Network for Mood and Anxiety Treatments</b>  2255 Westbrook Mall  Vancouver, BC	Major depressive disorder - functional outcomes	Specialty	Yes	<a href="#">More Details...</a>	Conference consensus.	Funding: CANMAT and unrestricted grant RxD Research Foundation.	COI disclosed by authors.	<b>Date:</b> 2015-May	Cycle not indicated.	Raymond W. Lam, MD
<sup>2</sup>	<b>Canadian Network for Mood and Anxiety Treatments</b>	Major depressive disorder. Section 1. Disease burden and principles of care	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funding: CANMAT	COI disclosed by authors.	<b>Date:</b> 2016-Sep	Cycle not indicated.	Raymond W. Lam, MD
<sup>2</sup>	<b>Canadian Network for Mood and Anxiety Treatments</b>	Major depressive disorder. Section 2. Psychological treatments	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funding: CANMAT	COI disclosed by authors.	<b>Date:</b> 2016-Sep	Cycle not indicated.	Sagar V. Parikh, MD, FRCPC
<sup>2</sup>	<b>Canadian Network for Mood and Anxiety Treatments</b>	Major depressive disorder Section 3. Pharmacological treatments	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funding: CANMAT	COI disclosed by authors.	<b>Date:</b> 2016-Sep	Cycle not indicated.	Raymond W. Lam, MD
<sup>2</sup>	<b>Canadian Network for Mood and Anxiety Treatments</b>	Major depressive disorder. Section 4. Neurostimulation treatments	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funding: CANMAT	COI disclosed by authors.	<b>Date:</b> 2016-Sep	Cycle not indicated.	Raymond W. Lam, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Network for Mood and Anxiety Treatments</b>	Major depressive disorder. Section 5. Complementary and alternative medicine treatments	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funding: CANMAT	COI disclosed by authors.	<b>Date:</b> 2016-Sep	Cycle not indicated.	Raymond W. Lam, MD
<sup>2</sup>	<b>Canadian Network for Mood and Anxiety Treatments</b>	Major depressive disorder. Section 6. Special populations: youth, women, and the elderly	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funding: CANMAT	COI disclosed by authors.	<b>Date:</b> 2016-Sep	Cycle not indicated.	Raymond W. Lam, MD
<sup>2</sup>	<b>Canadian Paediatric Society</b> <i>2305 St Laurent Blvd, Ottawa, ON</i>	Mental health problems in children with neuromotor disabilities	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Mar	3 year cycle.	Benjamin Klein MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Selective serotonin reuptake inhibitor medications for the treatment of child and adolescent mental illness	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2016-Feb	3 year cycle.	Daphne J Korczak MD
<sup>2</sup>	<b>Canadian Paediatric Society</b>	Suicidal ideation and behaviour	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Position statement process</a>	<a href="#">CPS receives unrestricted sponsorship.</a>	COI disclosed by working group.	<b>Date:</b> 2015-Jun	3 year cycle.	Daphne J Korczak MD
<sup>2</sup>	<b>Canadian Pain Society</b> <i>250 Consumers</i>	Fibromyalgia syndrome	Primary and Specialty	No	<a href="#">More Details...</a>	Evidence review and consensus.	Funding: Unrestricted grant – Valeant;	COI disclosed by	<b>Date:</b> 2013-May	2 year cycle.	Maryanne Fitzcharles, MB, ChB

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Road, Toronto, ON					Louise and Alan Edwards Foundation	authors.				
<sup>2</sup>	<b>Canadian Pain Society</b>	Neuropathic pain - pharmacological management	Primary and Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funding: CPS.	COI disclosed by authors.	Date: 2014- Nov	Cycle not indicated.	DE Moulin MD
<sup>2</sup>	<b>Canadian Psychiatric Association</b> <i>141 Laurier Ave W #701, Ottawa, ON</i>	Mental health care for people who identify as lesbian, gay, bisexual, transgender, and (or) queer	Primary and Specialty	Yes	<a href="#">More Details...</a>	Consensus.	Funding not disclosed.	Author COI not disclosed.	Date: 2014- Apr	5 year cycle.	Albina Veltman, MD, FRCPC
<sup>2</sup>	<b>Canadian Schizophrenia Guidelines Working Group</b> <i>3280 Hospital Drive NW, Calgary, AB</i>	Individuals at clinical high risk of psychosis	Specialty	Yes	<a href="#">More Details...</a>	ADAPTE process	Working group received no outside funding.	COI disclosed by authors.	Date: 2017- Sep	Cycle not indicated.	Jean Addington, Ph.D.
<sup>2</sup>	<b>Canadian Schizophrenia Guidelines Working Group</b>	Physical health and drug safety in individuals with schizophrenia	Specialty	Yes	<a href="#">More Details...</a>	ADAPTE process	Working group received no outside funding.	COI disclosed by authors.	Date: 2017- Sep	Cycle not indicated.	Tamara Pringsheim, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Schizophrenia Guidelines Working Group</b>	Psychosocial treatment of schizophrenia in adults	Specialty	Yes	<a href="#">More Details...</a>	ADAPTE process	Working group received no outside funding.	COI disclosed by authors.	<b>Date:</b> 2017-Sep	Cycle not indicated.	Ross Norman, PhD
<sup>2</sup>	<b>Canadian Schizophrenia Guidelines Working Group</b>	Psychosocial treatment of schizophrenia in children and youth	Specialty	Yes	<a href="#">More Details...</a>	ADAPTE process	Working group received no outside funding.	COI disclosed by authors.	<b>Date:</b> 2017-Sep	Cycle not indicated.	Tania Lecomte, PhD
<sup>2</sup>	<b>Canadian Schizophrenia Guidelines Working Group</b>	Schizophrenia and other psychotic disorders with coexisting substance use disorders	Specialty	Yes	<a href="#">More Details...</a>	ADAPTE process	Working group received no outside funding.	COI disclosed by authors.	<b>Date:</b> 2017-Sep	Cycle not indicated.	David Crockford, MD, FRCPC
<sup>2</sup>	<b>Canadian Schizophrenia Guidelines Working Group</b>	Schizophrenia and schizophrenia spectrum disorders	Specialty	Yes	<a href="#">More Details...</a>	ADAPTE process	Working group received no outside funding.	COI disclosed by authors.	<b>Date:</b> 2017-Sep	Cycle not indicated.	Donald Addington, MD
<sup>2</sup>	<b>Canadian Schizophrenia Guidelines Working Group</b>	Schizophrenia in adults - pharmacotherapy	Specialty	Yes	<a href="#">More Details...</a>	ADAPTE process	Working group received no outside funding.	COI disclosed by authors.	<b>Date:</b> 2017-Jul	Cycle not indicated.	Gary Remington, MD, PhD, FRCPC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Schizophrenia Guidelines Working Group</b>	Schizophrenia spectrum and other psychotic disorders in children and youth - pharmacological treatment	Specialty	Yes	<a href="#">More Details...</a>	ADAPTE process	Working group received no outside funding.  COI disclosed by authors.	COI disclosed by authors.	<b>Date:</b> 2017-Aug	Cycle not indicated.	Sabina Abidi, MD
<sup>2</sup>	<b>Canadian Society of Otolaryngology - Head &amp; Neck Surgery</b>  68 Gilkison Road Elora, ON	Bell palsy	Primary	No	<a href="#">More Details...</a>	<b>GRADE methodology</b>	No outside funding.	COI disclosed by authors.	<b>Date:</b> 2014-Jun	5 year cycle.	John R. de Almeida MD MSc
<sup>2,11</sup>	<b>Canadian Task Force on Preventive Health Care</b> 3280 Hospital Drive Northwest, Calgary, AB	Screening for depression in adults	Primary	No	<a href="#">More Details...</a>	<b>Procedure Manual</b>	Provided by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2013-May	Topic Selection Working Group to determine updates.	Michel Joffres, MD, PhD
<sup>2</sup>	<b>Cancer Care Ontario</b>  620 University Avenue Toronto, Ontario Canada M5G 2L7	Depression in patients with cancer	Primary and Specialty	Yes	<a href="#">More Details...</a>	<b>Guideline development handbook.</b>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	<b>Date:</b> 2015-May	<a href="#">Document assessment/review protocol.</a>	Madeline Li, MD, PhD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Cancer Care Ontario</b>	Positron emission tomography in epilepsy	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guideline development handbook.</a>	ON Min of Health. Editorially independent from its funding source.	COI disclosed by authors.	<b>Date:</b> 2015-Jan	<a href="#">Document assessment/review protocol.</a>	Jorge G. Burneo, MD, MSPH
<sup>2</sup>	<b>CanPainSCI Working Group</b> <i>550 Wellington Road, London, ON</i>	Rehabilitation Management of Neuropathic Pain after Spinal Cord Injury: recommendations for models system of care	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	ON Neurotrauma Foundation and Rick Hansen Institute.	COI disclosed by authors.	<b>Date:</b> 2016-Aug	Cycle not indicated.	Eldon Loh MD, FRCP(C)
<sup>2</sup>	<b>CanPainSCI Working Group</b>	Rehabilitation Management of Neuropathic Pain after Spinal Cord Injury: screening and diagnosis	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	ON Neurotrauma Foundation and Rick Hansen Institute.	COI disclosed by authors.	<b>Date:</b> 2016-Aug	Cycle not indicated.	Eldon Loh MD, FRCP(C)
<sup>2</sup>	<b>CanPainSCI Working Group</b>	Rehabilitation management of neuropathic pain after spinal cord: treatment	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	ON Neurotrauma Foundation and Rick Hansen Institute.	COI disclosed by authors.	<b>Date:</b> 2016-Aug	Cycle not indicated.	Dr. Eldon Loh MD, FRCP(C)
<sup>2</sup>	<b>CanPainSCI Working Group</b>	Rehabilitation Management of Neuropathic Pain after Spinal Cord Injury	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	ON Neurotrauma Foundation and Rick Hansen Institute.	COI disclosed by authors.	<b>Date:</b> 2016-Aug	Cycle not indicated.	Dr. Eldon Loh MD, FRCP(C)
<sup>5</sup>	<b>Centre for Addiction and Mental Health</b>	Buprenorphine Guideline for Treatment of Opioid Dependence	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	CAMH funding.	COI disclosed by	<b>Date:</b> 2011	3-5 year cycle.	Curtis Handford MD CCFP MHSc

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	150 Isabella St, Ottawa, ON						authors.				
<sup>2</sup>	<b>College of Family Physicians of Canada</b>  2630 Skymark Avenue  Mississauga ON	Cannabis - Authorizing dried cannabis for chronic pain or anxiety	Primary and Specialty	Yes	<a href="#">More Details...</a>	Evidence review; consensus.	CFPC internal.	COI disclosed by authors.	<b>Date:</b> 2014- Sep	Cycle not indicated.	Sharon Cirone, MD, CCFP(EM), FCFP; Chair
<sup>2</sup>	<b>College of Physicians and Surgeons of Ontario</b>  80 College Street Toronto, ON	Sleep medicine	Specialty	Yes	<a href="#">More Details...</a>	Task force consensus.	College funded.	No COI to disclose by authors.	<b>Date:</b> 2016- Oct	5 year cycle.	Judith Leech, MD, FRCP, D, ABSM (chair)
<sup>5</sup>	<b>College of Physicians and Surgeons of Ontario</b>	MMT Program Standards and Clinical Guidelines	Specialty	Yes	<a href="#">More Details...</a>	Adaptation of the Harbour and Miller (2001) system.	College funded.	No COI to disclose by authors.	<b>Date:</b> 2011- Feb	Cycle not indicated.	Sharon Cirone CCFP(EM) ASAM(Cert)
<sup>2</sup>	<b>Diabetes Canada</b>  1400-522 University Ave Toronto ON	Diabetes and mental health	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	<b>Date:</b> 2018- Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education  <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Heart and Stroke Foundation of Canada</b> <i>110-1525 Carling Ave, Ottawa, ON</i>	Mood and cognition in patients following stroke	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methodology</a>	No commercial interests.	Author COI not disclosed.	<b>Date:</b> 2015-Jun	Thematic annual updates.	Gail Eskes PhD (Chair)
<sup>2</sup>	<b>Institut national d'excellence en santé et en services sociaux</b> <i>2535 boulevard Laurier, 5e étage Québec, QC</i>	Rehabilitation of adults with moderate to severe TBI	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guideline development process.</a>	ON Neurotrauma Foundation; INESSS	<a href="#">Committee COI.</a>	<b>Date:</b> 2016-Oct	4 year cycle.	Josée Fortier, M.D., FRCPC
<sup>5</sup>	<b>McMaster University</b> <i>1280 Main St West, Hamilton, ON</i>	Opioids for Chronic Non-Cancer Pain	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Health Canada and CIHR.	<a href="#">Panel COI.</a> <a href="#">Expert COI.</a>	<b>Date:</b> 2017	5 year cycle.	Jason Busse, HBSc, MSc, DC, PhD
<sup>2</sup>	<b>Ontario Neurotrauma Foundation</b> <i>90 Eglinton Ave E, Toronto, ON</i>	Concussion/mild traumatic brain injury & persistent symptoms	Specialty	No	<a href="#">More Details...</a>	Evidence review (AGREE II) and consensus.	ONF funded.	COI disclosed by authors.	<b>Date:</b> 2017-Oct	Cycle not indicated.	Shawn Marshall, MD, MSc, FRCPC
<sup>2</sup>	<b>Ontario Neurotrauma Foundation</b>	Post-concussion care from diagnosis to the interdisciplinary concussion clinic	Specialty	Yes	<a href="#">More Details...</a>	Consensus.	ONF funded.	COI disclosed by authors.	<b>Date:</b> 2017-Jun	Cycle not indicated.	Diana Velikonja, PhD, CPsych (Chair)

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Ontario Neurotrauma Foundation</b>	Prevention and management of pressure ulcers in people with spinal cord injury	Primary and Specialty	Yes	<a href="#">More Details...</a>	Guideline review and consensus.	Rick Hansen Institute; ONF funded.	Author COI not disclosed.	<b>Date:</b> 2013-Feb	Cycle not indicated.	Pamela Houghton, PT, PhD
<sup>2</sup>	<b>Perinatal Services BC</b>  555 W 12th Ave, Vancouver, BC	Mental health disorders in the perinatal period	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Adapted from CTFPHC</a>	Provincial Health Services Authority.	No COI to disclose by authors.	<b>Date:</b> 2014-Mar	Cycle not indicated.	Deirdre Ryan MB, FRCPC
<sup>2,8</sup>	<b>Registered Nurses' Association of Ontario (RNAO)</b>  158 Pearl Street, Toronto, ON	Pain	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2013-Dec	3 year cycle.	Judy Watt-Watson, RN, MSc, PhD
<sup>8</sup>	<b>RNAO</b>	Adults at Risk for Suicidal Ideation and Behaviour	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2009-Jan	3 year cycle.	Elaine Santa Mina (Sta. Mina), RN, BA, BAAN, MSc, PhD, CPMHN(C)
<sup>8</sup>	<b>RNAO</b>	Engaging Clients Who Use Substances	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2015-Mar	3 year cycle.	Wayne Skinner, MSW, RSW  Panel Co-Chair
<sup>8</sup>	<b>RNAO</b>	Promoting Safety: Alternative Approaches to the Use of Restraints	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2012-Feb	3 year cycle.	Laura M. Wagner RN, PhD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>8</sup>	<b>RNAO</b>	Supporting Clients on Methadone Maintenance Treatment	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2009-Jul	3 year cycle.	Margaret Dykeman, RN, NP, PhD
1,2	<b>Toward Optimal Practice</b>  #200, 12315 Stony Plain Road Edmonton, AB	Cognitive Impairment - Part 1: Symptoms to Diagnosis	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2017-Feb	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
1,2	<b>Toward Optimal Practice</b>	Cognitive Impairment - Part 2: Diagnosis to Management	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2017-Feb	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
1,2	<b>Toward Optimal Practice</b>	Depression in Multiple Sclerosis (MS)	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2015-Dec	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
1,2	<b>Toward Optimal Practice</b>	<b>Headache in Adults</b>	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry	COI disclosed by authors.	<b>Date:</b> 2016-Sep	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
						funding.					
<sup>1,2</sup>	<b>Toward Optimal Practice</b>	Insomnia- Adult	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2015-Dec	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1,2</sup>	<b>Toward Optimal Practice</b>	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2016-Jan	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>10</sup>	<b>Winnipeg Regional Health Authority (WRHA) 650 Main St, Winnipeg, MB</b>	Delirium and Delirium in the Surgical Patient	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2012-May	Cycle not indicated.	Wendy Rudnick, RN, MSN, Surgery Program Director
<sup>10</sup>	<b>WRHA</b>	Pain Assessment and Management	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2012-Apr	Cycle not indicated.	Mike Harlos, MD, CCFP(PC), FRCP

## Nutrition, Metabolism and Diabetes / Endocrine

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>3</sup>	<b>BC Guidelines</b> <i>PO Box 9642 STN PROV GOVT Victoria BC</i>	Abnormal Liver Chemistry - Evaluation and Interpretation	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	<a href="#">BC Ministry of Health</a>	No COI to disclose by authors.	<b>Date:</b> 2011-Aug	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2,3</sup>	<b>BC Guidelines</b>	Chronic kidney disease - identification, evaluation and management of patients	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	<a href="#">BC Ministry of Health</a>	No COI to disclose by authors.	<b>Date:</b> 2014-Oct	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Cobalamin (Vitamin B12) Deficiency - Investigation and Management	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	<a href="#">BC Ministry of Health</a>	No COI to disclose by authors.	<b>Date:</b> 2013-May	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2</sup>	<b>BC Guidelines</b>	Diabetes care	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	<a href="#">BC Ministry of Health</a>	No COI to disclose by authors.	<b>Date:</b> 2015-Dec	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Dyspepsia with or without Helicobacter pylori infection	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	<a href="#">BC Ministry of Health</a>	No COI to disclose by authors.	<b>Date:</b> 2010-Mar	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Folate Deficiency - Investigation and Management	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee</a>	<a href="#">BC Ministry of Health</a>	No COI to disclose by	<b>Date:</b> 2012-Jan	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
					<a href="#">Handbook</a>			authors.			
<sup>3</sup>	<b>BC Guidelines</b>	Gastroesophageal Reflux Disease - Clinical Approach in Adults	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2010-Mar	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	HFE-Associated Hereditary Hemochromatosis	Specialty	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2013-Apr	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2,3</sup>	<b>BC Guidelines</b>	Hormone testing – indications and appropriate use	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2016-May	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Iron Deficiency	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2010-Jun	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Microscopic Hematuria	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2009-Apr	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>3</sup>	<b>BC Guidelines</b>	Overweight and Obese Adults	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2011-Apr	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Testosterone Testing	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2011-Jun	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Thyroid Function Tests in the Diagnosis and Monitoring of Adults	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2010-Jan	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>3</sup>	<b>BC Guidelines</b>	Vitamin D Testing	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2013-Jun	3-5 year cycle.	GPAC Working Group <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2</sup>	<a href="#">Canadian Association of Gastroenterology 189 Queen Street East, Suite 1, Toronto, ON</a>	Fecal microbiota transplant therapy	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	AbbVie Canada, Olympus, Pentax, Janssen, Takeda Canada funding.	COI disclosed by authors.	<b>Date:</b> 2014-Feb	Updated when approved by committee.	Paul Moayyedi BSc MB ChB PhD MPH FRCP FRCPC AGAF FACG

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Association of Gastroenterology</b>	Subsequent entry biologics for the management of inflammatory bowel disease	Specialty	No	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	AbbVie Canada, Olympus, Pentax, Janssen, Takeda Canada funding.	COI disclosed by authors.	<b>Date:</b> 2013-Oct	Updated when approved by committee.	Shane M Devlin MD
<sup>2</sup>	<b>Canadian Association of Gastroenterology</b>	Thiopurines for the treatment of inflammatory bowel disease	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	AbbVie Canada, Olympus, Pentax, Janssen, Takeda Canada funding.	COI disclosed by authors.	<b>Date:</b> 2014-Jul	Updated when approved by committee.	John K. Marshall MD
<sup>2</sup>	<b>Canadian Association of Gastroenterology</b>	Venous thromboembolism in inflammatory bowel disease	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	AbbVie Canada, Warner Chilcott funding.	COI disclosed by authors.	<b>Date:</b> 2014-Mar	Updated when approved by committee.	Geoffrey C. Nguyen, MD, PhD, FRCP(C)
<sup>2</sup>	<b>Canadian Association of Radiologists</b>  294 Albert St Suite 600, Ottawa, ON	Prevention of contrast-induced nephropathy	Specialty	Yes	<a href="#">More Details...</a>	Guideline update; consensus.	Funding not indicated.	No COI to disclose by authors.	<b>Date:</b> 2014-May	Cycle not indicated.	Richard J. Owen, MBBCh, MRCP, FRCR
<sup>2</sup>	<b>Canadian Men's Health Foundation</b>  609 West Hastings St. Vancouver, BC	Testosterone deficiency syndrome in men	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Cnd Men's Health Foundation.	COI disclosed by authors.	<b>Date:</b> 2015-Oct	Cycle not indicated.	Alvaro Morales CM MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Ophthalmological Society</b> <i>110-2733 Lancaster Road, Ottawa ON</i>	Management of diabetic retinopathy	Primary and Specialty	Yes	<a href="#">More Details...</a>	CMA Handbook on CPGs.	Unrestricted grants: Alcon Canada; Allergan Canada; AMO, Novartis; Pfizer.	COI disclosed by authors.	<b>Date:</b> 2012-Apr	Updated based on new evidence.	Philip Hooper MD, FRCSC
<sup>2</sup>	<b>Canadian Society of Nephrology</b> <i>P.O. Box 25255 RDP Montreal, QC</i>	CKD evaluation and management	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Internal CNS.	COI disclosed by authors.	<b>Date:</b> 2015-Feb	Cycle not indicated.	Ayub Akbari, MD, MSc, FRCPC
<sup>2</sup>	<b>Canadian Society of Nephrology</b>	Timing the initiation of chronic dialysis	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Cdn Kidney KT and General Network; CIHR research grant; Kidney Foundation.	COI disclosed by authors.	<b>Date:</b> 2014-Feb	Cycle not indicated.	Gihad E. Nesrallah MD MSc
<sup>2,11</sup>	<b>Canadian Task Force on Preventive Health Care</b> <i>3280 Hospital Drive Northwest, Calgary, AB</i>	Prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care	Primary	No	<a href="#">More Details...</a>	<a href="#">Procedure Manual</a>	Provided by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2015-Feb	5 year cycle.	Paula Brauer PhD, RD, FDC
<sup>2,11</sup>	<b>Canadian Task Force on Preventive Health Care</b>	Screening for abdominal aortic aneurysm in primary care	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Procedure Manual</a>	Provided by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2017-Sep	Topic Selection Working Group to determine updates.	Harminder Singh MD MPH

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Task Force on Preventive Health Care</b>	Screening for type 2 diabetes in adults	Primary	No	<a href="#">More Details...</a>	<a href="#">Procedure Manual</a>	Provided by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2012-Oct	5 year cycle.	Kevin Pottie, BSc, MD, MCISc, FCMF
<sup>2</sup>	<b>Canadian Urological Association</b>  <i>185 Dorval Avenue, Suite 401, Dorval, QC</i>	Adult overactive bladder	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">CUA Guideline methods</a>	CUA funding from Astellas, Pfizer, Bayer, Janssen, Sanofi.	COI disclosed by authors.	<b>Date:</b> 2017-May	5 year cycle.	Jacques Corcos, MD, FRCSC
<sup>2</sup>	<b>Canadian Urological Association</b>	Antibiotic prophylaxis for endoscopic urologic procedures and ESWL	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">CUA Guideline methods</a>	CUA funding from Astellas, Pfizer, Bayer, Janssen, Sanofi.	No COI to disclose by authors.	<b>Date:</b> 2015-Feb	5 year cycle.	Marko Mrkobrada, MD
<sup>2</sup>	<b>Canadian Urological Association</b>	Azoospermic males	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">CUA Guideline methods</a>	CUA funding from Astellas, Pfizer, Bayer, Janssen, Sanofi.	COI disclosed by authors.	<b>Date:</b> 2015-Jun	5 year cycle.	Keith Jarvi, MD, FRCSC
<sup>2</sup>	<b>Canadian Urological Association</b>	Cystic renal lesions	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">CUA Guideline methods</a>	CUA funding from Astellas, Pfizer, Bayer, Janssen, Sanofi.	COI disclosed by authors.	<b>Date:</b> 2017-Mar	5 year cycle.	Patrick O. Richard, MD

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Urological Association	Erectile dysfunction	Primary and Specialty	Yes	<a href="#">More Details...</a>	CUA Guideline <a href="#">methods</a>	CUA funding from Astellas, Pfizer, Bayer, Janssen, Sanofi.	COI disclosed by authors.	<b>Date:</b> 2015-Feb	5 year cycle.	Anthony J. Bella, MD, FRCSC
<sup>2</sup>	Canadian Urological Association	Evaluation and medical management of the kidney stone patient	Specialty	No	<a href="#">More Details...</a>	CUA Guideline <a href="#">methods</a>	CUA funding from Astellas, Pfizer, Bayer, Janssen, Sanofi.	COI disclosed by authors.	<b>Date:</b> 2016-Nov	5 year cycle.	Marie Dion, MD
<sup>2</sup>	Canadian Urological Association	Interstitial cystitis/bladder pain syndrome	Specialty	No	<a href="#">More Details...</a>	CUA Guideline <a href="#">methods</a>	CUA funding from Astellas, Pfizer, Bayer, Janssen, Sanofi.	COI disclosed by authors.	<b>Date:</b> 2016-Mar	5 year cycle.	Ashley Cox, MD, MSc, FRCSC
<sup>2</sup>	Canadian Urological Association	Multicystic dysplastic kidney (MCDK) in the neonate	Specialty	Yes	<a href="#">More Details...</a>	CUA Guideline <a href="#">methods</a>	CUA funding from Astellas, Pfizer, Bayer, Janssen, Sanofi.	No COI to disclose by authors.	<b>Date:</b> 2016-Feb	5 year cycle.	Karen Psooy, MD
<sup>2</sup>	Canadian Urological Association	Ureteral calculi	Specialty	Yes	<a href="#">More Details...</a>	CUA Guideline <a href="#">methods</a>	CUA funding from Astellas, Pfizer, Bayer, Janssen, Sanofi.	No COI to disclose by authors.	<b>Date:</b> 2015-Nov	5 year cycle.	Michael Ordon, MD, FRCSC

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Canadian Urological Association	Vasectomy	Specialty	No	<a href="#">More Details...</a>	CUA Guideline methods	CUA funding from Astellas, Pfizer, Bayer, Janssen, Sanofi.	No COI to disclose by authors.	Date: 2016-Aug	5 year cycle.	Armand Zini, MD
<sup>2</sup>	<a href="#">Diabetes Canada</a> <u>1400-522 University Ave</u> <u>Toronto ON</u>	Chronic kidney disease in diabetes	Specialty	Yes	<a href="#">More Details...</a>	Methods	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Diabetes nutrition therapy	Primary	No	<a href="#">More Details...</a>	Methods	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Diabetes self-management education	Primary	No	<a href="#">More Details...</a>	Methods	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Sexual dysfunction and hypogonadism in men with diabetes.	Primary and Specialty	Yes	<a href="#">More Details...</a>	Methods	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Diabetes: foot care	Primary	Yes	<a href="#">More Details...</a>	Methods	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Diabetes Canada	Diabetes: hypoglycemia	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Diabetes: monitoring glycemic control	Primary	No	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Diabetes: targets for glycemic control	Primary	No	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Diabetes: complementary and alternative health medicine	Primary	No	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Diabetes transplantation	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Diabetes: retinopathy	Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	Diabetes Canada	Hyperglycemic emergencies in adults	Specialty	No	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Pharmacologic management of type 2 diabetes	Primary	No	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Glycemic management in adults with type 1 diabetes	Primary and Specialty	No	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Physical activity and diabetes	Primary	No	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Reducing the risk of developing diabetes.	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Screening for diabetes in adults	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by authors.	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	Diabetes Canada	Weight management in diabetes	Primary	No	<a href="#">More Details...</a>	<a href="#">Methods</a>	Funding: <a href="#">Diabetes Canada</a>	COI disclosed by	Date: 2018-Apr	Annual cycle.	Ms. Jovita Sundaramoorthy, Vice President, Research and

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
								authors.			Education <a href="mailto:guidelines@diabetes.ca">guidelines@diabetes.ca</a>
<sup>2</sup>	<b>McMaster University</b> <i>1280 Main St. W. Hamilton, ON</i>	Allergic disease prevention (GLAD-P): prebiotics	Specialty	No	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Sponsors: Danone; Dicofarm; Bambino Gesù Ospedale Pediatrico; Heinz.	COI disclosed by authors.	<b>Date:</b> 2016-Mar	3 year cycle.	Holger Schünemann, MD, PhD, MSc, FRCPC
<sup>2</sup>	<b>McMaster University</b>	Allergic disease prevention (GLAD-P): probiotics	Specialty	No	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	World Allergy Organization.	COI disclosed by authors.	<b>Date:</b> 2015-Jan	3 year cycle.	Holger Schünemann, MD, PhD, MSc, FRCPC
<sup>2</sup>	<b>Ontario Association of Medical Laboratories</b> <i>1802, 5000 Yonge St, North York, ON</i>	Collection and testing of stool specimens for bacterial culture and antimicrobial susceptibility testing	Primary	No	<a href="#">More Details...</a>	<a href="#">Committee consensus</a>	<a href="#">Funding not disclosed.</a>	Author COI not disclosed.	<b>Date:</b> 2015-Sep	5 year cycle.	Anu RebbaPragada, Ph.D., D (ABMM), CIC
<sup>2</sup>	<b>Ontario Association of Medical Laboratories</b>	Transition from the MDRD to the CKD-EPI equation for the calculation of an estimated glomerular filtration rate (eGFR), and its interpretation in concert with the urine albumin/creatinine ratio (ACR)	Specialty	No	<a href="#">More Details...</a>	<a href="#">Committee consensus</a>	<a href="#">Funding not disclosed.</a>	Author COI not disclosed.	<b>Date:</b> 2015-Apr	5 year cycle.	Judy Ash, MPPAL, BSc, ART, CQMgr, CQA (ASQ)
<sup>2,8</sup>	<b>Registered Nurses' Association of Ontario (RNAO)</b>	Assessment and management of foot ulcers for people with diabetes	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2013-Mar	3 year cycle.	Laura M. Teague, RN, MN, NP

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	158 Pearl Street, Toronto, ON										
<sup>8</sup>	RNAO	BPG for the Subcutaneous Administration of Insulin in Adults with Type 2 Diabetes	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2004-Jun	3 year cycle.	Anna Brundage, RN, BHSc(N), CDE
<sup>8</sup>	RNAO	Decision Support for Adults Living with Chronic Kidney Disease	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2009-Jul	3 year cycle.	Gillian Brunier, RN(EC), MScN, CNeph(C)
<sup>8</sup>	RNAO	Ostomy Care & Management	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2009-Aug	3 year cycle.	Kathryn Kozell, RN, MScN, APN(AC), CETN(c)
<sup>8</sup>	RNAO	Reducing Foot Complications for People with Diabetes	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2004-Mar	3 year cycle.	Tazim Virani, RN, MScN
<sup>1</sup>	Toward Optimized Practice (TOP) #200, 12315 Stony Plain Road	Diagnosis and Treatment of Chronic Undiagnosed Dyspepsia in Adults	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2015-Dec	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	<i>Edmonton, AB</i>										
<sup>1,2</sup>	<b>Toward Optimized Practice (TOP)</b>	<b>Diagnosis and Treatment of Helicobacter pylori Infection in Adults</b>	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2017-Mar	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1,2</sup>	<b>Toward Optimized Practice (TOP)</b>	Investigation and Management of Erectile Dysfunction and Hypogonadism	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2016-Mar	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1,2</sup>	<b>Toward Optimized Practice (TOP)</b>	<b>Investigation and Management of Primary Thyroid Dysfunction</b>	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2014-Apr	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	<b>Toward Optimized Practice (TOP)</b>	Laboratory Endocrine Testing Guidelines for Acromegaly	Specialty	No	<a href="#">More Guidelines...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2014-May	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	<b>Toward Optimized Practice (TOP)</b>	Laboratory Endocrine Testing Guidelines: Adrenal Insufficiency (Addison's Disease)	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2014-May	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>1</sup>	Toward Optimized Practice (TOP)	Laboratory Endocrine Testing Guidelines: Cushing's Syndrome	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2014-May	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	Toward Optimized Practice (TOP)	Laboratory Endocrine Testing Guidelines: Galactorrhea	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2014-May	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	Toward Optimized Practice (TOP)	Laboratory Endocrine Testing Guidelines: Gonadal Disorders: Hirsutism	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2014-Apr	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	Toward Optimized Practice (TOP)	Laboratory Endocrine Testing Guidelines: Hypercalcemia	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2014-May	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	Toward Optimized Practice (TOP)	Laboratory Endocrine Testing Guidelines: Hypoglycemia	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2014-May	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1</sup>	Toward Optimized Practice (TOP)	Laboratory Endocrine Testing Guidelines: Pheochromocytoma	Primary and Specialty	Yes	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	Date: 2014-May	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>1</sup>	Toward Optimized Practice (TOP)	Treatment of Gastroesophageal Reflux Disease in Adults (GERD)	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2016-Jun	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>1,2</sup>	Toward Optimized Practice (TOP)	Vitamin D Testing and Supplementation	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2014-Aug	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>
<sup>2</sup>	Toronto Consensus  1001 Decarie Boulevard, Montréal, QC	Helicobacter pylori infection in adults	Primary	No	<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Cdn Association of Gastroenterology	COI disclosed by authors.	<b>Date:</b> 2016-Jul	Cycle not indicated.	Carlo A. Fallone, MD, CM, FRCP (C), AGAF, CAGF
<sup>2</sup>	Working Group on Deprescribing Proton Pump Inhibitors	Deprescribing proton pump inhibitors			<a href="#">More Details...</a>	<a href="#">GRADE methodology</a>	Institute for Healthcare Improvement and Commonwealth Fund.	COI disclosed by authors.	<b>Date:</b> 2017-May	Updated based on new evidence.	Barbara Farrell PharmD ACPR FCSHP
<sup>10</sup>	Winnipeg Regional Health Authority (WHRA)  650 Main St, Winnipeg, MB	Emergency Management of Hypoglycemia In the Primary Care Setting	Primary	No	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2015-Jan	Cycle not indicated.	Sheldon M. Perman MD CCFP
<sup>10</sup>	WRHA	Enteral Nutrition	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2017-Mar	Cycle not indicated.	Mary Anne Lynch, Program Director, WRHA Medicine Program

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>10</sup>	WRHA	Medication Pass Nutrition Supplement Program	Specialty	Yes	<a href="#">More Details...</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2015-Nov	Cycle not indicated.	Brenda Hotson, RD Msc
<sup>10</sup>	WRHA	Moderate (Conscious) Sedation and GI Endoscopy Procedures	Specialty	No	<a href="#">Moderate (Conscious) Sedation and GI Endoscopy Procedures</a>	Summary of guidelines. Consensus.	Winnipeg Regional Health Authority	Author COI not disclosed.	<b>Date:</b> 2010-Dec	Cycle not indicated.	Harminder Singh, MD, FRCPC

## Population and Public Health

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>3</sup>	<b>BC Guidelines</b> <i>PO Box 9642 STN PROV GOVT Victoria BC</i>	Problem Drinking	Primary	No	<a href="#">More Details...</a>	<a href="#">Guidelines and Protocols Advisory Committee Handbook</a>	BC Ministry of Health	No COI to disclose by authors.	<b>Date:</b> 2013-Apr	3-5 year cycle.	<a href="#">GPAC Working Group</a> <a href="mailto:hlth.guidelines@gov.bc.ca">hlth.guidelines@gov.bc.ca</a>
<sup>2</sup>	<b>Canadian Academy of Sport and Exercise Medicine</b> <i>55 Metcalfe St, Ottawa, ON</i>	Physical activity prescription: a critical opportunity to address a modifiable risk factor for the prevention and management of chronic disease	Primary	No	<a href="#">More Details...</a>	Consensus.	Funding not indicated.	No COI to disclose by authors.	<b>Date:</b> 2016 Sep	Cycle not indicated.	Jane S. Thornton, MD, PhD
<sup>2</sup>	<b>Canadian Task Force on Preventive Health Care</b> <i>3280 Hospital Drive Northwest, Calgary, AB</i>	Prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care	Primary	No	<a href="#">More Details...</a>	<a href="#">Procedure Manual</a>	Provided by PHAC.	No COI to disclose by authors.	<b>Date:</b> 2015-Feb	5 year cycle.	Paula Brauer PhD, RD. FDC
<sup>8</sup>	<b>Registered Nurses' Association of Ontario (RNAO)</b> <i>158 Pearl Street, Toronto, ON</i>	Oral Health: Nursing Assessment and Intervention	Primary	No	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2008-Dec	3 year cycle.	Toba Miller RN, MScN, MHA, GNC(C)
<sup>1</sup>	<b>Toward Optimized Practice (TOP)</b> <i>#200, 12315 Stony Plain</i>	Environmental Exposures from Oil and Gas Emissions	Primary	No	<a href="#">More Details...</a>	<a href="#">Development Methodology</a>	Funded by AB Health and AB Medical Association. No industry funding.	COI disclosed by authors.	<b>Date:</b> 2017-Mar	2-5 year cycle.	Guideline committee <a href="mailto:cpg@topalbertadoctors.org">cpg@topalbertadoctors.org</a>

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
	Road Edmonton, AB										

## Other

Source	Developer	Guideline	Primary/ Specialty Care	Co- Morbidity	Access/Link to CPG	Method used to create CPG	Funding	COI	Date	Cycle	Contact
<sup>2</sup>	<b>Canadian Acne Working Group</b>  <i>166 Brock St. Centenary 3-027 Kingston, ON</i>	Acne	Primary	No	<a href="#">More Details...</a>	ADAPTE	Funded: Valeant, Galderma, Cipher, Bayer and Mylan.	COI disclosed by authors.	<b>Date:</b> 2015-Nov	Cycle not indicated.	Yuka Asai MD MSc
<sup>8</sup>	<b>Registered Nurses' Association of Ontario (RNAO)</b>  <i>158 Pearl Street, Toronto, ON</i>	Risk Assessment and Prevention of Pressure Ulcers	Primary	Yes	<a href="#">More Details...</a>	<a href="#">Methodology Report</a>	Funded by ON Ministry of Health and LTC.	No COI to disclose by authors.	<b>Date:</b> 2005-Mar	3 year cycle.	Tazim Virani, RN, MScN, PhD(candidate)

## List of Sources

CPGs were initially identified through a review of the following databases and websites:

<sup>1</sup>[Toward Optimized Practice \(TOP\)](#)

<sup>2</sup>[Canadian Medical Association \(CMA\). CMA Infobase: Clinical Practice Guidelines](#)

<sup>3</sup>[British Columbia Ministry of Health: BC Guidelines](#)

<sup>4</sup>[Canadian Partnership Against Cancer Corporation: Cancer Guidelines Resource Centre](#)

<sup>5</sup>[The College of Physicians and Surgeons of Ontario \(CPSO\). CPGs & Other Guidelines](#)

<sup>6</sup>[Ontario Association of Medical Laboratories \(OAML\) Lab Test Guidelines](#)

<sup>7</sup>[Public Health Agency of Canada \(PHAC\). Disease Prevention and Control Guidelines](#)

<sup>8</sup>[Registered Nurses' Association of Ontario: Nursing Best Practice Guidelines](#)

<sup>9</sup>[University of Ottawa. School of Rehabilitation Science. Evidence-based Practice](#)

<sup>10</sup>[Winnipeg Regional Health Authority \(WRHA\). Evidence Informed Practice Tools](#)

<sup>11</sup>[National Guideline Clearinghouse \(NGC\)](#)

<sup>12</sup>[Canadian Standards Association](#)